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The transgenic rat line TGR(mREN2)27 has been previously shown to develop severe 
hypertension as a consequence of over -expression of the mouse Ren -2 renin gene (Mullins et al 
1990). It was observed that an alteration in phenotype occurred in hybrids (HanRen2/Edin --) 
derived from crossing homozygous Ren -2 transgenic rats with the Edinburgh Sprague -Dawley 
strain of rats. Investigations into this phenotypic change revealed it to be due to spontaneous 
development of malignant phase hypertension. Furthermore the incidence of the malignant 
hypertensive phenotype was altered by the genetic background into which the transgene was 
introduced. 
The introduction of this thesis has reviewed the literature on the genetics of human 
essential hypertension and rat models of genetic hypertension, the role of the kidney in essential 
hypertension and the pathogenesis of malignant hypertension. Techniques in molecular biology 
which include transgenesis have been used to investigate the role of individual genes in blood 
pressure regulation. In this context the literature concerning the transgenic rat line 
TGR(mREN2)27 was extensively reviewed. 
The heterozygote cross HanRen2/Edin -- was found to develop malignant phase 
hypertension within a relatively narrow age range. Seventy -three percent of male and 52% of 
female HanRen2/Edin -- developed malignant hypertension. In contrast, other heterozygote 
crosses HanRen2/Han-- and HanRen2/Lew -- had an incidence in males of 18% and 0% and in 
females of 4% and 0% respectively. Telemetry was used to record blood pressure continuously 
in unrestrained conscious rats and demonstrated an accelerated rise in blood pressure in rats 
with clinical features of malignant phase hypertension. Histopathology showed fibrinoid 
necrosis and myo- intimal proliferation of afferent arterioles and small renal arteries. An 
associated deterioration in renal function occurred with a rise in plasma urea and creatinine. 
TGR(mREN2)27 normally have a suppressed renal renin -angiotensin system but in malignant 
phase affected animals had a significant elevation of plasma renin, angiotensin II and 
aldosterone. Immunohistochemistry demonstrated increased renin at the site of the afferent 
arterioles near the vascular poles of glomeruli. Blood films demonstrated a microangiopathic 
haemolytic anaemia. A genetic basis for the differing incidence of malignant phase between the 
three heterozygote crosses was further supported by the results of an analytical cross set up to 
segregate Edinburgh Sprague -Dawley alleles. Results suggested that malignant phase 
hypertension complicated benign hypertension due to the effects of one or possibly two genetic 
loci. 
A further study looked at the role of endothelin in malignant hypertension. Previous 
investigators had suggested that endothelin may be involved in the pathogenesis of malignant 
phase hypertension. RNase protection assays demonstrated increased expression of endothelin- 
1 mRNA in kidneys from malignant hypertensive rats. Chronic inhibition of endothelin 
receptors using an oral non -specific endothelin receptor antagonist (Bosentan) did not prevent 
or reduce the transition from benign to malignant phase hypertension. It would therefore appear 
that endothelin synthesis occurs in response to the transition to malignant hypertension but it is 
not a central initiating factor. 
In conclusion, this is a representative model showing many of the characteristics of 
malignant phase hypertension in humans. The differing incidence between transgenic Ren -2 
crosses appeared to be a consequence of genetic factor(s). This may therefore be another 
example of a genetic pre -disposition to develop target organ damage from hypertension. 
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CHAPTER 1 
Introduction 
1.1 Genetics of Essential Hypertension 
Hypertension has been defined by the World Health Organisation criteria to be 
present if systolic blood pressure (SBP) is 140 mmHg or more and/or diastolic blood 
pressure (DBP) is 95mmHg or more. As such, it has been shown to affect up to 24% 
of all individuals from populations within developed societies, and up to 50% of 
people over fifty years of ages. Resulting complications, namely cardiovascular, 
cerebrovascular and renal, exert a significant impact on health care resources. A recent 
survey has shown that only 53% of all hypertensives are on treatment for hypertension 
in order to prevent secondary complicationsg, but despite that it still remains the 
commonest reason for initiating life -time medication2. In 95% of cases, hypertension 
is a primary condition labeled as essential hypertension, on the basis that no 
underlying or secondary causes for the elevation in blood pressure (BP) such as renal 
artery stenosis, renal parenchymal disease, hyperaldosteronism or 
phaeochromocytoma have been diagnosed3. However the causes of elevated BP in 
essential hypertension remain unclear. 
Hypertension does not have a defined phenotype, but is simply the tail of a 
skewed frequency- distribution curve for blood pressure (BP)4. The distribution of 
measured blood pressure amongst individuals from a population is a consequence of 
their biological diversity, their adopted lifestyle and errors or variation in the 
measurement. Various arbitrary values have been used to define hypertension of 
differing severities in the clinical setting, but measured BP has been shown both to 
increase with age and be influenced by situational effects at the time of measurement. 
Assessments of the distribution of BP within populations have often been based on 
single measurements thereby potentially over -estimating the true prevalence of 
hypertensions. In early studies complications such as heart failure, impaired renal 
function or retinopathy were often labeled as a symptom complex equating with 
'hypertension' and subsequently included in the analysis of some populations leading 
to falsely high estimates5,6 
Ward (1990) has reviewed many of the studies performed, since the 
observation by Morgagni in 1761 of a father and son dying of 'apoplexy' and cerebral 
haemorrhage respectively, which suggested that both familial and environmental 
factors might be important. Apparent familial aggregation of high blood pressure or 
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its complications could be a consequence of common environmental, genetic or 
combined factors but also it could be due to the influences of age, sex and other 
confounding genetic /environmental factors such as obesity. These might not be 
randomly distributed through affected families potentially introducing bias. Many early 
studies of 'essential' hypertension should also be interpreted with caution in view of a 
number of factors. The medical technology of today was not available to early 
investigators, and reports of quite severe hypertension in children8 does suggest that 
secondary causes, e.g. vesicoureteric reflux and nephropathy may not have been 
adequately excluded from the groups studied. 
Between populations, blood pressure differences appear to be influenced more 
by environmental and socio- cultural factors in particular dietary sodium intake, 
physical activity, obesity and psychosocial stress. Though genetic factors may play a 
role, for example by influencing sodium handling9 or the degree of obesity, 
'westernization' of lifestyle is clearly a major factor. However within groups from 
diverse ethnic and genetic backgrounds, the presence of familial aggregation has 
prompted investigators to look for a genetic aetiology. Platt (1947) found an excess of 
'hypertension' in parents of hypertensive probands, compared to the parents of 
normotensives, but relied on histories suggestive of hypertension related 
complications10. Reported transmission of high blood pressure through three 
generations8, together with an apparent partition in the frequency distribution curve of 
blood pressure measurements from siblings of hypertensive patients giving a bimodal 
curve with approximately equivalent portions, prompted him to suggest that blood 
pressure was inherited by a single autosomal dominant gene10,11. However it was 
shown by Murphy (1964) that apparent bimodality or polymodality could arise from a 
number of errors including observer differences, digit preference in BP recordings 
selecting against intermediate values, the class intervals used in presenting the data, 
and small sample sizes, even when taken from a population with a unimodal 
distribution12. Therefore conclusions about inheritance could not be made from such 
analyses. 
From a larger number of subjects in the 'Precursors of Hypertension and 
Coronary Disease Study', John Hopkins University, both SBP and DBP were shown 
to have distributions with a positive skew which could be restored to a binomial 
distribution following logarithmic transformation6. Hamilton et al (1954) recognised 
the need for adjustment of BP for age and sex, and found no natural dividing line 
between hypertensives and normotensives13,14 They did however find a consistent 
familial aggregation with a regression coefficient for SBP of 0.22 and of DBP 0.18 
irrespective of whether the probands were normotensive or hypertensive15. In a larger 
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population -based study taking a random sample from the general population in 
Rhondda Fach, UK, it was estimated that approximately 33% of SBP and 20% of 
DBP was genetically determined. No suggestion of bimodality was seen for BP, but it 
was accepted by the authors that single gene inheritance could account for a very small 
percentage of cases16. Other population -based studies from Tecumseh, USA, and 
Framingham, USA have found variable but significant regression coefficients for first 
degree relatives of hypertensive probands7. 
If genetic factors were important in the aetiology of essential hypertension, 
then they potentially could be operating prior to the clinical diagnosis, hence it was of 
interest to ascertain whether familial aggregation of BP existed from childhood. A 
study performed on children aged 2 -14 years from 192 families did demonstrate 
familial aggregation. This was made by observing that the distribution of mean family 
scores (in standard deviation units (SDU) where one SDU equals the individual's BP 
minus the mean for their specific age and sex group divided by the SD of BP in that 
group) differed significantly from the expected normal distribution (which would have 
a standard deviation of one and mean of zero). Stronger regression coefficients existed 
between child propositi and their siblings compared with their mothers17. A weak 
correlation between infant blood pressure and maternal blood pressure has been found 
at birth, but a significant relationship with paternal blood pressure was not found until 
one month old18. At birth, infant blood pressure could be affected by the intra- uterine 
environment which in turn may be influenced by both maternal genes and 
environment. A significant contribution to any expected correlation in BP between 
parents and offspring and between offspring could be a consequence of a shared 
environment. In the case of DBP, 67% of the expected correlation was calculated to be 
due to environment and 33% to be due to shared genes19. 
Pickering and Platt became engaged in a highly publicised debate over the 
inheritance of essential hypertension, but most have come to support Pickering who 
proposed a polygenic inheritance together with an environmental 
influence10,11,5,4,16,20. It has now been estimated that between 20 -60% of the 
population variability in BP is genetically determined7,21. 
Recently clear examples of autosomal dominant inheritance of hypertension 
mediated by single gene defects have been described. Glucocorticoid remediable 
hyperaldosteronism (GRA) does not reliably exhibit clinical features or blood 
chemistry that would have allowed clear distinction from essential hypertension after 
standard investigations. Diagnosis of GRA rests on finding elevated urinary excretion 
of steroid metabolites 18- hydroxycortisol and 18- oxocortisol. Lifton et al identified 
linkage of GRA with an RFLP arising from a fusion event occurring between the 
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ACTH responsive regulatory sequences of the 1113 hydroxylase gene and the coding 
sequences of the aldosterone synthase gene. This has resulted in ectopic expression of 
aldosterone synthase in the adrenal zona fasciculata which responds to stimulation by 
ACTH rather than angiotensin II (Ang II) or potassium22. 
Liddles Syndrome (pseudoaldosteronism) has long been recognised as having 
an autosomal dominant mode of inheritance with constitutive activation of the Na +H+ 
exchange channel in the distal tubule23. Recently polymorphisms for the gene coding 
for the ß subunit of the epithelial sodium channel have been found to be linked with 
hypertension in five kindred with the syndrome24. It is therefore quite possible that 
other single gene defects may be identified causing hypertension in certain kindred25. 
1.2 Rat models of Genetic Hypertension 
High blood pressure in humans may result from the interaction of a number of 
genes with each other (epistatic) and with the environment (ecogenetic)26, but analysis 
of the trait is complicated by its quantitative nature, incomplete and age related 
penetrance and sexual dimorphism. The genetic heterogeneity of the human race and 
the difficulty in controlling environmental factors makes the investigation of the 
genetics of hypertension in humans extremely problematic. Animal models of genetic 
hypertension have therefore been developed, derived from inbred strains and when 
maintained in controlled environments, they can provide a potential tool for study 
(Table 1.2.1). 
A number of genetically hypertensive rat models have been developed by 
selective breeding from relatively hypertensive pairs taken from originally 
normotensive rat strains to create inbred hypertensive strains. It was assumed that by 
selecting hypertensive animals and with further breeding and selection for high BP, 
inbred strains with a hypertensive phenotype would result from segregation of 
hypertensinogenic genes. Subsequent investigation into the genotypic differences 
between the new hypertensive strain and normotensive control strains might then 
identify candidate loci. Studies looking at the physiology of these hypertensive rat 
strains might also point to intermediate phenotypes and mechanisms by which blood 
pressure homeostasis might be disturbed. In reality this has not been so simple. A 
number of candidate genes have been suggested on the basis of both studies in human 




Hypertensive rat Control Original strain Reference 
GH (Dunedin) N Otago Wistar Smirk & Hall 1958 27 
SHR WKY Wistar Okamoto & Aoki 1963 28 
Dahl SS Dahl SR Sprague -Dawley Dahl, Heine & Tassinari 
1962 29 
Dahl SS /Jr Dahl SR/Jr Sprague -Dawley Rapp 1984 30 
SBH SBN Sabra rat Ben -Ishay, Saliternick 
& Weiner 1972 31 
LH LN, LL Sprague -Dawley Dupont, Dupont, Froment 
et al 1973 32 
MHS MNS Wistar Bianchi, Fox & Imbasciati 
1974 33 
Table 1.2.1 - A summary of the origins of genetic hypertensive rat strains developed by selective 
breeding. Abbreviations: GH = Genetically hypertensive strain (Dunedin), N = normotensive colony; 
SHR = spontaneously hypertensive rat, WKY = Wistar- Kyoto; Dahl SS = salt sensitive, Dahl SR = 
salt resistant; Dahl SS /JR = inbred salt sensitive strain, Dahl SR/JR = inbred salt resistant strain; 
SBH = Sabra hypertension prone, SBN = Sabra hypertension resistant; LH = Lyon hypertensive, LN 
= Lyon normotensive, LL = Lyon low blood pressure; MHS = Milan hypertensive strain, MNS = 
Milan normotensive strain. 
The spontaneously hypertensive rat (SHR) was a classic example. It was 
developed by Okamoto et al (1963) by selecting a breeding pair with a relatively higher 
blood pressure from a colony of Wistar rats. Continued breeding and selection for 
more than twenty generations resulted in the inbred hypertensive SHR strain28. A 
second inbred strain was bred without selection from the same original outbred Wistar 
colony and designated Wistar -Kyoto (WKY) and this strain has been used extensively 
as the 'normotensive' control for both physiological and genetic studies. It was 
subsequently noted that a differing incidence of cerebral haemorrhage existed between 
sub -strains of SHR. Selection by maintaining lines derived from parents that 




Candidate gene References 
Renin 36, 37, 38, 39 
Angiotensinogen 40, 41, 42, 43, 44 
Angiotensin II receptors 45, 46, 47 
Angiotensin Converting Enzyme 48, 49, 50, 51, 52, 53 
Nitric oxide synthase 54, 55, 56 
Endothelin 57, 58, 59 
Endothelin -A receptor 60 
Kallikrein gene family 61, 62 
Sodium - lithium counter transport 63 
Sodium -hydrogen exchangers 64, 65 
Sodium -potassium ATPase 66, 67, 68 
Atrial natriuretic peptide (ANP) 69, 70 
ANP /guanylyl cyclase A receptor 71 
Adrenergic receptors 72, 73 
Insulin receptor 




SA gene 77, 78, 79, 80, 81, 82 
Table 1.2.2 Candidate genes implicated in BP regulation and human and/or rat genetic hypertension. 
In SHR, the kidney has been implicated as the source of hypertension. Donor 
kidneys from five week old SHRSP (stroke -prone SHR strain) or WKY rats were 
transplanted into bilaterally nephrectomised F1 (SHRSP X WKY) recipients. By eight 
to ten weeks of age, recipients of SHRSP kidneys showed both elevated BP and 
plasma creatinine compared to WKY kidney recipients84. However further studies 
have suggested that neither changes in circulating or renal renin -angiotensin system 
(RAS) activity contribute to the post- transplant hypertension in F1 hybrids receiving 
an SHR -SP kidney85. SHR showed a relatively thickened arterial media and a greater 
increment in renovascular resistance in response to noradrenalin (though reduced 
sensitivity) compared to WKY even at a pre- hypertensive stage at four to five weeks 
of age86. Using laser -Doppler flowmetry it has been shown that renal papillary blood 
flow is reduced in the pre- hypertensive SHR, but that direct intra- medullary 
administration of Captopril at a dose (5 mg/kg/day) that does not lower systemic BP 
resulted in an increase in papillary flow, natriuresis and a lowering of blood 
pressure87. The ability of vasodilator prostaglandins, prostacyclin and PGE2, to 
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counteract both angiotensin II (Ang II) and Thromboxane A2 induced renal 
vasoconstriction was reduced in young SHR compared to WKY88,89. Relatively 
higher levels of renin mRNA have been found in kidney, liver, brain, adrenal and 
heart of five week old SHR compared to WKY by ribonuclease (RNase) protection 
assay. This increment persisted in liver, brain and adrenal tissue taken from twelve 
week old SHR compared to WKY, but similar levels were found in kidney and 
reduced levels in SHR heart and aorta by this stage. 
Evidence in SHR of increased levels of brain Ang II, renin and hypothalamic 
angiotensinogen mRNA have also implicated the brain RAS in hypertension. 
Antisense inhibition, using oligonucleotides complementary to mRNA coding for the 
target protein, are thought to inhibit effective translation by hybridization to the 
mRNA. This approach was used to study the effects of specific inhibition of both 
angiotensinogen and Ang II receptor (AT1) mRNA by intracerebroventricular (icy) 
administration of the respective oligonucleotides. These measures resulted in 
normalisation of BP91,92. It has also been suggested that in SHR compared with both 
WKY and Sprague -Dawley (SD), that an overactive kallikrein -kinin system 
particularly in the rostral ventrolateral medulla, is involved in BP regulation93,94 
The inbred Dahl salt- hypertension sensitive (DS) rat and salt -hypertension 
resistant (DR) strains were developed from selective breeding from outbred SD29. DS 
rats show a suppressed RAS with low plasma renin activity (PRA) and renal and 
adrenal tissue renin contents existing from the pre -hypertensive stage. DS rats have 
15% fewer glomeruli than the DR strain and reportedly show an inappropriate renal 
vascular response to a high salt diet30. The two inbred strains were crossed and a 
subsequent F1 intercross produced an F2 population (Fig 1.2.1) which was raised on 
a high salt (8% NaCl) diet from weaning and the blood pressure response determined. 
A 1.2 kb insertion/deletion (VD) polymorphism was found in the first intron of the 
renin gene which was able to differentiate the cloned s (DS) and r (DR) alleles. Using 
a specific probe for this I/D area, a significant difference in SBP was observed 
between the three possible genotypes in males, with an increasing blood pressure 
correlating with increasing dose of the s renin allele, though accompanying differences 





1-7 I I 
F1 sr T sr sr sr 
I I I I 
F2 ss sr sr rr 
F2 progeny are derived from an F1 intercross 
(all heterozygous at any one locus). 
Resulting offspring in F2 will have one of 
three possible genotypes - in this case 
homozygous ss or rr, or heterozygous sr. 
The Lyon hypertensive strain (LH) was developed by selective breeding from 
Sprague -Dawley stock. Normotensive and hypotensive inbred strains were also 
generated and subsequently combined to produce an inbred normotensive control 
strain (LN)32,95. In addition to hypertension, LH rats show altered lipid profiles with 
an elevated plasma cholesterol, and raised plasma insulin and insulin:glucose ratio. In 
an F2 cross derived from Lyon LH and LN progenitors, blood pressure was 
significantly below mid -parental values suggesting a recessive phenotype, with the 
degree of genetic determination for SBP estimated at 28% and DBP 13%. Positive but 
weak relationships were found in the F2 population which suggested cosegregation of 
MBP and total cholesterol (r = 0.393), phospholipids (r = 0.245) and triglycerides (r 
= 0.245)96. In F2 rats, two microsatellite markers were found to show significant 
linkage with both diastolic and systolic blood pressure. One of these was contained 
within the renin gene locus on chromosome 13, but a marker contained within the 
carboxypeptidase gene locus showed the highest LOD score statistic for linkage with 
pulse pressure97. 
A Bgl II RFLP occurs in the rat renin gene as a consequence of a variation of 
the number of tandem repeats (VNTR) of a 38óp sequence in the first intron. A 
number of renin alleles have now been identified in different hypertensive and 
normotensive rat strains39. Using a labeled probe complementary to the conserved 
region of the tandemly repeated sequence on Southern blots of Bgl II digested DNA, it 
was identified that inheritance of one or two SHR renin alleles in an SHR/Lewis F2 
cross resulted in higher MBP compared to F2 rats inheriting only Lewis alleles37. In 
sixteen week old normotensive Brown Norway (BN) rats, renal renin activity is 
increased compared to SHR, and the inheritance of the BN renin allele in recombinant 
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inbred strains was associated with increased renal renin activity and a tendency to a 
lower BP compared to those inheriting the SHR allele. Interestingly, the difference in 
renal renin activity persisted even when blood pressure was matched in recombinant 
inbred strains with lower renin activity linked to inheritance of the SHR allele98. It 
was found that both SHR and inbred Dahl salt- hypertension resistant rats (SR/Jr) 
carry the same renin allele based on assessment of the first intron VNTR and a 
distinguishing fifth intron Hind III site. Hence in an F2 cross of the inbred salt - 
hypertension sensitive Dahl rat (SS /Jr) and SHR, SHR contributed the blood pressure 
lowering r allele. Higher BPs were therefore seen in F2 progeny homozygous for the 
s allele derived from SS /Jr, while lower BPs were observed in rats homozygous for 
the r allele derived in this cross from SHR39. 
Therefore significant linkage has been demonstrated between the renin gene 
and high BP in three strains of inbred genetic hypertensive rat, the SHR, the LH strain 
and the Dahl SS strain. No linkage has been found between the angiotensinogen locus 
and either hypertension or cardiac hypertrophy in an F2 cross of SHR -SP and WKY 
rats using a polymorphism that distinguished the two strains99. 
Two groups have identified loci that show linkage with basal BP variation and 
stronger linkage with BP variance in response to sodium loading in F2 SHRSP/WKY 
crosses. Hilbert et al (1991) used a combination of minisatellite probes, microsatellite 
markers and an RFLP previously identified in the SHRSP renin gene49. Jacob et al 
(1991) developed a series of microsatellite markers for the rat based on simple 
sequence repeats (SSR)48. In common to both studies, a locus on chromosome 10 
named BP /SP -1 or Bpi respectively showed significant linkage disequilibrium with 
sodium loaded BP. Both groups identified the locus to be in the region of the 
angiotensin converting enzyme gene which by its very nature has always been a prime 
candidate. Screening cDNA libraries from SHRSP and WKY has shown that the 
sequences for the respective ACE cDNAs differed by 5 nucleotides in the coding 
regions, only one of which resulted in an amino acid substitution (Lys207- Arg207) in 
SHR -SP. No significant effect on function was apparent as enzymatic analysis 
revealed similar Km and Vmax for ACE extracted from lung tissue from the two 
strains100 Another study failed to identify linkage between ACE alleles and 
hypertension in an F2 (SHR x WKY) population using CA repeat elements to 
differentiate ACE alleles, but linkage was found in an F2 (Dahl SS /Jr x MNS) 
population71. 
Phenylethanolamine N- methyl transferase (PNMT) is involved in 
catecholamine synthesis and has been found to be elevated in the brains of SHR -SP. 
The gene for the enzyme has been mapped to the region 17g22 -17824 in humans 
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which is within the conserved linkage group syntetic to the region in the rat where the 
locus BP /SP -1 (or Bpl) was found101 The PNMT gene has now been located to 
Chromosome 10 in the rat, but no sequence differences were identified between the 
cloned genes obtained from SHRSP and WKY genomic DNA libraries, including 1.0 
kb of 5' sequence containing known regulatory regions and all exons102 
Weaker linkage was found with two chromosome X markers (BP /SP -2) with 
F2 progeny homozygous for the WKY allele, as opposed to the SHR allele, having 
the higher blood pressure49. Weak linkage with baseline DBP and sodium loaded BP 
was found for a locus on Chromosome 18, but the authors have suggested that more 
evidence is required to confirm genetic linkage with this region48. 
In addition to the RAS, other systems potentially involved in BP homeostasis 
have been implicated. An RFLP marking the kallikrein gene family or closely linked 
genes (using a pancreatic kallikrein cDNA probe which cross hybridizes with a 
number of closely related kallikrein genes) has demonstrated that inheritance of the 
SHR allele in recombinant inbred strains derived from SHR and BN progenitors, is 
associated with significantly greater median SBP, DBP and MBP62. 
In SHR, the SA gene was identified as a candidate gene on the basis of 
isolation of a cDNA by differential hybridization from an SHR kidney cDNA library 
using cDNA probes prepared from SHR and WKY rat kidneys77. It was subsequently 
localized to rat chromosome 1 showing tight linkage to both rat myosin light chain 2 
and leukosialin genes81. Increased expression of an mRNA species was seen in SHR 
kidney compared to that from WKY at 4 weeks, but not at 16 weeks. At 16 weeks of 
age, liver expression is only seen in SHR77. In contrast, a 10 -fold reduction in 
expression was seen in SHR brain compared to WKY brain78. To test whether the SA 
gene was related to hypertension, an F2 cross from SHR -SP and WKY found the 
SHRSP allele to be linked with increased systolic blood pressure on sodium loading, 
but no linkage with basal blood pressure was identified81. In an F2 cross between 
SHR and WKY, the SHR allele did cosegregate with hypertension79. However no 
effect of inheritance of the SHR SA allele on basal blood pressure was seen in F2 
males from an SHR/Lewis cross, but a small increase in MBP did occur with 
inheritance of the SHR derived allele compared to the Lewis allele in females78. 
Unfortunately the finding of considerable genetic heterogeneity between WKY 
strains available from different commercial sources, and even from within a single 
source, has suggested that this strain was distributed before full inbreeding had been 
achieved103 Divergence between SHR and WKY has also been found to be high 
using a method of RFLP analysis following digestion of genomic DNA with 
restriction enzymes and hybridization with a number of probes104 Comparison of 
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DNA 'fingerprints' by Southern Blot analysis of six different VNTR sequences 
showed that the median percentage of bands shared by SHR and WKY was only 
54 %. Relatively little genetic heterogeneity in the Dahl strains has been found, with 
Dahl SS rats sharing 80% of bands with the Dahl SR strain105 This would be greater 
than that expected between a parent and F1 offspring (50 %) or a parent and first 
backcross generation (75 %). More recently evidence of genetic contamination of the 
inbred Dahl salt sensitive (Dahl SS /Jr) strain with apparent phenotypic variability has 
been reported and could potentially call into question many studies that have used 
these strains106,107. However there still appears to be a close genetic relationship 
between hypertensive and control Lyon strains on the basis of the low percentage of 
informative microsatellite markers (11% of 241 markers) that detected allelic 
differences between the Lyon strains97. 
Selective breeding for a phenotype will result in the segregation of 
hypertensive genes and in the SHR it has been estimated that perhaps between three 
and six loci are responsible108. In an F2 (Dahl SS /Jr x MNS) population, it has been 
estimated that approximately half of the genetic variance is explained by a combination 
of the effects of ACE, GCA (guanylyl cyclase A) receptor and renin gene loci71. The 
segregation of 'hypertension' genes is likely to be accompanied by cosegregation of 
other loci which may become fixed in the 'hypertensive' strain, and therefore the 
presence of a genetic polymorphism at a specific locus does not necessarily imply 
causality109 
Interestingly the 'genetic' hypertension of SHR could be prevented by pre - 
treating females with the ACE inhibitor, captopril until they were mated at two months 
of age. They remained off treatment thereafter and their offspring were found to show 
a significantly reduced basal BP at both 4 and 9 months of age though their responses 
to exogenous Ang II (icy) and intravenous (iv) Ang II or Ang I were not significantly 
different to controls whose parents had not received any pre- treatment with ACE 
inhibitors prior to mating110 This serves as an example of the persisting difficulty in 
separating genetic and environmental contributions even in animal models. 
1.3 Genetics of Human hypertension 
The findings of linkage between candidate genes and hypertension in animal 
models of genetic hypertension can not be directly translated into the human situation. 
The techniques described above have been applied to the humans with necessary 
modification in view of the inability to direct mating to generate optimal genetic 
crosses for study! Association studies seek a difference in the observed frequency of 
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an allele at a marker locus comparing affected cases to unaffected, unrelated controls 
looking for evidence of the loss of expected random segregation of alleles in a 
population. An allele is said to exhibit linkage disequilibrium with a trait if it occurs at 
a significantly higher frequency in the affected group compared with the unaffected 
control group. However linkage of an allele does not imply causality. The allele may 
simply lie close to and be in linkage disequilibrium with the allele which is 
responsible. If the groups chosen for study are not relatively homogenous, with 
differences for example in ethnicity or gender between case and control groups, this 
may result in apparent but artefactual linkage111 In a condition like essential 
hypertension with an expected genetic basis, comparison of affected cases with a 
positive family history and unaffected cases with a negative family history may 
improve the likelihood of identifying a relevant genetic marker, and secondly reduce 
the risk of error arising from delayed penetrance of the phenotype. 
Linkage studies test for a departure in the random segregation of both traits and 
genetic markers in families and look for evidence of excess sharing of a particular 
allele in affected relatives that is not consistent with random Mendelian ions l 1 
Sibling or relative pairs may be examined, but analysis can be complicated by 
incomplete or delayed penetrance of the phenotype. Both these methods are very 
dependent on a low likelihood of recombination events ( <1 %) occurring between the 
marker and the trait. Association studies with non -specific markers are unlikely to be 
helpful due the low sensitivity of the method, but identification and use of functionally 
significant gene polymorphisms, which lie close to or within candidate gene loci, as 
specific markers may improve the likelihood of a positive result (Table 1.2.2). The 
development of increasingly detailed genetic maps will result in the availability of more 
informative markers in the future35,25. 
Multifactorial determination of a trait will also weaken the power of these 
methods, and in hypertension, either by restricting the analysis to severe hypertensives 
or by using intermediate phenotypes such as plasma renin concentration, total body 
sodium or ACE activity, the likelihood of detecting significant linkage may be 
improved. In the case of polygenic disease, the relatively small contribution to the 
overall phenotype made by a single locus may make its effects too small to detect by 
allele sharing methods. A different approach is to search directly for mutations in 
candidate genes. Sequence variations do not always alter function as they may not alter 
the amino acid sequence or they may occur in non -coding regions, but a mutation can 
be followed through a pedigree and its relationship with a phenotype be 
ascertained22,35 ,21 
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The finding of renin gene polymorphisms in rat models of genetic 
hypertension, as reviewed above, prompted Soubrier et al (1990) to look for similar 
findings in essential hypertensives with a positive family history (at least one affected 
parent and one sibling) compared with normotensives with no family history. RFLPs 
were detected after digestion of genomic DNA with three restriction endonucleases 
followed by probing with a renin cDNA fragment and a 5' genomic DNA fragment, 
but no significant difference in allele frequencies were seen between hypertensive and 
normotensive subjects in the French Caucasian population studied112. A similar result 
was found in a Japanese family with a high incidence of essential hypertension38. 
A linkage study using a dinucleotide repeat sequence 3' of the angiotensinogen 
gene, looked at hypertensive sibling pairs from Salt Lake City and Paris and found a 
significant excess of shared alleles in male Parisian hypertensive siblings, but greater 
statistical significance was achieved when severe hypertensives from both populations 
were analysed together40. DNA sequence analysis of fifteen angiotensinogen variants 
identified five with 5' nucleotide substitutions and ten with silent or missense variants. 
Only variants with the resulting amino acid substitutions M235T and T174M (occurs 
with M235T) showed linkage disequilibrium, and both elevated BP and increased 
plasma angiotensinogen levels were found in heterozygote and homozygote M235T 
carriers40. In two association studies performed on Caucasian and Japanese 
populations, the M235T variant again occurred at a higher frequency in hypertensives 
and was associated' with elevated plasma angiotensinogen41 ". Substrate level may 
well be important as the Km for the enzymatic cleavage of angiotensinogen by renin is 
close to the plasma level. Two groups have reported linkage of the angiotensinogen 
locus with pre -eclampsia, using the 3' dinucleotide repeat sequence in a linkage study 
and the M235T variant in an association study 42,43. 
However both the M235T and T174M polymorphisms are at some distance 
from the cleavage sites of the human angiotensinogen molecule. Significant linkage 
has been demonstrated between hypertension and the angiotensinogen locus using a 3' 
dinucleotide repeat sequence in sixty -three UK families with two or more members 
with essential hypertension, but in this study no specific linkage was demonstrated 
with either the M235T or T174M polymorphisms113. 
An insertion /deletion (I/D) polymorphism within intron 16 of the ACE gene 
has been found to account for approximately half of the total phenotypic variance in 
serum ACE in a population of healthy, normotensive Caucasians, with higher serum 
ACE in those homozygous for the deletion (DD) allele114 Despite the findings of 
linkage between the ACE gene, or a locus in close proximity to it and hypertension in 
rats, linkage has not been found in the majority of studies in human 
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populations115,52,51,53. However in one report, linkage of the I allele was described 
in essential hypertensives with a positive family history when compared with 
normotensives with a negative family history50 
Interestingly this insertion/deletion (I/D) polymorphism in the ACE gene has 
been found to be linked with myocardial infarction (MI)116, parental history of MI117, 
hypertrophic cardiomyopathy118, ischaemic and idiopathic dilated cardiomyopathy119 
The DD genotype appeared to act as an independent risk factor for MI and was 
associated with a significant increase in plasma ACE116 In groups matched for age, 
sex and BP, a statistically significant association between LVH by ECG criteria and 
the ACE DD genotype was apparent in men, with a stronger association observed in 
normotensives120. This has raised the interesting possibility of screening populations 
for underlying genetic risk factors for development of hypertension related target 
organ damage, and might also have implications for the strategies directed at primary 
prevention of MI121 -123, particularly where it may be possible to modify the gene - 
environment interaction20. However some investigators have found that the DD 
genotype may be overestimated due to the occasional failure of the insertion allele to 
amplify using the polymerase chain reaction in DNA samples from heterozygotes, so 
mistyping ID as DD124. 
The SA gene, a candidate gene for hypertension on the SHR chromosome 1, 
was found to have a human counterpart on chromosome 16 with a deduced amino acid 
sequence showing 84% identity with the deduced rat sequence which suggests that the 
gene may well be functional and under selection pressure. No function has yet been 
ascertained despite searching for sequence homology with known proteins, but 30.6% 
homology was seen with acetyl coenzyme A synthase. A Pst 1 polymorphism was 
found to be linked with hypertension in a middle -aged Japanese population but not 
linked with potential confounding traits such as body mass index, plasma cholesterol 
or fasting glucose80. However other investigators have found no such linkage 
between hypertension and this RFLP or with other markers for the SA gene82. No 
intermediate phenotype or gene product has been identified as yet and the role of SA 
remains obscure, but it may simply be a marker for another gene in close proximity. 
Two studies have shown linkage of hypertension but not obesity with the 
insulin receptor (R1 -) allele based on an Rsa 1 RFLP arising from the insertion of a 
CA repeat sequence in intron 974. This is of interest in view of the association of 
insulin resistance and essential hypertension. Conflicting results were obtained using a 
microsatellite polymorphism located in intron 2, where derived allele frequencies 
showed similar distributions between hypertensive and normotensive subjects 
suggesting that the causative polymorphism may lie closer to intron 9 than to intron 
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275. Recently linkage has been described between a marker in close proximity to the 
a- adducin locus and hypertension in an association study76. This membrane skeleton 
protein has previously been implicated as a potential factor in the genetic hypertension 
of the MHS rat by altering ion transport125. 
These results support the concept that variants of 'candidate genes may 
contribute to the heritable aspects of an individual's variation in BP and affect their 
response to the environment. The important contribution to BP homeostasis of the 
RAS and the finding of genetic polymorphisms occurring in components of this 
system in both rat models and in humans, has led to the desire to study the 
contribution of individual genes, in particular by subtle alterations in the regulation of 
their expression and function. New methods, in particular transgenesis (section 1.6), 
have been developed which could help identify how hypertension might result from 
altered gene regulation and function126. The physiological and pathological roles of 
the RAS and the kidney in BP homeostasis and in hypertension will be considered 
next. 
1.4 The Renin -Angiotensin System and its regulation 
Renin is a single chain glycosylated carboxypeptidase of MW 41 kD. Unlike 
most members of the aspartyl protease family it is quite substrate specific, cleaving 
angiotensinogen with optimal function at pH 5.5 -6.0. The active site of the renin 
molecule is located in a cleft between two almost symmetrical lobes (reviewed in 127). 
Human and rat genomes contain one renin gene located on Chromosome 1. 
These are expressed highly in the kidney, but in mice high expression is also found in 
the submaxillary glands (SMG). Some strains of mice e.g. C57BL /6 and Balb /c have 
one renin gene (Ren -lc), but certain strains such as DBA/2J and Swiss have two, 
namely Ren -ld and Ren -2d128 -131_ Ren -2d is thought to have arisen as a consequence 
of a gene duplication event occurring between 2.75 - 7.2 million years ago and it 
encodes a thermolabile, non -glycosylated isozyme which is expressed at high levels in 
the granular convoluted tubules of the SMG132. Ren -ld is expressed in two gene 
strains principally in the JGA cells of kidney at an approximately equivalent level to 
Ren -2d expression in the SMG on a per cell basis. Both Ren -ld and Ren -2d mRNA 
levels were found to be approximately equivalent in kidneys of two -gene strains 
(DBA/2J) by Field and Gross (1985) using primer extension analysis133 This 
conflicted with earlier findings suggesting that Ren -ld was mainly responsible for 
renin synthesis in the kidney of two -gene strains on the basis of thermostability 
analysis of kidney renin activity and the observation that antibody raised against SMG 
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renin failed to reduce renin activity in kidney132. Ren -ld expression was found at 
significantly lower levels in SMG compared to Ren -2d on a per cell basis134 (Table 
1.4.1). 
Table 1.4.1 
Tissue Cell type Ren -lc Ren -ld Ren -2d 
kidney JGA cells + ++ + ++ + ++ 
SMG gland granular convoluted tubule cells + +/- + ++ 
Adult adrenal Zona fasciculata, X zone +/- ++ ++ 
Testes Leydig cells + ++ + 
Ovary Theca, corpus luteum ? ++ ++ 
Differential expression of mouse renin genes on a per cell nucleus basis - adapted from Sigmund & 
Gross (1991)135. 
All mouse renin genes consist of 9 exons and 8 introns with relatively high 
homology existing between cDNA sequences, 97% between Ren -lc and Ren -2d and 
99% between Ren -lc and Ren -1d135 Sequence divergence is found between Ren -ld 
genes and Ren -2d in the 5' region, but it is not clear that this region is responsible for 
the differing tissue -specific expression of the mouse renin genes134 -137. Renin gene 
expression does appear to be influenced by hormone levels showing higher levels of 
expression particularly in male mouse SMG, but also in female rat and mouse liver138. 
Approximately 88% homology exists between mouse Ren -1 (mRen -1) and rat 
renin (rRen) genes, and 78% homology between mRen -1 and human renin (hRen) 
genes at the cDNA level. At the amino acid level, all three mouse gene products exhibit 
-97% homology with the most significant differences between the Ren -1 and Ren -2 
gene products occurring at three asparagine- linked glycosylation sites, which may 
account for the differences in glycosylation and thermostability139, (reviewed in 135) 
The physiological role of Ren -2 in two gene strains of mice is not clear and awaits the 
results of experiments designed to knock out individual renin genes140, but Ren-lc, 
Ren -ld and Ren -2d derived mRNA have all been seen to respond appropriately to 
dietary NaC1 by an RNase protection assay measuring steady state levels of 
mRNA141 Tissue distribution of rat renin transcripts is similar to mouse Ren -1, but 
no expression is found in the rat SMG136,138_ 
In cells of the juxta -glomerular apparatus (JGA), translation of renin mRNA 
produces pre -prorenin which then undergoes cleavage of its amino terminal 20 amino 
acid signal sequence and glycosylation during passage through the endoplasmic 
reticulum to give prorenin. Prorenin is then packaged in the Golgi apparatus, and a 
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proportion is directly secreted as prorenin in vesicles via the constitutive pathway 
while other protogranules coalesce to form larger secretory granules142. The 
constitutive secretion of prorenin appears to be dependent on the rate of transcription 
of the renin gene. In the secretory granules the prosegment is cleaved by the action of 
lysosomal enzymes, most probably cathepsin B in the kidney143, and removal of the 
prosegment results in exposure of the active site or cleft. 
The main site of synthesis of renin in the kidney is within the specialised cells 
of the juxtaglomerular apparatus (JGA). Juxta- glomerular (JG) cells are derived from 
modified smooth muscle cells which adopt the morphology of secretory cells with 
between five and twenty cells located in the afferent arteriolar wall of the vascular pole 
of the glomerulus. Electron microscopy studies have suggested that renin secretion 
from granules involves exocytosis in response to stimulatory events. JG cells are 
innervated by renal sympathetic nerves and via Di adrenoceptors, rapid release of the 
renin contained in granules occurs resulting in a rise in PRA. Stimulation of the renal 
nerves reduces both renal blood flow (RBF) and glomerular filtration rate (GFR) and 
increases renin mRNA particularly at higher levels of stimulation. Such effects can be 
reduced or blocked by pre- administration of the ßt antagonist, atenolo1144. Likewise 
renal denervation or 0-antagonists result in a reduction in both kidney preprorenin 
mRNA content and renin immunoreactivity145. 
Tubular epithelial cells of the thick ascending Loop of Henle and distal tubule 
form the macula densa in association with modified extra -glomerular mesangial cells. 
The macula densa is thought to sense distal tubular sodium delivery and an increase in 
distal tubular luminal NaC1 concentration results in a reduction in renin synthesis and 
release. Postulated mediators include nitric oxide (NO), as suggested by both in vivo 
inhibition of renin release in response to L -NAME, an NO synthase inhibitor146 and 
stimulation in response to NO liberators such as sodium nitroprusside in cultured 
mouse renal JG cells147. A constitutive form of NO synthase (NOS I) has been 
identified in the macula densa148 and there is evidence to support a mediator function 
for NO in afferent arteriolar constriction, JG cell renin release, mesangial cell and 
podocyte contractility and hence glomerular haemodynamics and tubulo- glomerular 
feedback149 An adenosine (Al) receptor analogue had been shown to mimic the effect 
of increased NaC1 delivery inhibiting renin release, but though adenosine itself did 
induce inhibition of renin secretion in a dose responsive way, the maximum degree of 
inhibition attained was considerably less than that resulting from increased luminal 
NaC1 delivery itself in isolated perfused rabbit kidney JGA. This suggested that 
adenosine alone could not be the sole mediator of the macula densa response150 
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An increase in the number of secretory JG cells, their renin mRNA content 
and post -translational processing and release of renin occurs in response to stimuli 
such as low plasma sodium, diuretic use, ACE inhibition and in pathological 
conditions such as renal artery stenosis, malignant hypertension or in the clipped 
kidney of experimental two kidney - one clip (2K -1C) rats151- 156,127. A decrease in 
whole kidney renin mRNA content occurs in the contralateral kidney of the 2K1C 
hypertensive rat, and this effect is mimicked by exogenous infusion of Ang II by 
osmotic minipump into uninephrectomized rats. This supports a role for Ang II in 
down -regulating renin gene transcription157,158. However the clipped kidney is also 
exposed to high Ang II but an elevated renin mRNA content is found suggesting that 
additional factors, perhaps raised infra -renal pressure might be necessary. 
In addition to JG cells, renin has also been found in proximal tubular cells. 
This could be due to glomerular filtration and endocytosis of filtered renin, peritubular 
delivery or synthesis de novo. Though previous investigators had failed to identify 
renin transcripts by in situ hybridization, Moe et al (1993) showed the presence of 
renin mRNA in cultured rabbit proximal tubular cells (PTC) and microdissected rat 
proximal tubules. Contamination of the PTC culture with JG cells could not be 
excluded, but renin synthesis by JG cells in PTC culture media could not be 
demonstrated. Stimulation by five to six days pretreatment with enalapril was however 
necessary to detect renin mRNA in the microdissected tubules159. 
In plasma from humans and other species, circulating active renin is derived 
from the kidney, but cryoactivation (0 -4 °C), trypsin activation or acidification of 
plasma increases this five to ten fold due to conversion of 'inactive renin' to renin. The 
nature of 'inactive renin' has been a subject of much debate (reviewed in 160) 
Measurement of prorenin has been problematical due to the variability in values 
observed as a consequence of the methods used for blood retrieval, the type of 
anaesthesia administered or the method used for prorenin activation161 Bilateral 
nephrectomy in rats removed all circulating active renin, and significantly reduced but 
did not abolish 'inactive' renin. This therefore suggested that 'inactive' renin may be 
derived from or sequestered in other tissues with similar findings being reported in 
humans162 It has been reported however that the remaining Ang I generating activity 
measured in plasma of nephrectomized animals is not due to either prorenin or renin, 
but to an alternative molecule which elutes from a G3000SW column as a single peak 
with a MW of 65,000, close to the MW of angiotensinogen (compared with MW 
48,000 of prorenin and MW 40,000 for active renin in normal rat plasma)163 These 
findings were supported by immunological data using polyclonal antibodies directed 
against the pro- fragment of prorenin, which confirmed the absence of prorenin from 
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nephrectomized rat plasma163 This Ang I immunoreactive material (AI -IM) which 
interferes with radioimmunoassay of renin, is thought to be generated by trypsin 
digestion of angiotensinogen, which is inevitably higher in nephrectomized plasma162. 
Radioimmunoassays which do not include a step for AI -IM removal by a cation 
exchange resin should therefore be interpreted with caution162. 
In another study of trypsin activated plasma from nephrectomized rats, a renin 
inhibitor CH -732 inhibited Ang I generating activity by approximately 20 %, compared 
with 75 to 90% inhibition using N- ethylmaleimide which inhibits sulphydryl enzymes. 
It was concluded that the prorenin concentration in 24 hour nephrectomized rat plasma 
was only 10% of that seen in intact rat plasma with the majority of prorenin -like 
activity present being due to an unknown sulphydryl enzymelM. 
The role of prorenin remains to be clarified and has been the source of some 
controversy, partly due to the methodological problems briefly commented on above 
which may have overestimated prorenin levels following nephrectomy, thereby 
leading to a search for physiological functions and extra -renal sites of synthesis. The 
fording of prorenin in high levels at extra -renal sites e.g. placenta and ovary have led 
some investigators to postulate either direct involvement in tissue RAS, as no in vivo 
extra- renal 'convertase' has yet been identified165,166, though a number of candidates 
exist that could function as local prorenin activating enzymes (reviewed in 167). Other 
putative roles for prorenin have been suggested, including a vasodilator function 
opposing renin mediated vasoconstriction168 and as a growth factor contributing to 
cardiac hypertrophy following tissue uptake of circulating prorenin by the heart' . 
The substrate of renin is angiotensinogen which is primarily synthesized in the 
liver and cleaved by renin to release the decapeptide Ang I. Species specificity of the 
cleavage reaction appears to be a consequence of the amino terminal amino acid 
sequence around the cleavage site169 Rat and mouse angiotensinogen cDNAs have 
been cloned and the deduced amino acid sequence is 453 residues with a signal 
sequence of 24 residues170,171. Sequencing of the human angiotensinogen gene from 
a genomic DNA library has shown the gene to be 12 kb in length with five exons and 
four introns and like rat and mouse genes, considerable similarity with other serine 
protease inhibitors e.g. a1- antitrypsin, and anti -thrombin exists. Putative regulatory 
sequences in the 5' flanking region respond to glucocorticoids, oestrogens, cAMP and 
mediators of the acute phase response resulting in increased plasma angiotensinogen 
levels172,173. Rat hépatocyte cultures have been used as an in vitro system and results 
have suggested that interleukin -6 (IL -6) may be a mediator of the increase in 
angiotensinogen synthesis seen in acute inflammation, but that this effect appears to 
depend on the presence of glucocorticoid, and may be partly mediated via an increase 
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in intracellular cAMP173. Regulatory mechanisms of angiotensinogen gene activation 
have also been studied in adipose tissue using a pre- adipocyte culture transfected with 
a mouse angiotensinogen promoter -CAT (chloramphenicol acetyl transferase) reporter 
chimaeric construct174. Induction of adipocyte differentiation resulted in accumulation 
of angiotensinogen mRNA. Constructs with deletion mutants of a specific 5' sequence 
( -96 to -52) within the promoter region exhibited reduced adipocyte differentiation 
coupled activation175 
Angiotensinogen mRNA has been identified in a number of extra -hepatic 
tissues including kidney, brain, spinal cord, adipose tissue and aorta. Two studies 
have shown that sodium depletion induced by low dietary sodium and frusemide 
resulted in an increase in renal angiotensinogen mRNA. One group found no 
significant effect of low sodium on hepatic mRNA while another found a significant 
increase176,177. In situ hybridization of kidney has demonstrated angiotensinogen 
mRNA to be localized mainly to the proximal tubules with increased expression in 
response to salt depletion178. In the 2K1C rat, whole kidney angiotensinogen mRNA 
levels were not significantly different in either the clipped or the contralateral kidney 
when compared to respective control kidneys from sham operated animals, in contrast 
to the observed changes in renin mRNA157. However angiotensinogen mRNA, 
measured by densitometry of Northern blots (relative to 13actin mRNA) was found to 
increase at relatively low levels of renal nerve stimulation possibly concurrent with the 
increase in JGA cell renin release144. 
ACE is a zinc protease which catalyses the hydrolysis of dipeptides from the 
carboxyl terminus of polypeptides. It converts the inactive decapeptide Ang I to the 
active octapeptide Ang II. It also inactivates bradykinin by two sequential dipeptide 
hydrolysis reactions. Two ACE isoforms are derived from a single gene by 
transcription from two alternative promoters resulting in the somatic form, a 
glycoprotein of 170 kD, and the germinal form with a lower MW of 110 kD consisting 
of the active carboxyl terminal domain. Somatic ACE gene expression and enzymatic 
activity are found in highest concentrations in vascular endothelium and in absorptive 
epithelial cells of the small intestine, renal proximal tubular epithelium and 
epididymus. The germinal form is uniquely expressed in a stage- specific pattern in 
developing spermatozoa179. In all species, both forms consist of an intracellular 
hydrophilic carboxyl -terminal sequence and a trans -membrane hydrophobic domain 
indicating that ACE exists as an integral membrane protein. In vivo soluble circulating 
ACE is found though the source is not clear, but it is thought to be primarily derived 
from vascular endothelium lining pulmonary capillaries. An active soluble from of 
ACE is produced by cultured Chinese Hamster Ovary (CHO) cells by proteolytic 
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cleavage at the carboxyl terminal region (Arg -1137 and Leu- 1138)180. Along with the 
other components of the RAS, ACE mRNA transcripts have been found in whole 
kidney. Specific patterns of mRNA expression relating to development have been 
reported in kidney, heart, aorta, lungs and liver along with a changing profile of serum 
ACE activity with age181. 
Exogenous infusion of Ang II has been found to exert a negative feedback 
effect reducing both ACE activity and pulmonary mRNA levels. However the 
resulting change in BP and possible effects of Ang II on other neuroendocrine systems 
does not exclude the possibility that this may be an indirect effect. ACE inhibition with 
Quinapril caused a statistically insignificant fall in plasma Ang II, but both pulmonary 
and serum ACE activities were significantly reduced while an increase in pulmonary 
ACE mRNA resulted. In contrast testicular ACE activity and mRNA content were 
unaffected reflecting the fact that the ACE inhibitor did not cross the blood- testis 
barrier182. 
The product of the proteolytic cleavage by ACE on Ang I is the active 
octapeptide Ang II. The physiological and potentially hypertensive effects of Ang II 
can be summarised in Fig 1.4.1. Ang II is a potent vasoconstrictor with a preferential 
effect on the efferent arteriole producing a modest decrease in GFR, profound 
decrease in RPF, while filtration fraction, MBP and renal vascular resistance increase 
in response to infusion183. The peptide exerts a net anti -natriuretic effect by inducing 
retention of sodium by direct action on Ang II receptors in the proximal tubule184. Via 
ATt receptors, Ang II appears to be involved in both basal and stimulated aldosterone 
synthesis and release185 -187_ A tubulo- glomerular feedback system exists whereby 
afferent arteriolar tone and glomerular filtration rate responds to distal tubular 
perfusion pressure and sodium delivery and this is modified by altered peritubular Ang 
II concentration188. Ang II has been reported to act centrally causing increased thirst 
and appetite for salt, and release of ACTH, [3- endorphin, prolactin, luteinizing 
hormone and vasopressin189 and act peripherally on presynaptic receptors stimulating 
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Fig 1.4.1 Mechanisms by which RAS activity and Ang 11 generation may elevate BP. 
The pro -mitogenic actions of Ang II, like other growth factors PDGF, FGF -1, 
and TGF3I, may via induction of proto- oncogenes including c -myb, c -myc, c-fos 
and c jun, be partly responsible for the smooth muscle cell hyperplasia occurring in 
myo- intimal proliferation, vascular wall remodeling and left ventricular hypertrophy in 
response to hypertension or endothelial damage192 -198. Following endothelial cell 
injury and denudation by balloon catheterisation in rats, the normal process of smooth 
muscle cell proliferation and migration into the intima was decreased by continuous 
treatment with an ACE inhibitor (ACEI), cilazepri1199 A greater inhibition of 
neointimal thickening seen with an ACEI compared to a calcium antagonist at equi- 
hypotensive doses200. Balloon catheter induced endothelial damage leads to both 
increased medial expression of angiotensinogen mRNA, maximal at one week post 
injury, and the appearance of angiotensinogen mRNA in the neointima of the damaged 
vesse1201. Rat cardiac angiotensinogen gene expression is also seen to increase in non - 
infarcted myocardium following coronary artery ligation202. 
In response to hypertension, smooth muscle cell hypertrophy is seen to 
predominate over hyperplasia in walls of larger conducting vessels. In vitro Ang II 
has been shown to induce hypertrophy but not hyperplasia of cultured, quiescent and 
relatively differentiated, rat thoracic aortic smooth muscle cells (in serum -free medium) 
and this effect was blocked by a specific Ang II antagonist. Ang II did not however 
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potentiate the growth response to 10% fetal bovine serum or partially purified platelet 
derived growth factor203. In a rat model of volume overload cardiac hypertrophy 
where eccentric left ventricular hypertrophy (LVH), right ventricular hypertrophy 
(RVH) and LV dilatation occurred, such changes were inhibited by losartan (Ang II 
antagonist) but not by enalapril at 28 days post- surgery, despite similar cardiac and 
peripheral haemodynamics at 7 and 28 days2°4. This implicated Ang II, though the 
lack of effect by the ACEI suggested either incomplete inhibition of myocardial ACE 
or an alternative cardiac converting enzyme which was resistant to enalapril. An 
isoenzyme with converting enzyme activity has recently been isolated from bovine 
myocardium with a smaller MW than either endothelial or testicular ACE and which 
showed an altered amino acid sequence at the amino termina1205. However in a rat 
model of pressure -overload cardiac hypertrophy induced by surgical coarctation, 
enalapril did attenuate the increase in LV /BW ratio by day 15 post- surgery despite 
there being no significant difference in blood pressure proximal to the coarctation 
between treated and control groups206 
The pathological hypertrophy of the myocardium in response to hypertension 
involves both cardiomyocytes and non -myocyte cells, in particular fibroblasts. These 
may contribute to the impaired diastolic relaxation and contractile function with 
reduced ventricular compliance seen with increasing fibrillar collagen content of the 
ventricular wall. Some studies have suggested that circulating Ang II and aldosterone 
may be implicated in this cardiac fibroblast response207, 208. 
Most of the known systemic effects of Ang II appear to be mediated by AT1 
receptors which are G protein coupled with a seven transmembrane domain structure 
and which either activate phospholipase C or inhibit adenylate cyclase. Two isoforms 
have been identified, AT1A and AT1B, with differing tissue distributions167. A second 
receptor (AT2) has been found which is expressed highly in embryonal tissues, 
possibly having a role in vascular growth during development, but in addition it is 
expressed at low levels in adults167. Interestingly low protein feeding in rats has been 
shown to increase the binding of Ang II to isolated glomeruli as a consequence of 
increased receptor number, associated with an increase in AT1 receptor mRNA 
expression as demonstrated by Northern blotting and in situ hybridization in cortex 
and medulla. No change in receptor affinity was reported2°9. A reduced RPF and 
GFR but an increased intra -renal vascular resistance and a fall in PRA occurred in 
response to the low protein diet. Such changes were reversed by ACE inhibitors or 
losartan (a specific AT1 receptor antagonist). 
The classic view of the RAS has been of a circulating endocrine system 
whereby circulating angiotensinogen produced by the liver was cleaved by plasma 
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renin to produce Ang I which was then converted to Ang II on passage through the 
lungs and other vascular beds. Active circulating Ang II was then available to act on 
target tissues and exert its physiological effects. This view has been challenged by the 
increasing amount of evidence suggesting that local RASs are present and operating 
within tissue types in a paracrine fashion and are not dependent on either circulating 
enzyme or substrate levels (reviewed in 210 -213,189) The efficacy of ACE inhibitors 
in 'normal' and 'low' renin essential hypertensives, referring to patients with normal 
or low plasma renin activity has suggested that either ACEI lowered blood pressure by 
methods independent of the RAS or they inhibited ACE and reduced Ang II generation 
within tissues where PRA did not reflect the level of RAS activity214. In the heart, 
adrenal, testes, and brain various investigators have identified the necessary 
components, in particular renin, angiotensinogen and ACE mRNAs215,216,211. Even 
within the kidney, there is evidence for a local RAS217, possibly acting within the 
proximal tubule with both angiotensinogen and renin mRNA reported together with 
ACE activity in the apical brush border159. 
Evidence for a cardiac RAS is more controversia1213,218. Tissue culture 
experiments e.g. stretch induced cardiac hypertrophy in neonatal cardiac myocytes 
was associated with production of Ang II213, though this may not reflect the in vivo 
situation. In rat models of myocardial infarction, left ventricular hypertrophy219 and in 
the LV of aging rats220, up- regulation of cardiac ACE and angiotensinogen mRNA 
levels have been reported, though there may be species variation. However the lack of 
convincing and reproducible demonstrations of renin mRNA in the normal, healthy 
heart has been the missing link for a cardiac RAS138. PCR artifact or non -specific 
hybridization conditions during Northern blot analyses can erroneously identify 
mRNA species (reviewed by 218). The presence of renin in cardiac tissue could reflect 
either in situ synthesis or uptake of circulating renin. Binephrectomy led to the 
disappearance of tissue renin activity suggesting that uptake was the main source, but 
persistence of Ang II in anephric rats particularly in aorta, heart and adrenal did 
suggest that Ang II could be formed by alternative pathways in rats e.g. cathepsin G 
or chymase could cleave Ang I to give Ang II167,205. However in pigs, 30 hours after 
nephrectomy there was no detectable renin, Ang I or Ang II in either plasma or in LV 
tissue suggesting that in the healthy heart, uptake of circulating renin accounted for 
any angiotensin peptides detected in atrial and ventricular tissue221. 
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1.5 The kidney in essential hypertension 
In many primary renal diseases such as glomerulonephritis, pyelonephritis or 
polycystic kidney disease, hypertension is a common finding. What is the role 
however of the kidney in essential hypertension? This question was addressed by 
Luke (1993) in his review222. The three main areas of experimental evidence 
implicating the kidney lie with the ability to transplant hypertension or normotension 
with the kidney84,223, the presence of abnormal renal vascular responses during the 
pre- hypertensive state224, and the association of high sodium chloride intake with 
hypertension in epidemiological studies225,222. The first two points are dependent on 
the assumption that there is no secondary damage to the kidney occurring during the 
pre -hypertensive period when there is no measurable systemic hypertension, but if any 
such damage was present, it might alter the kidney's response to vasoactive agents or 
its ability to excrete a sodium load. The findings of normal exchangeable sodium, 
plasma volume and extracellular fluid (ECF) volume in established essential 
hypertensives are found with an observed right shift and resetting of the pressure - 
natriuresis curve226. Increased sodium intake and/or a degree of sodium retention may 
initially lead to an increase in ECF volume, an increase in cardiac output and GFR but 
no change in peripheral resistance. An initial consequence of this may be increased 
ouabain -like sodium/potassium ATPase inhibitory activity225 and synthesis and 
release of atrial natriuretic peptide (ANP)227,177. A raised intracellular sodium could, 
as a consequence of the reduced sodium gradient result in an increase in cytosolic 
calcium and enhanced smooth muscle contractile activity possibly accompanied by a 
compensatory increased natriuresis induced by ANP. Hence the transition to a state of 
normal ECF volume, normal cardiac output but raised peripheral resistance could 
result, as seen in established essential hypertension. Thereafter adaptive structural 
changes in vessel walls may maintain the elevation in blood pressure228, 229. 
It has also been postulated that altered renal haemodynamics and the renal RAS 
may be central to inducing hypertension even in apparent 'normal' or 'low' renin 
hypertension (reviewed in 224). Laragh (1992) discussed the concept of a sub - 
population of relatively ischaemic nephrons which might show increased renin 
synthesis relative to the basal blood pressure and fail to suppress plasma renin activity 
in response to a stimulus such as a sodium load. There is some pathological evidence 
in favour of this166. Patients with 'normal' renin may in effect show an 
inappropriately high plasma renin activity for their blood pressure. The efficacy of 
ACE inhibitors in apparent low or normal renin essential hypertension supports this 
hypothesis. Lower GFR and RBF in young, pre- hypertensive four week old SHR 
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correlated with higher BP during the development phase of hypertension in eleven 
week old SHR, but not with BP in established hypertension (sixteen weeks old). 
These haemodynamic alterations were shown to be genetically linked to hypertension 
in an SHR/WKY F2 population, and appeared to relate to the higher PRA and greater 
sensitivity to ACE inhibition found in four week old SHR compared to WKY230 
Again in an SHR/WKY F2 population, it was observed on regression analysis that 
afferent arteriolar diameter at seven weeks of age correlated with SBP at twenty -three 
weeks of age (r = -0.36) suggesting that a specific renal pathology was in some way 
responsible for development of genetic hypertension231. 
Stop -flow pressure (SFP) tubuloglomerular feedback responses have indicated 
that physiological increases in renal interstitial Ang II concentration, independent of 
circulating Ang II, enhance tubuloglomerular feedback response sensitivity. A lower 
glomerular capillary pressure is seen at equivalent end proximal tubular fluid flow 
rates in the presence of increased interstitial Ang 11232,188 Therefore any increase in 
single nephron GFR ( SNGFR) is attenuated in the presence of increased interstitial 
Ang II. Together with the Ang II mediated decrease in distal tubular sodium delivery 
(due to proximal tubular sodium reabsorption), this results in a sustained reduction in 
distal tubular sodium delivery. The vasoconstrictor effects on afferent and efferent 
arterioles and on glomerular capillaries (via mesangial cell contraction) act together to 
reduce SNGFR and glomerular plasma flow, and hence further reduce distal tubular 
flow. The actions of aldosterone on the distal tubule form another mechanism by 
which Ang II leads to a sustained reduction in sodium excretion. 
Other authors have argued that the primary renal abnormality initiating essential 
hypertension is a congenital reduction in filtration surface area leading to a limited 
capacity to excrete a sodium load233. Reduced nephron number arising from disease 
or surgery will often give rise to systemic hypertension. In the clinical situation, 
progression of hypertension may well result from a further reduction in nephron 
number as a consequence of glomerular hypertension and progressive hypertensive 
glomerulosclerosis. MHS rats show smaller kidney to body weight ratios compared 
with the MNS from 25 days to 100 days of age234. SHR do not however show a 
statistically significant reduction in nephron number and though slightly lower values 
for the glomerular capillary ultrafiltration coefficient were seen compared with WKY, 
there was no significant difference in filtration surface area or permeability235. SHR 
exhibit a similar ability to exhibit a sodium load236. 
In summary there are a number of reasons to implicate the RAS in essential 
hypertension. The finding of linked polymorphisms of candidate genes for 
components of the RAS to hypertension in both humans and experimental animal 
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models, the known physiological effects of RAS activation leading to elevation in 
blood pressure, the likely involvement of the kidney in hypertension, and the 
subsequent adaptive structural changes that may in part be Ang II dependent has 
directed attention towards this system. It is important to bear in mind that hypertension 
is a polygenic disease and other factors are undoubtedly involved. This interest in the 
RAS in essential and genetic hypertension has therefore led to the application of 
transgenic technology in order to study gene function and regulation in vitro and in 
vivo (reviewed in 237,238). 
1.6 Transgenesis: Materials and Methods 
A transgene may be defined as a gene or gene construct introduced into a 
species by one of a number of methods and following stable chromosomal integration, 
the transgene is transmitted through the germ line by Mendelian inheritance to 
subsequent generations239, 240. For experimental purposes most transgenic animal 
work has been done in mice and more recently in rats. Developments of the 
technology has led to extension of the work into larger animals which has offered 
increased opportunity for both experimental and commercial use241. The effects of 
manipulating an individual gene within a complex system and the subsequent genetic 
and environmental interactions giving rise to the resulting phenotype can then be 
studied in vivo. 
The genetic material forming the transgene construct may consist of DNA from 
either the same species or from a different species. A gene's own promoter sequence 
can be used to direct appropriate tissue specific and temporal expression. Alternatively 
an heterologous promoter can be used to direct expression of a transgene to specific 
tissues, or allow expression to be switched on in response to a defined and controlled 
stimulus. For example the a1- antitrypsin promoter can be used to direct expression 
principally to the liver, thereby resulting in synthesis and secretion of the gene product 
from hepatocytes242. Metallothionein promoters can respond to dietary heavy metals 
mediated by heavy metal sensitive response elements within the promoter sequence. 
These can circumvent problems of transgene expression during foetal development or 
allow the study of the effects of transgene function starting at a defined time point. 
Regulatory elements within promoter sequences of genes can be studied using 
'reporter' gene constructs where a promoter sequence is linked to a gene encoding an 
easily detectable enzyme174,243_ These may be designed to express either a 
conveniently assayable product e.g. the Escherichia coli Lac Z gene codes for 13- 
galactosidase which produces a blue colour on cleavage of the substrate X -gal (5- 
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bromo -4- chloro- 3- indolyl -(3 -D- galactosidase), and the bacterial enzyme 
chloramphenicol- acetyl transferase (CAT) catalyses transfer of an acetyl group from 
acetyl CoA to chloramphenicol and hence promoter driven expression of a CAT 
reporter can be quantified by generation of acetylchloramphenicol244. Other markers 
of gene expression used have included SV40 which by production of T antigen leads 
to tumourigenesis245. Promoter -reporter constructs can then be designed with 
systematic deletions of putative regulatory regions within promoter sequences so 
enabling identification of the specific sequences which are important for determining 
regulation of gene expression (see review 240). 
Fig 1.6.1. 
A 
A Microinjection of a construct into 
4 the pronucleus of a fertilised oocyte. 
at C B Genetically manipulated embryonic 
stem cells are created by homologous 
recombination or random integration 
and injected into a blastocyst. 
C Retroviral infection of a four cell 
embryo. 
D Retroviral infection of an embryo. 
Embryos are then returned to pseudo - 
pregnant females. 
D 
Fig 1.6.1 Methods used for introduction of genetic material into the genome of the mouse. 
Genetic material can be introduced by a number of methods which are 
summarised in Fig 1.6.1. Direct microinjection of DNA into the pronucleus of 
fertilised one cell embryos will be discussed in more detail below. Retroviral infection 
of 4 -cell and later stage embryos is followed by re- implantation into a pseudo -pregnant 
foster mother. More recently techniques for inhibiting or abolishing endogenous gene 
function have been developed. Selective inactivation or mutation of a targeted gene can 
be performed in vitro by homologous recombination in embryonic stem (ES) 
cells246,247 (reviewed in 248). The gene of interest is interrupted by the introduction 
of a homologous sequence carrying a selectable marker, usually sequences which 
confer antibiotic resistance. Genetically altered ES cells carrying the mutation are then 
selected for by resistance to the relevant antibiotic e.g. neomycin, in culture and are 
then introduced into a blastocyst. Resulting progeny will be chimaeric with coat colour 
28 
being used to identify the relevant ES cell origin and confirm germ -line transmission 
of the mutated gene in subsequent generations. Gene knock -out technology and 
phenotype analysis is limited at present by the ability to culture ES cells only in certain 
strains of mice. Targeted disruption can be lethal during embryogenesis, but results of 
such studies are identifying new roles for some genes in development and apparent 
functional redundancy of others249-252. 
Partial loss of gene function can be achieved by introducing genes which 
produce high levels of antisense RNA which may interfere with pre -mRNA transport 
or hybridize to the target mRNA and interfere with splicing and translation. Inducible 
promoters have been used with some success in plants allowing some control over 
antisense mRNA production. Improved efficiency with this technique is being 
attempted by using antisense RNA with catalytic properties or ribozymes to cleave the 
target mRNA at lower concentrations (see review 253) 
The effects of varying the copy number of a gene on a quantitative trait such as 
blood pressure has become a technical possibility with the report of one -copy (by 
targeted disruption), two -copy (wild -type) or three copy (by targeted tandem 
duplication) angiotensinogen gene mice who showed alterations in plasma 
angiotensinogen level, but BP was not measured254. However transgene copy number 
simply resulting from random integration following microinjection as detailed below 
has not been shown to correlate well with transgene expression255. 
Production of transgenic animals by microinjection 
To obtain a maximal number of donor oocytes for microinjection, 
superovulation is necessary, aiming for a two to three fold increase in the number 
retrieved. This is achieved in mice by an intraperitoneal dose of pregnant mare serum 
gonadotrophin (PMSG), containing both follicle stimulating hormone (FSH) and 
luteinising hormone (LH) activity on Day -2 and human chorionic gonadotrophin 
(hCG) on Day 0, following which the females are placed with fertile males for 
mating239,256_ Modification of this was found to be necessary in rats, who required 
continuous infusion of purified pig pituitary FSH administered by osmotic minipump 
subcutaneously for 50 hours prior to an intraperitoneal dose of hCG to induce 
superovulation257. 
The fertilized eggs are then removed, separated from surrounding cumulus 
cells by enzymatic digestion with hyaluronidase and maintained in culture medium in a 
CO2 incubator. When the pronucleii are visible, microinjection of the DNA construct 
(1 tg/m1) is performed using a glass holding pipette and microinjection needle ( <1 tm 
diameter) and approximately 2 pl of DNA solution is introduced, usually into the 
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larger male pronucleus. Fertilized eggs surviving this process are reimplanted into the 
oviducts of pseudopregnant females (mated with vasectomized males) and a variable 
proportion of the progeny born will then carry the transgene258. 
The transgene exists in the form of concatamers of DNA and randomly 
integrates into the genome of the recipient. Integration is tested by Southern blot 
hybridization and analysis of tail DNA from the resulting progeny using a transgene 
specific sequence as the probe or alternatively by polymerase chain reaction (PCR) 
using transgene specific sequences for primers. Multiple integration events can occur 
and this can be assessed by diagnostic Southern blot hybridization. Integration may 
disrupt endogenous gene sequences or function, and hence any phenotype observed in 
transgene positive (TG +) animals must arise in more than one TG+ littermate to be 
certain that an insertional mutagenic effect is not responsible259. In situations where 
insertional mutagenesis may have led to a phenotype, sequencing of the flanking 
regions around the integration site using the transgene DNA as a template for a probe, 
may lead to identification of endogenous genes that have undergone sequence 
rearrangement and are responsible for the new phenotype2 °. 
Expression of the transgene is then assessed by detecting mRNA by Northern 
blot analysis and in situ hybridization determining both tissue distribution and 
temporal patterns of expression. The protein product or other intermediate phenotype 
can be quantified and the resulting phenotype characterized. Breeding strategies can be 
developed to obtain animals homozygous for the transgene, segregate multiple 
insertion events or by crossing with a different transgenic line a new transgene can be 
introduced to create a double transgenic261. The species into which the transgene is 
introduced may directly influence transgene expression. For example strain specific 
modifiers may affect transgene methylation and hence expression and phenotype262. 
1.7 Studying thé Renin -Angiotensin system using transgenesis. 
As described above, two distinct renin genes were identified and subsequently 
cloned from the DBA/2 mouse129, with Ren -2 lying upstream of Ren -1 producing a 
non -glycosylated thermolabile renin isozyme that appeared to have no effect on blood 
pressure263. In order to assess the physiological role and identify regulatory 
sequences of renin genes in mice, various transgenic mice have been made. Ren -1 c 
mice transgenic for 'the Ren -ld gene showed appropriate tissue -specific expression2M, 
and suppression of transgene expression in the kidney in response to dietary sodium 
loading suggesting that the Ren -ld transgene construct contained the appropriate 
regulatory sequences2M. 
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A 24 kb Xho I genomic fragment containing the Ren -2 gene with 5.3 kb and 
9.5 kb of 5' and 3' flanking sequence respectively was microinjected into fertilized 
pronucleii of one renin gene mice, homozygous for Ren-1c265. This almost 
recapitulated the situation found in two renin gene mice, but for the presence of the 
Ren -lc allele in place of Ren -ld. Expression of the Ren -2 transgene was qualitatively 
similar to endogenous Ren -2 expression in DBA/2 mice, with appropriate tissue 
specific and cell specific expression. Expression of the transgene was relatively higher 
in female adrenal glands, but lower in the SMG and kidney with levels approaching 
only 5 -10% of those seen in the wild -type. Expression in female SMG was barely 
detectable but was induced appropriately to levels equivalent to those found in males 
by testosterone. The main difference between Ren -2 transgene expression in 
transgenics and Ren -2 in DBA/2 was the high constitutive expression of the transgene 
in the X -zone of the adrenal without an oestrus cycle dependent variation, compared 
with the normal cycling of expression seen between the zona fasciculata and X- 
zone266. This suggested that a further DBA/2 dependent trans acting factor was 
necessary for such hormonal regulation in expression or certain cis acting elements 
were not included in the microinjected construct. In a similar experiment a genomic 
fragment containing the same Ren -2d gene with only 2.5 and 3 Kb of 5' and 3' 
flanking sequence respectively was introduced into one renin gene mice of a different 
genetic background. In male transgenics, wild -type levels of Ren -2d transgene 
expression were achieved. In females relatively lower expression was seen in SMG 
and kidney but this responded to testosterone with increased expression255. Adrenal 
gland expression levels were not reported in this study. The genetic background of the 
recipient strain or the reduced length of flanking sequence in the construct may explain 
the disparity of observed transgene expression between the two studies. 
TGR(mREN2)27 
The 24 kb Xho -1 fragment of mouse genomic DNA containing the Ren -2d 
gene as described above265 was microinjected into fertilised oocytes (F1 embryos of a 
Sprague -Dawley /WKY cross). Thirty -seven eggs were re- implanted and eight 
progeny were delivered. Five were transgene positive (TG +) by Southern blot, of 
which three (founders #25, #26, and #27) transmitted the transgene to the next 
generation. Four of the five TG+ founders were found to be hypertensive with 
SBP >200 mmHg by ten weeks of age confirming a transgene position- independent 
phenotype267. The normotensive TG+ founder #26 was found to be mosaic for the 
transgene however, inheritance of the transgene in her offspring was associated with 
blood pressure elevation comparable to the other positive founders. Significant 
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hypertension persisted in subsequent generations in two lines, #26 and #27268, 
though male infertility in line #26, a probable consequence of transgene insertional 
mutagenesis, has prevented the subsequent generation of homozygotes in this line. 
The line TGR(mREN2)27 as derived from founder #27 has now been the subject of 
extensive investigation. 
Serial measurements of SBP by tail cuff plethysmography of TGR(mREN2)27 
rats (hemizygous for the transgene) showed an increasing blood pressure with age, 
attaining a plateau at nine to ten weeks. Initial characterization of the phenotype 
showed high plasma prorenin, and elevated adrenal tissue renin content267. 
Adrenalectomy with maintenance therapy of oral NaC1 resulted in a fall in plasma 
prorenin to transgene negative (TG -) levels together with a fall in SBP suggesting that 
the adrenal was the principal source of the high circulating prorenin269. In situ 
hybridization and immunohistochemistry of adrenal gland showed both over - 
expression of the mouse Ren -2 transgene and renin protein to be principally in the 
zona glomerulosa and outer zona fasciculata. Northern blot and ribonuclease (RNase) 
protection assays also identified high transgene mRNA transcripts in the adrenal, 
-2500 fold higher than endogenous rat renin gene expression, and between 10 and 
500 fold higher expression in this tissue compared with any other tissues assayed270. 
Expression of the transgene in adrenal tissue, as shown by Ren -2 mRNA levels was 
high from birth and progressively increased with age271. 
Transgene expression in the kidney however, was highest at birth and 
decreased markedly at two to four weeks of age with further reductions occurring with 
developing hypertension. A similar profile was seen for endogenous rat renin 
expression with evident suppression in adult TGR compared to SD controls271. 
Suppressed kidney tissue renin and PRA was seen in TG+ compared to TO- 
littermates267. 
Detectable transcripts were also found in brain (cortex/septum), pituitary, 
aorta, mesenteric vessels, lung, testes, ovary, coagulation gland, thymus, small 
intestine, stomach and uterus, all being sites of normal Ren -2 expression in the 
mouse. However, Ren -2 expression was not found in the rat SMG gland suggesting 
an absence of necessary trans acting factors. Other notable sites of absent expression 
as determined by Northern hybridization included liver, heart, parotid gland, spleen 
and cerebellum270. Others have reported Ren -2 mRNA in the heart by RNase 
protection assay at the limits of detection271. In TG- controls, using a Ren -2 derived 
probe that hybridized to rat renin mRNA, endogenous rat renin gene expression has 
been only detected in kidney270, but others have reported low levels of expression in 
adrenal, brain, pituitary and thyroid by RNase protection assay271. 
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The underlying cause of hypertension in the TGR(mREN2)27 rat line is yet to 
be clarified. Interest has focused on the adrenal gland in view of the high transgene 
expression and concomitant elevation of adrenal tissue renin and prorenin which were 
predominantly transgene derived, while renal tissue renin and plasma renin reportedly 
remained suppressed272,273. In association with the elevated adrenal transgene 
expression, mineralocorticoid levels were altered with increased 24 hour urinary 
excretion rates for 18 -OH cortisol, deoxycorticosterone (DOC) and aldosterone in 
TG+ rats from six to eighteen weeks of age, but not at thirty weeks, compared with 
age matched SD rats. Conflicting results were found for plasma measurements with 
decreased DOC, in both transgenic homozygotes and hemizygotes compared to SD 
controls while plasma corticosterone levels were similar in SD and transgenic 
homozygotes but were significantly elevated in hemizygotes. No significant 
differences were observed for either plasma sodium or potassium levels in the three 
groups274. Electron microscopy of adrenal tissue has revealed evidence of cholesterol 
accumulation in zona glomerulosa (ZG) cells. Studies on dispersed ZG cells from 
female transgenics showed a higher basal aldosterone secretion compared to cells from 
SD rats, but no difference between transgenics and controls in the net increase in 
aldosterone release in response to either Ang II or ACTH (adrenocorticotrophic 
hormone) stimulation was found275. 
An increase in active renin release, from cultured adrenal cells from transgenic 
rats was seen in response to both Ang II and raised intracellular Cat+ 
273. Such 
mediators would normally be expected to elicit a negative feedback response on the 
kidney, suggesting that the normal negative feedback control does not operate on 
cultured adrenal cells derived from TG+ animals. Prorenin release in vivo was clearly 
stimulated by ACTH with a 10 -fold rise in plasma levels compared with only a 4 -fold 
rise in non -transgenics. However plasma renin concentration remained unaffected or 
fell respectively274. If transgene expression in the adrenal does lead to deranged 
mineralocorticoid synthesis and metabolism, it seems unlikely that it is the sole factor 
inducing hypertension as spironolactone therapy did not lower blood pressure or 
prevent the development of high blood pressure in TG+ rats despite treatment leading 
to an elevation of plasma renin concentration in both SD and TG+ animals276,274 
Measurement of free intracellular sodium in intact lymphocytes from 
TGR(mREN2)27 using a sodium sensitive fluorescent dye method showed an 
increase relative to SD. This appeared to be secondary to reduced Na + -K +ATPase 
activity measured in erythrocytes, which also argued against a mineralocorticoid 
mediated effect277. It was not however established in this paper as to whether the 
animals studied had established hypertension or were pre- hypertensive. 
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Dexamethasone suppression of pre- hypertensive TGR(mREN2)27 did attenuate the 
BP rise, with a concomitant rise in mineralocorticoid levels, but a fall in plasma 
glucocorticoids (D. Ganten, unpublished observations)278. 
No evidence of increased insulin resistance in TGR(mREN2)27 hemizygotes 
has been demonstrated as shown by similar fasting plasma glucose and insulin levels 
together with equivalent fasting rates of hepatic glucose production and glucose 
utilization during a hyperinsulinaemic euglycaemic clamp279. 
The blood pressure lowering effects of both ACE inhibitors and Ang II 
antagonists in TGR(mREN2)27 have argued in favour of an Ang II dependent 
hypertension with salt/volume sensitivity280- 283,276. Even within the kidney, studies 
have suggested that an inappropriately high Ang II level may modify tubulo- 
glomerular feedback responsiveness in Ren -2 transgenic rats284. While some groups, 
as outlined above, have reported suppression of plasma renin levels, an elevation in 
PRC and Ang II have also been reported in TGR(mREN2)27 rats compared to SD 
controls on a normal (0.1% Na) diet285. Possible explanations for discrepancies 
include the method of blood collection, use of anaesthesia, storage of blood or method 
for assay161 Nephrectomy in TGR resulted in an increase in PRC, in contrast to the 
fall to near -undetectable levels seen in SD suggesting mainly extra -renal sources of 
renin in TGR. Additional adrenalectomy blunted the rise by -50% implicating the 
gland as the major but not sole source of plasma renin285. A fall in PRA and Ang II 
followed ovariectomy but no change in prorenin levels were observed. A concomitant 
fall in transcription of both the Ren -2 gene and endogenous rRen in the kidney argued 
in favour of an ovarian hormone dependent regulation of gene transcription or a role 
for the ovary in conversion of prorenin to renin in TGR286. 
The finding of Ren -2 transcripts in vascular tissue together with the 
observation that a perfused isolated rat hind -limb preparation demonstrated increased 
release of both Ang I and Ang II in transgenics compared to SD has suggested that a 
major source may be the vascular wall. Bilateral nephrectomy prior to perfusion 
reduced angiotensin peptide release from SD, but not from TGR supporting a non - 
renal origin for the derived vascular wall renin in TGR287. 
The kinetics of the reaction of mouse renin acting on rat angiotensinogen have 
been studied and show a different pH optimum for the reaction when compared with 
endogenous rat renin acting on homologous substrate. The speed of reaction for 
mouse renin cleaving rat angiotensinogen was ten -fold higher than for the cleavage of 
mouse angiotensinogen, which appears to be due to the relative lack of substrate in the 
mouse 288. In view of evidence suggesting that most circulating renin in 
TGR(mREN2)27 is transgene derived288, this could explain an Ang II dependent 
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hypertension without a significant elevation of PRA, but the physiological significance 
of these in vitro findings need to be investigated further in an in vivo situation. 
Initial comment on this transgenic rat suggested that it was a model of low 
plasma renin hypertension, with the implication that either disturbed adrenal 
mineralocorticoid or glucocorticoid regulation resulting from an overactive adrenal 
RAS or elevated prorenin might be responsible for the hypertension289. Further work 
has not clarified the issue, but the studies described above would support the 
suggestion that tissue (extra -renal) RAS activity is leading to an Ang II dependent 
hypertension. Much of the controversy may be a consequence of the methodological 
problems that exist in measurement of PRA and angiotensin peptides, but the relative 
lack of suppression of PRA, Ang I and Ang II as first described by Mullins et al 
(1990)267 despite the very elevated BP is a hint of the likely involvement of the RAS. 
Pathological changes of hypertension related target organ damage in transgenic 
heterozygotes were more apparent in males than females and developed from 4 -6 
months of age. These included progressive medial thickening in resistance arteries and 
arterioles. Thickness of the aortic wall was also increased, in particular the tunica 
media with disruption and formation of additional layers of elastic laminae. Hearts 
showed development of left ventricular hypertrophy (LVH) with thickening of the 
media of myocardial arterioles and perivascular fibrosis290. In the kidneys, vascular 
changes were prominent from four to six months of age, but fibrinoid necrosis was 
not described. Glomerulosclerosis, in some cases progressing to end -stage sclerosis, 
with areas of focal tubular atrophy were seen from six to eight months of age 
indicative of chronic hypertensive and ischaemic damage269. Increased proteinuria 
was found in 400g TGR (approximately four month old) compared to age -matched 
SD, which is a likely consequence of early glomerular damage291 ,278_ 
In summary the TGR(mREN2)27 rat line has provided an interesting model of 
monogenic hypertension which has led to further work being directed towards 
developing a better understanding of renin gene regulation and function, and the 
development of strategies for ascertaining the relative contributions of prorenin, the 
adrenal gland, tissue RAS activity and species specific enzyme kinetics towards the 
hypertensive phenotype. Other transgenic models utilising other components of the 
RAS have been developed and have helped contribute to the overall picture. These will 
be described in brief below and are summarised in Table 1.7.1 
Transgenic mice have been generated that carry the rat angiotensinogen gene as 
a genomic fragment with 1.6 kb of 5' flanking sequence. Four founders were 
generated, of which three transmitted the transgene to their progeny. Expression of the 
transgene was high in the liver in one founder together with elevated plasma 
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angiotensinogen and Ang II. Significant elevation of SBP was found in the high 
expressor line, but not in a low expressor line292. A similar experiment involved 
microinjection of constructs comprised of a mouse metallothionein I (MT -1) promoter 
fused to the rat angiotensinogen gene or rat renin gene, with the aim of a controlled 
induction of transgene expression by administration of zinc in the drinking water. 
Table 1.7.1- Transgenic studies of the Renin -Angiotensin system 
Trans:ene Species BP Reference 
Mouse Ren -1 d Mouse ..4 141 
Mouse Ren -2 Mouse 265 
Mouse Ren -2 Rat T 267 
Rat angiotensinogen Mouse T 292 
MT -1 Rat angiotensinogen Mouse - 293 
MT -1 Rat renin Mouse 293 
Human renin Mouse - 294, 295 
Human angiotensinogen Mouse _> 294 
Human renin Rat _> 296 
Human angiotensinogen Rat -> 296 
Summarises published transgenic experiments in rodents using renin and angiotensinogen constructs 
and their effects on measured blood pressure. (MT -1 = metallothionein promoter). 
In contrast to the previous study, hypertension was not induced on expression 
of either transgene alone, but by crossing transgene positive mice to give double 
transgenics, hypertension was induced293. The species specificity of the cleavage 
reaction alluded to earlier, may well be responsible for the absent phenotype in the 
MT -1 rat renin transgenics, as it had been previously demonstrated that mouse 
angiotensinogen was resistant to cleavage by renin from other species including rat, 
hamster, rabbit, pig and human297,169. Therefore as expected mice transgenic for the 
human renin gene were neither hypertensive nor had an elevated PRA295. When they 
were crossed with mice transgenic for human angiotensinogen, resulting in double 
transgenic mice with coexistent human renin and substrate for cleavage, an elevated 
BP was observed. The resultant hypertension could be lowered by a specific human 
renin inhibitor (ES 8891), which had no effect on BP in non -transgenic mice, 
transgenic mice when carrying the human renin gene (TGM(hREN)) alone or human 
angiotensinogen genes (TGM(hAOGEN)) alone. In contrast, both ACE inhibition and 
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Ang H antagonists lowered BP in both the single and double transgenics and in non- 
transgenics294. 
The relative suitability of rats for physiological and pharmacological studies 
compared to mice has been a major incentive for developing transgenic lines despite 
the relative technical difficulties mentioned earlier. Rats transgenic for a genomic 
fragment containing human renin (TGR(hREN)) show elevated plasma human renin to 
levels -12 fold higher than found in normal human plasma but no change in 
endogenous rat renin levels were found. Other parameters of the rat RAS e.g. 
prorenin, Ang II and angiotensinogen remained unchanged and systolic blood 
pressure was normal suggesting that there was no evidence of human renin cleaving 
rat angiotensinogen to produce Ang II or a hypertensive phenotype and there was no 
evidence of feedback inhibition on the endogenous rat RAS. Appropriate increases of 
both endogenous rat renin and human renin occurred on salt depletion suggesting that 
the required regulatory regions of the transgene were present. Transgenic rats carrying 
human angiotensinogen TGR(hAOGEN) exhibited levels of human angiotensinogen 
ranging from 2 to 8 fold higher than found in normal human plasma, but again the rat 
RAS parameters were unaffected. No evidence of cross -species enzyme- substrate 
interactions were found using specific human renin inhibitors, which could only 
inhibit the hypertensive response elicited by infusion of human renin but not rat renin 
into TGR(hAOGEN). Surprisingly double transgenics TGR(hREN X hAOGEN) did 
not develop spontaneous hypertension296. In an experiment using a different approach 
whereby the human renin gene was introduced and expressed in rat liver, following an 
in vivo gene transfer method utilising HVJ- liposomes (Haemagglutinating Virus of 
Japan or Sendai virus), elevation of blood pressure was found. This correlated with 
plasma human active renin levels and did respond to a specific human renin 
antagonist298. 
Recently the first study of targeted inactivation of a component of the RAS was 
published. Mice were made hypotensive and deficient in angiotensinogen by 
homologous recombination. It was found that BP was significantly lower in 
homozygous mutaras ( -/ -) who had no detectable plasma angiotensinogen, while 
heterozygotes ( + / -) had in fact a slightly higher level of plasma angiotensinogen 
relative to wild type ( +1 +) mice and no significant change in BP299. This may be due 
to an altered feedback effect. 
An alternative transgenic experiment targeted production of the oncogenic T 
antigen protein to renin producing cells by using a construct comprised of the SV40 T 
antigen reporter with a promoter consisting of Ren -2 5' regulatory sequences. 
Expression of the construct in TG+ mice resulted in neoplastic transformation of 
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renin- expressing cells in SMG, adrenal gland, testes, and sub -cutaneous tissue. In 
kidney tissue either tumours developed or ischaemic features appeared with evidence 
of proliferation of smooth muscle cells in both medial and intimal layers of arterial 
walls, affecting in particular the interlobar, arcuate, and interlobular arteries and 
afferent arterioles resulting in luminal narrowing. In addition changes were seen in 
glomeruli with some evidence of cellular hyperplasia within the mesangial stalk. Such 
changes were found in four independent transgenic lines. Despite the afferent vascular 
pathology, both PRA and renal renin content were significantly reduced in TG+ mice, 
together with reduced expression of the endogenous renin gene Ren -le. This 
inhibition of endogenous renin synthesis did not seem to be a function of Ang II 
mediated feedback inhibition245,300. An important finding from this study was the 
identification of the extent to which smooth muscle cells within the renal vascular tree 
have the capacity to synthesize renin, with the caveat that transformation of them had 
occurred. It has also allowed study of the physiological effects of inducing a primary 
renal vascular hyperplasia in the absence of hypertension. 
1.8 Malignant phase hypertension 
Malignant or accelerated phase hypertension classically presents with a rapidly 
rising blood pressure and deteriorating renal function. The term 'accelerated phase' 
was traditionally applied to patients with grade III hypertensive retinopathy (retinal 
haemorrhages and exudates) while 'malignant phase' hypertension was reserved for 
those who had grade IV retinopathy with papilloedema301,302. In the light of present 
knowledge regarding the underlying renal pathology in both situations, and with no 
clear distinction between them in terms of survival, such a demarcation is probably not 
warranted303 -305 and therefore in this thesis, the term malignant phase hypertension 
(MH) will be applied to the syndrome of clinical and pathological features observed 
with either Grade III or IV retinopathy. 
Typical clinical features that have been described include headache, dizziness, 
visual blurring and central scotomata, fatigue, weight loss and nocturia of varying 
duration prior to diagnosis. Many patients however remained asymptomatic306,302 
No specific symptoms indicative of impending MH have been described. Additional 
signs and symptoms resulting from renal impairment and hypertensive encephalopathy 
included nausea, vomiting, confusion, somnolence, focal neurological signs, ataxia 
and occipital blindness. Chest pain, orthopnea and exertional dyspnoea were 
frequently described in the presenting histories from an early series301 
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The incidence of MH as a complication of hypertension was difficult to 
ascertain in early studies as there was no clear data on the prevalence of benign 
hypertension in the population, and assumptions had to be made from population 
based studies 14. Referrals of patients with MH to hospitals whose catchment areas 
could be estimated, then gave an incidence of about 1% across the complete age 
range306 Few further estimates have been made, but it was recognised that the 
incidence declined considerably in the early 1970s, particularly when occurring as a 
complication of essential hypertension307. Yaqoob et al (1991) reported eleven cases 
referred to a regional renal unit catering for a population of two million which 
suggested an incidence of MH with significant renal impairment amongst their 
hypertensive population of about 0.004 %308 though this is probably an underestimate 
as patients managed outwith the specified unit or those whom perhaps did not develop 
significant renal impairment would have been excluded. 
The underlying cause of hypertension was relevant with a relatively smaller 
decline in incidence of MH as a complication of secondary forms of hypertension 
being reported307. Classification of Kincaid -Smith's series of 124 MH patients 
presenting from 1935 - 1955 showed that essential hypertension was the underlying 
cause in 42 %, while renal artery stenosis only accounted for 3 %306 Other studies 
have shown a similar contribution from essential hypertensives (38 %), but up to 26% 
of cases were secondary to renal artery stenosis, and 25% due to renal parenchymal 
disease307. Overall the incidence of MH as a complication of essential hypertension 
has declined and now accounts for at most 10% of all cases309 This may be a 
consequence of increased treatment options for managing essential hypertension 
resulting in fewer refractory cases. 
It was noted that relatively younger patients tended to be affected with the 
highest incidence of MH reported in the forty to fifty year age group with a falling 
incidence in older age groups representing a leftward shift of the age -distribution curve 
for MH as compared to that for hypertension in the population301,306. Though not 
significant, there was a suggestion that MH occurring in much younger patients tended 
to be due to renal parenchymal disease or chronic pyelonephritis, while renovascular 
causes were found in older men. The age range for essential hypertension complicated 
by MH was midway between. Increased susceptibility has been observed in blacks, 
though this may be a function of social factors leading to delayed diagnosis and 
management of underlying hypertension310 -313 or it may be due to underlying genetic 
differences. 
Prognosis was extremely poor in early series with two year survivals of 
untreated MH ranging from 5 -10 %301,306. This compared with a five year survival of 
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untreated mild essential hypertension of >97 %. Even early methods of treatment, 
consisting of sympathectomy, adrenalectomy or nephrectomy314, reportedly improved 
this two year survival, and a series of studies of treated MH from 1957 -1973 showed 
five year survivals ranging from 25 to 50% 311,302 and in 1986, five year survivals of 
75% were reported in series of white patients315,304 
The early reports of MH by Keith et al (1928) and Klemperer and Otani (1930) 
described the natural history of the condition without treatment. No marked 
macroscopic changes of the kidneys were seen apart from petechial haemorrhages over 
the cortical surface in occasional cases. The main renal findings were at the 
microscopic level, with diffuse changes affecting smaller arteries and arterioles, but 
sparing larger arteries. In particular, intimai hyperplasia with deposits of 'lipoids, fatty 
acids and calcium' were seen resulting in significant luminal narrowing301 In all cases 
renal involvement was apparent and profound, but lesions of varying severity were 
found in all other organs examined. Pathological examination of a further series of 
cases described, in addition to the dominant arteriolar changes, some degree of 
glomerular capillary tuft collapse, capillary thrombosis, glomerulosclerosis, evidence 
of some crescent formation, and tubular dilatation with occasional casts316. 
More recent studies have documented the light microscopic changes in 
considerable detail. Necrosis of medial smooth muscle cells, with loss of nuclei and 
deposition of fibrin was seen together with swelling of overlying endothelial cells and 
nuclear pyknosis. Luminal narrowing and thrombosis was seen, but the generally 
patchy nature of these changes was apparent. Intimal cellular hyperplasia more often 
affected afferent arterioles and was a lesser feature in interlobular arteries306,317. Light 
microscopic studies of affected kidneys showed that smooth muscle cells were 
responsible for the characteristic 'onion skinning' intimal proliferation, with concentric 
lamellae of basement membrane and granulofilamentous material and a thin layer of 
hypertrophic medial cells stretched around the circumference. Insudative lesions 
consisted of deposited granular protein within a pre -existent connective tissue matrix, 
though fibrin filaments were not typically found in the intramural lesions. 
Electron microscopy showed that fibrinoid necrosis consisted of three 
components, fibrin, fibrinoid and cellular necrosis. Fibrinoid tended to be relatively 
electron dense and either granular or foamy, lacking the fibrillar structure of true 
fibrin. Cellular necrosis was not consistently present in all areas, and often fibrin and 
fibrinoid would be found lying between an intact endothelial layer and viable intimal 
and medial cells. Necrosis of individual muscle fibres were seen with occasional 
neutrophils. Arterial luminal thromboses consisted of both fibrin and platelets3l7 -320. 
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Affected glomeruli characteristically showed thickened basement membranes, 
with reduplication of an inner basement membrane in severe cases and relative 
shrinkage of the glomerular tuft. Occasionally in association with a necrotizing lesion 
of the afferent arteriole fibronecrotic, haemorrhagic or glomerulitic lesions were seen. 
The latter was typified by the presence of neutrophils within the glomerular capillaries, 
fibrin in Bowman's space and a glomerular epithelial proliferative response leading to 
crescent formation. Swelling and detachment of endothelial cells was seen. 
Hyperplasia and hypergranularity of the juxta -glomerular cells is 
reported318,319,321,155 
It was observed that lesions occurring in blacks with MH tended towards a 
myointimal proliferative response in arterioles with marked hyalinization rather than 
fibrinoid necrosis. Likewise glomerular fibrinoid necrosis and proliferative changes 
were not common, though thickening of basement membranes, tuft collapse and 
deposition of eosinophilic material inside Bowman's capsular basement membrane 
were seen322. 
Other organs are affected to varying extents by MH. Post -mortem studies, 
radiological and echocardiographic studies have shown that the degree of cardiac 
hypertrophy is more dependent on the duration of antecedent hypertension rather than 
the severity of hypertension in MH301,323. Even with no evidence of LVH, patients 
may present with pulmonary oedema showing left ventricular functional abnormalities 
with impaired diastolic relaxation, abnormal filling and incoordinate systolic 
contraction despite normal cavity dimensions and ejection fractions. Left atrial 
enlargement was relatively more common than that found in benign hypertension, 
particularly in MH patients without a previous history of hypertension, suggesting that 
an inadequate time for adaptive processes to occur was responsible. Such functional 
changes were not completely reversible following treatment to lower BP323. Fibrinoid 
necrosis and vascular alterations have been observed in varying tissues including 
mesenteric arterioles, liver, spleen, pancreas, adrenals, cardiac vessels, brain and of 
course the retina though they remain most florid in the kidney 301,316,324,314,325. 
Why does a situation of previously stable but elevated blood pressure 
transform to a situation where there is an accelerating rise in BP with a rapid 
deterioration in renal function, characterized by the described pathological changes. 
Volhard and Fahr described in 1914, a form of arteriosclerosis with inflammatory 
renal changes, thought to be responsible for a 'Kombinationsform' or malignant form 
of hypertension, and they postulated that a toxic factor superimposed on the 
atherosclerosis of small vessels was responsible for the clinical and pathological 
presentation. It was later suggested by the same authors that an ischaemic aetiology, 
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possibly prolonged vascular spasm, was occurring though it was apparent that 
inflammatory aetiologies could give rise to similar clinical presentations (reviewed in 
316) Sanerkin (1971) reviewed the evidence in favour of ischaemic or obliterative 
arteriolar spasm accounting for arteriolar and endothelial necrosis. Combined medial 
and intimai necrosis with intraluminal thrombosis was thought to result from an 
obliterative spasm lasting over three hours with failed reflow. Fibrinoid change 
occurred from continued seepage of plasma proteins through the necrotic vascular wall 
into viable surrounding tissue leading to the progressive eosinophilic change on light 
microscopy. Medial necrosis with preservation of endothelium could follow an 
obliterative spasm of a lesser duration. It was therefore suggested that the overall 
picture was of recurrent obliterative spasm affecting different groups of vessels317. 
It has been argued that exudative lesions may simply be a function of high 
blood pressure. The commonest precipitating factor in chronic essential hypertension 
has been said to be a sudden rise in BP, often due to sudden withdrawal from anti- 
hypertensive medication302,313. Other drug induced causes have included oestrogen 
containing oral contraceptives326,327, corticosteroids, non -steroidal anti- inflammatory 
drugs, sympathomimetics, tricyclic antidepressants328, ingestion of catecholamine 
precursors while on monoamine oxidase inhibitors and even the use of a non -selective 
(3- antagonist in the context of a high circulating adrenalin during hypoglycaemia329, all 
of which could acutely elevate BP. Secondary causes of hypertension, particularly 
those associated with labile BP are associated such as phaeochromocytoma, renin 
secreting tumours, and eclampsia302 
It was observed that rapid resolution of the retinopathy occurred if blood 
pressure was reduced, though not necessarily to normotensive levels314 Protection of 
the kidney from the effects of high pressure from whatever cause, can occur naturally 
by virtue of a proximal renal artery stenosis. The expected pathological changes were 
not observed in the kidney distal to a stenosis while the contralateral kidney exposed to 
systemic hypertension showed fibrinoid damage330 Commencing anti -hypertensive 
medication prior to renal biopsy in MH resulted in altered histology with 
disappearance of fibrin deposits within three to four days, less evidence of necrosis, 
and thus more emphasis on intimai smooth muscle hyperplasia, variable tubular 
atrophy, and interstitial fibrosis318,309. These studies suggest that a loss of reno- 
vascular auto -regulation might well be important in the pathogenesis of transition to 
MH. 
A possible role for inflammatory mechanisms in the initiation or triggering of 
MH is supported by the similarities observed between observed pathology in MH and 
certain clinical conditions with an obvious immune aetiology. Examples include 
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scleroderma, the vasculitides, haemolytic -uraemic syndrome and renal transplant 
rejection with renal lesions often developing in normotensive individuals331,332 
Immunological parameters have been studied and an excess of HLA Bw35 and linked 
Cw4 was found amongst a mixed group of patients with MH compared to healthy 
blood donors, but this excess was not statistically greater than the small excess also 
found in patients with glomerulonephritis but without MH333 A small excess in HLA 
B -15 was observed in patients with a previous history of grade IV retinopathy, but 
this did not reach statistical significance (p= 0.088)334 A higher percentage of MH 
patients had auto -antibodies compared to controls. Lymphocyte stimulation tests using 
arterial antigen indicated an increased T cell response and significantly elevated IgG 
and IgM, but not IgA levels in MH patients335 Whether these changes are primary or 
secondary to the vascular damage was not clear from these retrospective studies. 
Smoking has been linked with an increased risk of developing MH, more 
advanced retinopathy, a greater risk of developing renal failure and a poorer 
prognosis336 -338. It has been suggested that smoking may promote platelet 
aggregation, luminal thrombosis and hence endothelial damage. 
Following initiation of MH, there is good evidence supporting a role for the 
RAS in maintaining the vicious circle of accelerating blood pressure, renal impairment 
and pathological damage (reviewed in 339,340) A pressure induced diuresis and 
natriuresis could create a state of relative sodium depletion, thus activating the RAS. 
The afferent vascular pathology may result in a further stimulation of renin synthesis 
and secretion suggested by observed hyperplasia of the renin containing cells of the 
JGA155 Significantly elevated levels of aldosterone were reported in a series of 
fourteen patients with MH of varying duration despite being on treatment341 PRA, 
measured on admission in eight MH patients was found to be elevated in five and 
aldosterone was elevated in nineteen out of twenty- two342. Striking anti- hypertensive 
responses were reported in seven patients with MH and high PRA in response to 
propranolol, with the falls in BP correlating with both the reduction in PRA and 
aldosterone leve1343 The ACE inhibitor captopril given to MH patients lowered BP by 
reducing total peripheral resistance, and the response again correlated closely with pre- 
treatment PRAM. 
Various experimental animal models of MH have been described of which the 
majority rely on either surgical, pharmacological or dietary manipulation to induce 
transformation to MH. A proportion of both 1K1C (one kidney, one clip)345 and 
2K1C rats324 develop pathological features of MH. In all 2K1C rats, the initial rise in 
BP occurred during a period of sodium retention, but in a sub -group of rats who 
developed features of MH, higher BP was associated with onset of sodium loss due to 
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both increased urine output and fractional sodium excretion. 2K1C MH rats showed 
both a higher PRA and renal renin content compared to 2K1C benign hypertensive 
rats, though there was a wide scatter in values346 Sprague -Dawley rats (SD) treated 
with aldosterone developed hypertension associated with suppression of plasma renin, 
but when given additional partially purified renin, they developed a syndrome typical 
of MH with focal necrosis of small arteries and arterioles347. Similarly exogenous rat 
renin given to uninephrectomized SD rats resulted in hypertension, a reduction in renal 
renin content, and by 10 days of treatment, hyalin deposition in glomerular tufts was 
evident with tubular dilatation, cast formation and arteriolar necrosis348. The absence 
of a reported elevation of renal tissue renin content in this study deserves comment 
with perhaps two possible explanations. The duration of MH was not clear from the 
study with no rise in BP apparent by Day 4 of treatment and tissues were obtained on 
Day 10 leading to the possibility that an inadequate time period had elapsed for 
malignant transformation of the hypertension to occur. AlternativelyQ ogenous rat 
renin synthesis may have been suppressed by an overriding negative feedbaclç despite 
stimulation of the JGA following initial afferent vascular damage. In contrast rabbits 
given large doses of exogenous Ang II (0.9 -1.8 tg/kg/min) for 3 days developed an 
initial rise in BP which was not sustained and subsequently developed renal 
impairment with rising urea and histological evidence of widespread ischaemic tubular 
necrosis, but both glomeruli and arterioles remained norma1349 However SD rats 
infused with Ang II for over two weeks demonstrated a rising SBP to -170 mmHg, 
and evidence of focal fibrinoid necrosis and proliferation of vascular smooth muscle 
cells particularly in afferent arterioles with tubular injury350 
A proportion of stroke -prone SHR (SHR -SP) rats when given 1% NaC1 to 
drink develop MH with fibrinoid necrosis. Involvement of the RAS was shown by the 
hypotensive response elicited by treatment with the Ang II antagonist (1- sarcosine, 8- 
alanine Ang II) on salt loaded SHR -SP, though such a response was not found in 
ordinary hypertensive SHR -SP given water. This implied that the 'benign' 
hypertension of SHR -SP was not Ang II dependent in contrast to salt loaded SHR -SP 
hypertension351 Chronic treatment with Enalapril dramatically improved survival in 
salt -loaded SHR -SP to >90% compared with 0% survival by 25 weeks of age in 
untreated controls. This was despite an ultimately higher BP being reached by the 
surviving treated group after 15 weeks of age in comparison with the BP in those 
untreated animals at the time of development of terminal cerebrovascular events. Renal 
pathology consisted of arterial and arteriolar necrosis and was evident in all untreated 
animals at the time of death, but was not found in any SHR -SP on the ACE 
inhibitor352. At a dose of 30 mg/kg/day, the Ang II antagonist Losartan both delayed 
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the rise in BP on salt -loading in SHR -SP, and prevented or delayed the appearance of 
arterial necrosis353, but losartan also reduced the development of fibrinoid necrosis 
and arterial thickening in SHR -SP, even at a dose of 1 mg/kg/day which had no 
significant hypotensive effect3M. Despite elevated adrenal renin activity in 5 week old 
SHR -SP compared with WKY, there was no significant difference in tissue Ang I or 
Ang II levels at this age, but by 25 weeks, when severe hypertension and occasional 
pathological evidence of focal fibrinoid necrosis was found325, significantly higher 
adrenal tissue Ang I and Ang II levels are found in the SHR-SP355. 
Infusion of noradrenalin into dogs produced initial hypertension with RAS 
suppression, following which a transformation to MH occurred characterized by an 
abrupt rise in BP, sudden deterioration in renal function and fibrin deposition in the 
intima and media of renal vessels. Initial salt and water depletion led to hyponatraemia, 
and activation of the RAS coincided with the period of accelerating hypertension356. 
Uninephrectomized rats given deoxycorticosterone and 0.1% NaCl to drink, 
developed an initial benign hypertension associated with a positive sodium balance, 
rising BP and normal renal histology, but on transition to MH, weight loss, a negative 
sodium balance, a slight fall in BP and fibrinoid necrosis occurred. During both 
phases however, there was no evidence of an increase in plasma renin activity, nor in 
the malignant phase was there any BP response to Ang II antagonism357. However 
oral treatment with TCV -116, an Ang II (AT1) receptor antagonist or enalapril for 
three weeks both decreased urinary protein excretion, and reduced the development of 
glomerular and arteriolar fibrinoid change in this model despite having no measured 
effect on BP. Though PRC was elevated in the treated groups, there was a small but 
not statistically significant reduction in kidney renin /GAPDH mRNA levels in the 
treated groups compared to the untreated control group given vehicle358. 
A small percentage of patients with MH also present with apparently normal 
PRA, and either elevated or normal aldosterone levels342. It has therefore been 
suggested that the trigger initiating MH might in fact be related to the natriuresis, and 
not necessarily be dependent on RAS activation357. In both experimental and clinical 
situations it has been observed that the correction of sodium depletion in MH may 
result in a fall in BP and recovery359 -361. However in SHR -SP drinking 1% NaCI, 
chronic diuretic use reduced the incidence of pathological changes of MH but this was 
in the context of a coexistent anti -hypertensive effect362. 
Microangiopathic haemolytic anaemia is a well described feature of malignant 
hypertension in both the clinical situation363 -365 and in experimental models357,366. 
Fragmentation of erythrocytes result in the appearance of irregular shaped 'burr cells', 
schistocytes, spherocytes, microspherocytes and red cell fragments, without either an 
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intrinsic membrane abnormality or increased osmotic fragility being demonstrated366. 
Reticulocyte counts are consequently increased as a result of red cell damage. Similar 
pathology is seen in a number of other clinical states including haemolytic -uraemic 
syndrome /thrombotic thrombocytopenic purpura (HUS/TTP)367, systemic lupus 
erythematosus, and in acute glomerulonephritis. 
It has been postulated that either the passage of red cells through damaged 
arterioles due to fibrinoid necrosis leads to MAHA363 or the onset of MAHA is 
important in initiating endothelial cell damage leading ultimately to fibrinoid 
necrosis357. The question has therefore been which comes first? The lack of 
correlation between haematological changes and either blood pressure or degree of 
retinal damage argued against the first of these hypotheses. It was found that red cell 
fragmentation correlated weakly with the degree of impairment of renal 
function364,365. These findings were supported by Isles et al (1984) who showed that 
similar haematological abnormalities were found in both MH and non -MH patients, as 
defined by the presence or absence of grade III/IV retinopathy, but with equivalent BP 
and renal impairment which suggested that uraemia might be responsible for the red 
cell fragmentation365 Some caution is required in the interpretation of this study as the 
MH group incorporated a spectrum of patients of which the majority had had between 
1 -10 weeks of treatment prior to blood sampling, and it has previously been shown 
that fibrinoid clears quickly following institution of treatment3 °. 
In contrast it was observed in the experimental DOCA/salt rat model of MH 
that changes of MAHA coexisted with a normal BUN (blood urea nitrogen) in a third 
of animals366 suggesting that MH can develop without pre -existing uraemia. It would 
therefore appear that the role of MAHA in initiating MH is not clear, but that it is an 
important associated feature of MH which might contribute to the presentation359. 
In summary, the critical factors that lead to the transition from a benign or 
stable hypertension to malignant phase are not clear. To quote Kincaid -Smith (1958), 
"malignant hypertension may be determined by some new and unknown factor in 
addition to a high level of blood pressure "306 Considerable overlap in actual blood 
pressures are found between MH patients and benign hypertensives3ó8, but rate of rise 
may be important. The presence of a triggering factor acting in conjunction with high 
BP in benign hypertension may then create a situation of positive feedback with a 
vicious circle involving sodium depletion, afferent vascular pathology and RAS 
activation leading to an accelerating rise in BP (Fig 1.8.1). Logically, putative triggers 
might act to alter vascular reactivity to vasoactive hormones or affect endothelial cell 
permeability leading to plasma extravasation and myointimal proliferation which 
characterizes MH305 Which patients with existing essential hypertension or secondary 
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forms of hypertension are most at risk of developing MH would be the clinically 
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1.9 Endothelin as a trigger factor in malignant hypertension 
The factors which initiate the transition from benign to malignant phase 
hypertension, with the development of the characteristic pathological damage and 
activation of the renal RAS, have yet to be identified. The role of the endothelium in 
BP homeostasis may be critical in view of the presence of both endothelium derived 
vasodilators such as nitric oxide (NO)369 and vasoconstrictor peptides. A candidate, 
potentially involved in the endothelial response to hypertension, which may be a 
determining factor in the initiation of MH is endothelin (ET). 
An endothelial cell derived peptide with potent vasoconstrictor activity was 
first isolated by Yanagisawa et al (1988) from porcine aortic endothelial cells and the 
preproendothelin cDNA and amino acid sequences were identified370. It was 
subsequently recognised that three endothelin isopeptides (ET -1, ET -2 and ET -3) were 
produced from their corresponding preproendothelins coded for by separate genes. 
Cleavage of preproendothelin ( -200 AA residues) by endopeptidases released big - 
endothelin (big -ET), a 39 (porcine) or 38 (human) AA intermediate which 
subsequently undergoes specific cleavage at Trp21 - Va122 by a membrane bound 
metalloprotease (ECE -1 or endothelin converting enzyme) to release the active ET 
peptide of 21 AA residues. ECE -1 appears to be expressed principally in vascular 
endothelial cells with cleavage of endogenously produced big -ET occurring possibly 
via transit through the constitutive secretory pathway involving the Golgi apparatus, 
but probably by expression of a portion of ECE -1 on the cell surface membrane 
leading to extra -cellular cleavage of big- ET371. Apart from the posterior pituitary, 
there is no clear evidence that endothelin is stored and hence synthesis and release 
appears to be dependent on regulation of ET gene expression. Furthermore, ET 
peptides have a short plasma half -life and are removed on first pass through the lungs, 
suggesting that any function is likely to be paracrine or autocrine in nature372. It has 
been hypothesized that ET may be released abluminally and cause contraction of 
underlying smooth muscle. Circulating levels are normally only 1 -5 pg/ml, though 
these may in part be derived from other sources such as the posterior pituitary373,374 
Studies have suggested that increased ET -1 gene expression and protein 
synthesis occurs in response to Ang II, ischaemia and thrombin in vitro 370,375,376, 
with mobilization of intracellular Ca2+ stores and activation of protein kinase C being 
implicated375. A transient increase in endothelial cell ET -1 gene expression has also 
been reported in response to low levels of shear stress377,378 possibly mediated by 
actin filament disruption379,380. Aging endothelial cells in vitro have been shown to 
express increased ET -1 mRNA381, whilst down -regulation of ET gene expression 
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was seen in cells of an endothelial cell line (transfected with preproendothelin cDNA) 
in response to NO donors376. 
Two functionally distinct receptors, ET -A and ET -B, have been cloned and are 
related to G protein coupled receptors374. A third ET -C receptor has been proposed. 
ET -A receptors preferentially bind ET -1 compared to the other two peptides, while 
ET -B receptors show equally high affinity for all three peptides but a lower efficacy. 
Both smooth muscle cells (SMC) and endothelial cells express ET -B receptors and 
these induce both direct vasoconstriction and a transient endothelium dependent 
vasodilatation, which probably results from endothelin induced release of NO and 
prostacyclin (reviewed in 374)382,383, though conflicting data has been reported384. 
NO mediated effects appear to less important relative to those of prostacyclin in 
transient ET induced venodilatation as opposed to arterial vasoconstriction382,383. 
ET -A receptors are expressed on vascular smooth muscle cells and may 
mediate vasoconstriction through either activation of voltage dependent calcium 
channels, protein kinase C and/or intracellular Ca2+ release58,385 -387. They may also 
weakly induce intimai and medial SMC proliferation via induction of protooncogenes 
including c-fos and c -myc (in common with Ang II but showing a supplemental 
effect in vitro )388,389,390. 
Heterogeneous ET -A receptor gene expression was found on intimai SMC just 
deep to the endothelium in 50% of internal mammary artery specimens taken from a 
group of hypertensive patients, with more severe intimai SMC proliferation and 
intimai thickening apparent in those that did express ET -A receptor mRNA. No 
hybridization signals were detected from the intima of normotensive controls60 
However a study which looked at plasma immunoreactive ET -1 levels in groups of 
human essential hypertensives, ranging from mild untreated essential hypertension 
through to poorly controlled hypertension, no significant difference was found either 
between them or with normotensives57. No evidence of co- segregation of the ET -1 
locus with either SBP or relative heart weight was found in two F2 populations, 
(SS /Jr X Lewis and SS /Jr X SHR) both raised on 8% sodium chloride diets, but 
linkage between ET -3 alleles and SBP and heart weight was demonstrated for the 
inbred Dahl SS /Jr strain59. However in the DOCA -salt hypertensive rat, it has been 
demonstrated that immunoreactive ET -1 content and ET -1 gene expression is increased 
in aorta and mesenteric vessels, despite normal circulating levels391,392 but three 
weeks of treatment with the non -specific ET receptor antagonist, Bosentan, only 
slightly diminished the increment in BP with time compared with untreated DOCA -salt 
controls suggesting that BP in this hypertensive rat model was partially ET dependent. 
Bosentan also appeared to attenuate the reduction in lumen diameter and the increment 
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in media cross -section and media -lumen ratio that was normally seen with time in 
hypertensive DOCA -salt rats393. 
Exogenous administration of endothelin to anaesthetized rats resulted in an 
initial transient hypotensive response associated with a reduction in systemic vascular 
resistance, principally in musculo- cutaneous vascular beds, and a transient increase in 
cardiac index394 The initial vasodilatation did not occur in either renal or mesenteric 
vascular beds. The subsequent effects of exogenous ET -1 in rats and dogs consisted 
of systemic hypertension394,395, renal bed vasoconstriction396,397, decreased renal 
plasma flow and glomerular filtration rate398,399, with glomerular hypertension and an 
overall increased filtration fraction as a consequence of preferential efferent arteriolar 
effects400 Such effects may however be both species and dose dependent401 
Decreased glomerular ultrafiltration coefficient and single nephron filtration rates have 
also been reported in anaesthetized rats402,403. Sustained increases in both plasma 
renin activity and aldosterone concentrations were observed in dogs following 
intravenous ET, though these effects could have been mediated directly or via reduced 
sodium delivery to the macula densa as a consequence of a reduced urinary sodium 
excretion404,398_ Both natriuresie° and salt/water retention have been reported in 
response to intravenous endothelin, though such effects again may be dose and 
species dependent404,398,394 Within the kidney both mesangial cell contraction and 
increased mitogenic activity have been reported in response to endothelin402. In 
isolated cultured mouse JGA cells, all three ET peptides inhibited cAMP stimulated 
renin release but had no effect on basal renin secretion. This appeared to be mediated 
by the ET -B receptor «5. 
In humans arterial vasoconstriction, microvascular vasoconstriction and 
venoconstriction have been reported406,383 and it is postulated that ET -1 mediated 
vasoconstriction may be normally attenuated by endothelium derived relaxant factors 
forming a local endothelial autoregulatory system382, (reviewed in 374). Continuous 
infusions of both ET -1 and ET -3 into SD rats could induce sustained increases in 
MBP possibly due to small increases in total peripheral resistance, though with the 
numbers of rats used, these did not reach levels of statistical significance with either 
peptide. Tachyphylaxis was not demonstrated395 In essential hypertension, both 
unchanged and increased basal plasma endothelin levels have been reported57,407. 
A pathological role for endothelin has been suggested in a number of clinical 
conditions. Reperfusion injury in ischaemic myocardium408 and liver have been 
shown to be aggravated by the production of ET. Gastric mucosal ulceration induced 
by intravascular ethanol has been shown to result from mucosal vasoconstriction 
mediated by ET -1410 In patients following sub -arachnoid haemorrhage, both 
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increased and unchanged levels of immunoreactive ET -1 (ir -ET -1) have been reported 
in the cerebro- spinal fluid, and it has been postulated that this could be involved in 
subsequent cerebral arterial vasoconstriction411 An increase in circulating plasma ir- 
ET occurs following haemorrhage in rats and is associated with an increase in total 
peripheral resistance that serves to maintain BP in haemorrhagic shock412. In a study 
looking at pre -eclamptic women, increased ET -1 mRNA levels were found in placental 
villous tissue compared to normal gestational placental tissue suggesting that there may 
be a role for ET in the placental vasoconstriction that results in foetal growth 
retardation413. 
In the kidney, experimental renal ischaemia led to increased ET -1 mRNA 
levels in the rat41`t. In another study performed in rats, supra -renal aortic cross 
clamping induced an increase in circulating ir-ET which could be abolished by prior 
nephrectomy suggesting that the kidney was contributing to the systemic rise in 
plasma ir-ET in this mode1415 ET has also been implicated in cyclosporin- induced 
renal vasoconstriction and nephrotoxicity. Elevated levels of urinary ET have been 
reported in a model of chronic renal failure in rats induced by renal mass reduction 
while chronic administration of an ET -A receptor antagonist (FR 139317) significantly 
reduced the progressive rise in urinary protein excretion observed in this model 
(reviewed in 416) Similarly in a rat model of focal glomerulosclerosis, induced by 
puromycin aminonucleoside in conjunction with unilateral nephrectomy, progressive 
development of glomerular sclerosis was accompanied by increasing levels of mRNA 
for ET -1 and ET -A and ET -B receptors in the glomeruli. A low protein diet both 
reduced the prevalence of sclerotic glomeruli and attenuated the rise in ET -1, ET -A and 
ET -B receptor mRNA levels417. 
With the recognition that hypoxia, mechanical shear stress, thrombin and Mg 
II are all capable of inducing ET gene expression, it was of interest to ascertain the role 
of ET peptides in the transition to MH. In SHR -SP, a significant anti -hypertensive 
effect was seen in response to the selective ET -A antagonist BQ -123, but this was not 
seen in either SHR or normotensive WKY suggesting that ET did not have a 
significant role in maintaining hypertension in SHR, but that BP in MH may well be 
more sensitive to ET antagonists418. It was not however ascertained in this study 
whether pathological evidence of MH was present in SHR -SP. M anti -hypertensive 
response to the same antagonist was reported by a second group looking at SHR419. 
In two other rat models of MH, namely SHR treated with DOCA -salt for four or eight 
weeks and 2K1C rats treated with caffeine for six weeks, increased plasma it -ET -1 
levels were found relative to their hypertensive controls (WKY treated with DOCA -salt 
and sham -operated rats given caffeine respectively)420. However both MH models 
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had significantly higher BP and impaired renal function relative to their respective 
controls and histological confirmation of MH was not obtained. To date, a clear 
pathological role for ET has not been described, both in MH and in other clinical states 
where elevated plasma ET levels have been found421. 
The development of an animal model that would both spontaneously and 
predictably develop MH from a background of benign hypertension without the 
requirement for surgical, dietary or pharmacological manipulation would prove to be a 
valuable tool to address some of these issues. The following chapters describe the 
characterization and investigation of a spontaneous phenotype exhibited by 
TGR(mREN2)27 rats hemizygous for the Ren -2 transgene. 
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CHAPTER 2 
Materials and Methods 
2.1 Animals 
Animal husbandry and all procedures were performed in accordance with the 
regulations set down by the Animal (Scientific Procedures Act) 1986. Rats were all 
housed in the Centre for Genome Research, and were maintained in controlled 
conditions with regulated temperature (18 -20 °C) and humidity (45 -65 %). A 12:12 
hour light/dark cycle was used. 
For studies requiring rats hemizygous for the Ren -2 transgene, male 
homozygote TGR(mREN2)27 rats were crossed with non -transgenic females. Male 
homozygotes used for breeding purposes were maintained on Lisinopril (dose 25 mg/1 
in drinking water). They had been previously confirmed to be homozygous for the 
Ren -2 transgene by Southern Blot analysis of tail DNA taken from at least three litters 
using a Ren -2 derived probe according to methods previously described267. After 
application of local anaesthesia (ethyl chloride B.P. jet), the distal 1 cm of tail was cut 
off pups at weaning and placed immediately on dry ice. Haemostasis was achieved 
with tissue adhesive (VetBondTM). Tail DNA was prepared by digestion of cut tail in 
fresh tail buffer (50 mmo1/1 Tris HC1, pH 8.0; 100 mmol/1 EDTA, 100 mmol/1 NaCI, 
1% v/v SDS) with Proteinase K 10 mg/ml (Boehringer) at 55 °C. Phenol extraction 
was followed by precipitation in ammonium acetate (6 mol/I) and 70% ethanol 
washes. DNA was resuspended in TE (pH 8.0) before Southern analysis. 
Strains used for crossing with homozygous Ren -2 males to obtain desired 
heterozygote crosses were Sprague -Dawley (SD) obtained from the Centre for 
Genome Research, Edinburgh UK; SD from the Central Institute for Laboratory 
Animal Breeding, Hannover, Germany; and Lewis rats from Harlan -Olac, Oxford, 
UK. 
Pups were weaned at 21 - 25 days of age onto normal pelleted diet (CRM diet, 
SDS, Witham, Essex, UK) unless stated otherwise. Sodium content of this diet was 
0.32% (64 mg/day assuming an average daily intake of 25 g of feed) and chloride 
content was 0.43 %. For the study designed to exclude any effects of a small change in 
dietary sodium intake an alternative feed was used which had a sodium content of 
0.2% (40 mg/day) and chloride content of 0.35% (CRM -X diet, SDS). There was no 
change in potassium content between the two diets. Tap water was given ad libitum to 
drink. 
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Animals were housed in plastic cages and bedded on shavings. They were kept 
in groups of two to three, unless on telemetry when they were housed singly. 
2.2 Measurement of Blood pressure 
Three methods have been employed in the studies described. Direct 
measurements were obtained by telemetry (Data Sciences International, St Paul, 
Minnesota, USA) or by carotid arterial catheterisation while indirect blood pressure 
measurements were obtained by tail cuff plethysmography. These methods will be 
described below, together with the study performed in order to validate indirect BP 
measurement by tail cuff plethysmography in this model. 
(I) Telemetry 
Continuous recording of blood pressure was desirable, but most conventional 
methods using direct BP recording have required anaesthesia, restraint or tethering. 
These methods have been shown to induce stress responses in rodents manifesting as 
an increase in body temperature and elevation of circulating catecholamine levels with 
a rise in BP, heart rate and oxygen consumption which may in part be strain 
dependent422. Indirect methods of BP measurement using tail cuff plethysmography 
therefore require animals to be frequently handled and accustomed to restraint or 
anaesthesia for the measurement to be taken. Only intermittent measurements can be 
made. However even with training, tail cuff plethysmography was still found to be 
associated with a significant rise in systolic blood pressure (SBP) which persisted 
through out the period of restraint and for at least 30 minutes after release, in a study 
which looked at the effects of this procedure on rats undergoing simultaneous direct 
BP recording by radio-telemetry423. 
These methods were therefore not considered suitable for measuring BP on a 
continuous basis in conscious, unrestrained and relatively unstressed animals. It was 
therefore decided to use a radio -telemetry system (Data Sciences International, St Paul, 
Minnesota, USA) which allowed continuous direct infra- aortic recording of SBP, 
mean blood pressure (MBP), diastolic blood pressure (DBP), heart rate (HR) and 
motor activity (Fig 2.2.1) with minimal disturbance to the animals following initial 
implantation of the recording devices. In addition it eliminated movement artefacts 
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Fig 2.2.1 A represents the set-up for telemetric recording of SBP, MBP, DBP and motor activity. 
B illustrates the implant used (TA11PA-C40) and the details of the catheter tip (Adapted from 425) 
Equipment 
The implanted transmitter (TA11PA-C40) weighing 9 g consisted of a module 
containing a battery powered sensor (a stable ion implant semiconductor strain gauge 
sensor). Arterial pressure was conducted to the sensor via a 0.7 mm diameter catheter. 
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To maintain patency, the distal 1 cm of the catheter was coated with an anti - 
thrombogenic film and the tip was filled with a biocompatible gel plug to prevent 
blood refluxing into the tip. Receivers (RA 1010) were placed under standard plastic 
rat cages. Telemetered animals were housed singly and aluminium sheets were placed 
between cages to reduce radio -interference between animals. 
A dual ambient pressure monitor (Cl IPR) measured barometric pressure to 
correct for the implant measuring pressure relative to a vacuum and all input signals 
were transmitted to a BCM 100 consolidation matrix. SBP, MBP, DBP and HR data 
were then transmitted to an Everex 386/25 computer for processing, storage and 
analysis using the data acquisition system (Dataquest IV) with Microsoft OS /2. 
Periodic analyses of waveform traces did show some damping leading to a diminution 
of the pulse pressure occurring with time. However MBP and HR were not 
significantly affected. Motor activity was measured by movement of the implanted 
sensor, and hence the animal, relative to a point in the receiver pad and data stored as 
events per unit time. 
Diurnal changes in BP, HR and motor activity were also analysed using 
Fourier transformation to assess the periodicity of any rhythm. Cosinor analysis 
derived the acrophase, mesor and amplitude of any statistically significant circadian 
rhythm detected. 
Implantation technique 
Male rats were used in all studies described. At age 37 -49 days implantation of 
a transmitter (TA11PA -C40) was performed by aseptic technique. Animals were 
weighed, and induction of anaesthesia was achieved by 4 -6% halothane (M &B, RMB 
Animal Health Ltd., Dagenham, UK) in oxygen using an Acoma vaporizer F 
(International Market Supply, Congleton, UK) via a chamber. The anterior abdominal 
wall was then shaved and the rat placed supine on a heating mat (33 °C) while 
anaesthesia was maintained with 1 - 3% halothane in oxygen via a mask. Seventy 
percent ethanol was used to clean the skin. A midline incision was made through the 
skin and muscle layer and the peritoneal cavity was opened. Saline (0.9 %) swabs 
were used to cover small and large bowel and the retroperitoneum was exposed. 
Using an operating microscope (Wild 650) the descending aorta distal to the origin of 
the renal arteries was dissected free from surrounding retroperitoneal fat by blunt 
dissection using a cotton bud. A tie (2/0 ethilon) was placed around the aorta distal to 
the origin of the renal arteries. About 2 - 5 mm above the iliac bifurcation the aorta was 
again dissected free of surrounding tissue and while aortic flow was transiently 
restricted by lifting the upper tie, the aorta was punctured with a 19 gauge needle tip 
56 
and the distal portion of the sensing catheter was inserted into the aorta and advanced 
up to the level of the upper tie. The sensing catheter was fixed in situ using tissue 
adhesive (VetBondTM, Braun -Melsungen, Germany) with a 2 mm square piece of 
gauze placed beneath the catheter at the point of entry. The upper tie was released and 
removed. Patency of the sensing catheter was verified at this stage by eliciting an 
audible fluctuating note from a radio tuned to a low frequency AM band. Saline swabs 
were then removed and the transmitter module was placed in the abdominal cavity and 
sutured to the anterior abdominal wall. The muscle layer was sutured and skin was 
closed with surgical clips. 
During the post- operative period rats were kept on heating pads until recovery 
and were usually eating and drinking within four hours. Antibiotics and anti- 
coagulants were not given prophylactically. During the course of the study no cases of 
overt infection of implanted transmitters occurred within six months of implantation. 
Where early complications of implantation did occur, such as haemorrhage or signs of 
distal aortic occlusion, animals were humanely put down. After animals had recovered 
from surgical implantation, data collection for analysis was commenced. An initial 
post- operative hypertensive period lasting up to three days was seen after which blood 
pressure was stable and a normal circadian rhythm of motor activity, HR and BP was 
observed. 
(II) Tail cuff plethysmography 
BP recording by tail cuff plethysmography was used for certain studies. Rats 
were anaesthetized with 2% halothane in oxygen with induction in a chamber and 
subsequent maintenance using a mask. Animals were placed in a prone position on a 
heating pad (33 °C) for the actual measurement, but were not actively pre -heated. This 
avoided inducing heat stress, which has been shown to significantly elevate BP in 
rodents pre- heated to temperatures of 38 °C before measurement422. The duration of 
anaesthesia prior to taking BP recordings was kept to a minimum and was similar for 
all animals. BP was measured using a cuff (size 3/8" or 7/16" depending on the size of 
the rat) placed around the tail with a photoelectric sensor (IITC Life Sciences, 
Woodland Hills, California, USA). SBP was defined as the pressure at which initial 
flow in the tail artery was detected. MBP corresponded to the pressure at which no 
further increase in the amplitude of the pulse pressure was detected. DBP was derived 
from the recorded SBP and MBP from the equation DBP = ((3XMBP) - SBP) /2, 
however both MBP and DBP measurements were dependent on not using an artefact 








Example of an analog recording obtained using an IITC system for measuring BP by tail cuff 
plethysmography. SBP corresponds to the pressure at which a pulse pressure is detected indicated by a 
tick mark. The upper panel shows the cuff pressure during controlled deflation starting at 300 mmHg. 
SBP in this case was 240 mmHg. 
A minimum of five readings were taken from each animal to derive a mean 
value for recording at each time point. The cuff was inflated to 250 mmHg in all 
animals except where the SBP was greater than 200 mmHg, when the cuff was 
inflated to 300 mmHg. Deflation rate was controlled to 2 mmHg/second. Tail cuff 
inflation pressures were calibrated and checked using an aneroid sphygmomanometer 
before each session. Validation of tail cuff plethysmography was performed by 
simultaneous comparison with BP recorded by direct carotid arterial pressure 
measurement and the results are reported below. 
(III) Direct carotid arterial catheterisation 
Rats were anaesthetized with ketamine HCl 12 mg /100 g BW (VetalarTM, 
Parke- Davis) and xylazine 0.3 mg/100 g BW (RompunTM, Bayer). Rats were placed 
on a thermostatically controlled heating mat at 33 °C and the anterior neck area was 
shaved and swabbed. The left carotid artery was exposed and a tie placed distally. A 
small clip placed proximally transiently occluded blood flow while a polyethylene 
cannula (PE20) was introduced through a small incision in the carotid arterial wall. 
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The cannula was tied in situ, the clip was removed and the cannula was attached to a 
pressure transducer (model CK -590, Gould, Cleveland, Ohio) connected to a chart 
recorder. The cannula was flushed with a heparinised colloid/crystalloid solution 
(0.9% NaC1/0.1% bovine serum albumin with 10 U /ml Heparin) prior to insertion. 
Further flushes were given if required up to a maximum volume of 1.0 ml. Readings 
were taken after a minimum period of five minutes had elapsed and a stable baseline 
had been achieved. SBP, DBP and HR were read directly from the chart, while MBP 
was derived from the formula MBP = DBP + 1 /3(SBP -DBP). 
(IV) Validation of tail cuff plethysmography 
There were two objectives in this study. Firstly the specific effect of carotid arterial 
cannulation on BP, as recorded by tail cuff plethysmography in the anaesthetized rat, 
was to be assessed. Secondly simultaneous recordings of direct carotid arterial 
pressure and indirect tail cuff plethysmography at normal body temperature were made 
in order to validate the latter method as a means of measuring BP and HR. 
Eleven male SD rats were used with body weights ranging from 130 -250 g. 
They were anaesthetized with VetalarTM (12 mg /100 g BW) and RompunTM (0.3 
mg/100 g BW) and cannulation of the right carotid artery was performed as described 
above. Two rats did not give a stable direct arterial BP measurements due to recurrent 
occlusion and damping. Their BP traces were deemed inadequate and were therefore 
excluded from further analysis. 
Effects of carotid arterial cannulation on BP measured by tail cuff plethysmography 
Between three and seven indirect measurements of BP were taken by tail cuff 
plethysmography from each of nine anaesthetized rats prior to commencing carotid 
arterial cannulation. Following surgery, from three to twelve further measurements 
were taken. Unpaired t - tests were used to compare SBP immediately pre- and post - 
arterial cannulation for each individual animal, with a p value <0.05 considered to be 
significant (Table 2.2.1) 
In conclusion, there was no predictable BP response to the effects of surgery 
with four rats showing a significant rise in SBP, three showing no significant change 
and two showing a significant fall. On comparing pre- operative mean SBP ± standard 
deviation (SD) of 133.14 ± 30.3 mmHg with the post- operative mean of 141.67 ± 
27.7) mmHg by paired t -test, the small increment was not significant (p= 0.423). 
59 
Table 2.2.1 
Rat Pre -op 
SBP ± SD 
Post -op 





1 163.3± 11.2 191.0 ±2.8 T <0.001 
2 95.7 ± 9.0 157.8 ± 21.7 1' 0.004 
3 128 ± 12.2 123 ± 5.3 -9 ns 
4 130.8 ± 26.1 107 ± 10.9 1 0.039 
5 118.3 ± 5.5 134.6 ± 14.1 T 0.048 
6 145.5 ± 7.9 123.2 ± 9.1 -* ns 
7 125.7 ± 8.9 157.7 ± 8.6 T <0.001 
8 191.7 ± 8.1 165.1± 5.0 1 <0.001 
9 99.3± 6.8 115.5 ± 17.7 -3 ns 
BP responses of individual rats to carotid arterial cannulation as measured by tail cuff 
plethysmography. 
Comparison of SBP, MBP, DBP and HR obtained by direct carotid arterial 
cannulation 
From eight of the nine rats, an acceptable direct BP trace was recorded and 
simultaneous recordings of BP by tail cuff plethysmography and by direct carotid 
arterial cannulation were obtained. For each animal between five and twelve combined 
readings (mean 8.1) were obtained giving a total of 65 simultaneous recordings. A 
paired t -test directly compared the means and SD of the readings for SBP, MBP, DBP 
and HR obtained by the two methods (Table 2.2.2). 
Table 2.2.2 
r p value Direct BP ± SD Indirect BP ± SD p value 
SBP 0.833 0.01 135.6 ± 22.5 144.1± 28.6 0.173 (ns) 
MBP 0.643 ns 119.2 ± 18.2 112.6 ± 25.8 0.376 (ns) 
DBP 0.529 ns 111.0 ± 16.4 99.0 ± 22.6 0.128 (ns) 
HR 0.975 <0.001 344.4 ± 62.6 332.5 ± 56.1 0.053 (ns) 
Correlation coefficient (r) with a p -value for significance is given for the linear relationships between 
simultaneous direct and indirect measurements. Means ± standard deviation (SD) of averaged direct and 
indirect measurements (n =8) are shown together with p values for comparison by a paired t -test. ns = 
not statistically significant. 
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Correlation coefficients between simultaneous measurements were calculated 
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For MBP, y= 4+0.9x 
p = ns 
r2 = 0.41 
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For heart rat, y= 30.1+0.9x 
p<0.001 
r2 = 0.95 
The mean difference, and SD for the difference between the average SBP as measured 
by the two methods was 8.5 mmHg ± SD 15.9 mmHg) (Fig 2.2 4). 
In conclusion, a significant correlation was found between direct and indirect 
methods for measuring SBP and HR, with no significant difference in the mean values 
obtained. However the correlation coefficients for MBP and DBP were not statistically 
significant, despite the mean values obtained from the two methods being not 
significantly different. It was therefore decided that where BP was to be measured by 
tail cuff plethysmography, only SBP and HR data would be valid. It was recognised 
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2.3. Assessment of target organ damage 
Mean and SD of the differences 
for averaged SBP obtained by tail 
cuff plethysmography and by 
direct carotid arterial cannulation 
(Bland -Altman plot)426 
The effects of BP on target organs was studied in transgenic heterozygotes and non- 
transgenic control strains. All animals were kept in the same conditions as detailed 
above and dietary protein intake was assumed to be constant as intake of food between 
groups studied did not differ significantly as reflected by similar gains in body weight. 
(I) Renal Function 
Changes in renal function were quantified by plasma creatinine and urea. 
Formal clearance studies were not performed, as this was not practical in sick animals. 
Blood was taken from anaesthetized animals (2% halothane in oxygen) by either retro- 
orbital bleed using 50 µl microcapillary pipettes or by cardiac puncture using a 19 
gauge needle and syringe. Blood was immediately put into lithium heparin (1 ml tube, 
Teklab M. L. Ltd., Durham, UK) on ice, spun at 4000 g for 10 minutes at 4 °C and 
plasma was stored at -20 °C before analysis. GEMENI Reagent kits (Electro- 
nucleonics, Fairfield New Jersey, USA) were used for assay of both plasma urea and 
creatinine using a Gemstar analyzer. 
The urea assay utilized the enzyme urease (urea aminohydrolase) to hydrolyse 
urea to give ammonia and carbon dioxide. Quantification of generated ammonia was 
done by reaction with 2- oxoglutarate and NADH (reduced nicotine adenine 
dinucleotide) in the presence of glutamic dehydrogenase at 37 °C to give glutamic acid 
and NAD. The rate of conversion of NADH (which absorbs light at 340 nm) to NAD 
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(no absorbance at 340 nm) is directly proportional to the initial concentration of urea. 
A standard with a known concentration of urea and distilled water allowed calculation 
of the urea concentration in the sample (10 µl). 
Creatinine reacts with picric acid in alkaline buffer to form a yellow product. 
The absorbance change at 500 nm is proportional to the initial concentration of 
creatinine. 50 p1 of plasma was mixed with 700 µ1 of sodium hydroxide and picric 
acid (equal volumes). Controls were provided by distilled water plus NaOH/picric acid 
and a known standard (of concentration 350 µmol/1) with reagents. In both assays 
distilled water blanks were used and quality control was verified with all assays by 
checking the QC factor (Standard concentration/AAbs /min of standard). For urea 
standards assayed (standard concentration = 13.3 mmol/l, n =15), the mean was 13.49 
mmol/1 with a variance of 0.04 and for plasma creatinine (standard concentration 177 
p.mo1/1, n =20) the mean was 176.8 p.mol/1 with a variance of 63.4. 
(II) Development of left ventricular hypertrophy 
Two methods were used to assess development of left ventricular hypertrophy 
(LVH) in hypertensive Ren -2 transgenic heterozygotes and non -transgenic controls. 
Animals were sacrificed by rapid induction of anaesthesia (6% halothane in oxygen) in 
a chamber followed by cervical dislocation. The chest was then opened and heart and 
lungs were removed. The ventricles were dissected free from lungs, great vessels, 
mediastinal tissue and atria, blood was removed by gently rolling the heart on blotting 
tissue and the free right ventricular wall was removed by dissection. Direct weights of 
whole heart (WH) and left ventricle including septum (LV) were expressed as a ratio 
to body weight. Tissues were then placed in 4% formal saline for fixing prior to 
processing for histopathological examination. 
A second method of measuring left ventricular mass was required that was not 
invasive and would therefore allow serial measurements in longitudinal studies. 
Assessment of left ventricular mass index (LVMI) using echocardiography has been 
well described in humans and the method compared with both radiological and 
angiographic determination of left ventricular wall thickness in patients and with LV 
mass measurements at autopsy427-429. Recently the technique as applicable to rats, 
has been described and validated by Jones et al (1992)430 
It was therefore decided to compare this technique with LV weight as 
measured directly at sacrifice and if valid, use it in studies requiring serial 
measurement of LV mass. Echocardiography was performed using a Toshiba Capasee 
(Toshiba Medical Systems, Tokyo, Japan) with a 7.5 MHz wide band probe held 
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perpendicular to the anterior chest wall of anaesthetized (2% halothane in oxygen) 
animals lying on their back on a heating pad (33 *C). The anterior chi 
shaved, ultrasound couplant gel applied (Diagnostic Sonar, Livingston, UK) 
long axis view of the left atrium and ventricle was btained on a 2D ima .- T 
standardize the long axis view for measurement, the apex of the LV, the aiolrtïc 
mitral valve and left atrium were all required to '; v "i le (Fig 2311)._ 
potential for error arising from oblique transecti z ", : =.e av :: _' ..- 
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A two dimensional (2D) image in the longitudinal axis has been obtained by echocardiography. The 
top panel is a diagrammatic representation of the anatomy of the rat heart for reference. The lower 
panel shows the obtained image. LV = left ventricle; MV = mitral valve; LA = left atrium; AO = 
aortic root; PA = pulmonary artery. M -mode scans were taken from the level of the tips of the mitral 
valve leaflets. 
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Accordingly this method was used in the following study which directly compared LV 
mass as measured by echocardiography with direct LV weight. 
(HI) Validation of Echocardiography as a means of measuring LV mass 
Methods 
Hypertensive transgenic Ren -2 heterozygotes (HanRen2 /Han --) (n =23) 
derived from crossing homozygous Ren -2 males with Hannover SD females ( HanSD) 
and normotensive HanSD controls (n =21) were used for age- matched comparison at 
25, 35, 45, 55, 65 and 75 days of age. Animals were kept according to the conditions 
as detailed above and fed on a normal (0.32 %) sodium diet. On the day of sacrifice 
SBP and HR was measured in anaesthetized rats by tail cuff plethysmography as 
described above. A mean of five readings was taken. Rats were then placed on their 
backs and three echocardiographic measurements of LV mass were taken. Blood was 
obtained by cardiac puncture for later assay for the purposes of another study 
(Veniant, Whitworth, Menard et al, submitted for publication). Animals were then 
killed by cervical dislocation, the chest was opened and the heart removed. LV and 
IVS together were weighed directly after being blotted dry and dissected free of atria, 
right ventricle and great vessels. 
Points were plotted for data pertaining to each animal, and a linear relationship 
with a correlation coefficient r of 0.86 (P <0.001) was observed between the two 
methods (Fig 2.3.2). Some increase in scatter was seen in animals with larger LVM or 
LV weight. However it has been well recognised that a correlation coefficient is not an 
adequate means of comparing two methods of measurement426, and on plotting the 
relationship of the difference between the two methods with the mean value obtained, 
it was found that relative to direct measurements of LV weight, echocardiography 
systematically underestimated the LV mass relative to the LV weight, again with an 
increased discrepancy apparent between the two methods for larger LV weight/mass 
(Fig 2.3.3 A). Bias was calculated from the mean difference (d =287.1 mg) and the 
standard deviation of the difference (SD = 194.1 mg), but in addition the error was not 
normally distributed and so is illustrated after log transformation in Fig 2.3.3 B. 
Intra- observer variation in the determination of LV mass using this method 
was assessed by repeated measurement of LV mass on one rat ( HanSD male, 530g 
body weight). Ten independent measurements of LV mass were made, where each 
was based on the average of three determinations of IVS, PW and EDD as described 
67 
above. The mean LV mass was 1345.2 mg with a SD of 145.4 mg giving 95% 










0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 
Direct LV weight (g) 
Least squares regression analysis of relationship between LV mass (mg) measured by 
echocardiography and direct LV weight (g). y = 1.5 + 667x, r2 = 0.76. 
68 
Fig 2.3.3 
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A. Plot of the difference between the two methods of measurement against the mean of the two 
measurements (Bland -Altman plot). B. Log10 plot of the difference against the mean. 
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PW thickness and EDD and used a modified formula: LVMI = 1.04 ((EDD +2 X 
PW)3 - EDD3 - 14) /BW. However though they reported a reasonable correlation 
between LVMI obtained in this fashion and post -mortem weight (r = 0.70, 
p <0.0001), they have not applied the Bland- Altman analysis426 to their 
measurements. 
In conclusion, echocardiography has been shown in this study to have a linear 
relationship with LV weight measured directly post -mortem with a correlation 
coefficient of 0.86 (p <0.001), but as a method it under -estimated LV mass relative to 
direct weighing. Such an error may arise either from over -estimating LV weight on 
direct measurement due principally to inclusion of tissue other than the LV or from 
applying formulae derived for use in human echocardiography to the rat which may 
not be justified because of differences in LV shape. As a method for serial 
measurements of LV mass, it is satisfactory but interchangeable use of 
echocardiographic and direct assessments of LV mass may give rise to unacceptable 
error particularly with larger hearts. Echocardiography is also subject to inter -observer 
variation428,429, and in longitudinal studies this would be an important and avoidable 
source of error. Intra- observer variation appears also to be a significant problem. The 
variable use of equations reported in the literature for determination of LVMI in rats by 
echocardiography together with the results above suggests that an improved formula 
specifically designed for use in rats is needed. 
(IV) Measurement of Lung water content 
Lung water content was measured as a crude indicator for the presence of 
pulmonary oedema arising from left ventricular failure. At sacrifice and immediately 
on removal of the heart and lungs, peripheral lung tissue was dissected free from 
major vessels and bronchi, lightly blotted and weighed. Lung tissue was then heated 
to dryness for at least 24 hours at 80 °C and re- weighed. Percentage water content was 
calculated from (wet weight -dry weight) /wet weight. 
(V) Histopathological examination of tissues 
At sacrifice left ventricle, right ventricle, descending aorta, kidneys, brain and 
superior mesenteric artery were taken and fixed 4% formal saline. Tissues were 
processed using a Citadel tissue processor (Shandon Southern Products Ltd., 
Cheshire, UK) on an 18 hour programme passing through serial dehydration steps in 
graded ethanol concentrations (70 %, 80 %, 90 %, 100% X3), followed by de- 
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alcoholisation with a clearing agent HistoclearTM (National Diagnostics, Atlanta, 
USA), X3, and paraffin wax immersion X2 at 60 °C. One half kidney (longitudinal 
axis), LV, RV, brain (coronal sections at the level of the mid -brain), descending aorta 
and superior mesenteric artery were embedded in wax blocks (Raymond Lamb 
Blockmaster III embedding centre, London, UK) prior to sectioning and staining. 
Sectioning, staining and mounting of tissues was kindly performed by 
personnel from the Department of Pathology, University of Edinburgh. Three p.m 
sections were sectioned and stained according to methods as described elsewhere433. 
Haematoxylin & eosin stain was used for all tissues. Briefly sections were de -waxed 
in xylol, rehydrated through graded ethanols to water, stained with an alum 
haematoxylin, washed in running water, immersed in 1% HC1 in 70% ethanol for 10 
seconds, washed again for 5 minutes, stained with 1% eosin for 10 minutes and 
washed again. Slides were then serially dehydrated through graded ethanols, cleared 
with xylol and mounted with DPX (BDH Laboratory Supplies, Poole, UK). 
In addition heart and kidney tissue were stained using a periodic acid -Schiff 
technique (PAS)434 to specifically stain for tissue carbohydrates of extra- cellular 
matrix. To stain for fibrin, kidney tissue was stained with a standard MSB ( Martius 
Scarlet Blue) stain435 With this method fibrin stains red, though early fibrin may 
appear yellow and old fibrin blue. 
Sections of aorta and superior mesenteric artery were additionally stained with 
Elastic van Gieson (EVG) and brain with Luxol Fast Blue. All sections were then 
examined by light microscopy (Leitz Laborlux S) and photographed with a Leica Wild 
MPS46/52 camera. 
(VI) Blood films 
Selected animals were bled either by retro- orbital bleed or by cardiac puncture 
under halothane anaesthesia, and the blood collected into tubes containing EDTA 
(ethylene diamine tetra -acetic acid, Sarstedt Monovette 2.7 ml tubes). Full blood 
counts were performed automatically using a Coulter counter. Films were then spread 
and stained (Wrights stain) by personnel at the Department of Haematology, Royal 
Infirmary of Edinburgh. Films were examined under light microscopy, by an observer 
(L Manson) blinded to the clinical status of the animals, for the presence of 
spherocytes, microspherocytes, red cell fragments and a reticulocyte count was 
determined. 
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2.4 Renin -angiotensin system parameters 
(I) Plasma RAS 
Plasma renin concentration (PRC), angiotensin II (Mg II) and aldosterone 
assays were performed. Blood was obtained by either retro- orbital bleed or cardiac 
puncture from anaesthetized animals and put into lithium heparin (1 ml tubes Teklab 
Ml Ltd.) on ice, spun immediately at 4000g for 10 min at 4 °C and plasma was then 
stored at -70 °C before assay of PRC. 
Radioimmunoassays (RIA) for PRC and Ang II were kindly performed by Dr 
J.J. Morton, MRC High blood Pressure Unit, Western Infirmary, Glasgow according 
to methods described previously436 -439_ Briefly for PRC assay, duplicate samples of 
rat plasma (3 µl) were incubated at 0 °C and 37 °C with a mixture (14 p.1) of Ang I 
antiserum (1:80 dilution in 3 mo1/1 Tris, pH 7) and rat renin substrate in a ratio of 
1:6. Rat renin substrate, shown to be free of renin, was obtained from bi- 
nephrectomized rats438. The enzyme incubation was terminated by rapid cooling in 
ice/water after 5, 30 or 60 minutes depending on renin content. Generated Ang I was 
then measured by RIA. 300 µl of cold Tris 0.5 mol/1, pH 7.5 was added to each 
sample followed by 10 pg of i25I- labeled Ang I (in Tris 0.5 mol/1, pH 7.5). Samples 
were incubated at 5 °C for 18 hours, and bound and free labeled Mg I was separated 
by the addition of plasma- coated charcoal with the free labeled fraction quantified by 
an automatic y- counter. Standard curves were prepared from dilutions of AspL- 
Ileu5 -Ang I from 323 to 2.5 pg in 0.2 ml 0.5 mol/1 Tris (pH 7.5), 0.2 ml of anti- 
serum (1:80,000) and 10 pg of labeled peptide. 
For Ang II assay, blood was collected into fresh S2phenanthroline (0.05 
mo1/1)/EDTA (0.1 mol/1) inhibitor on ice in a ratio of 10 µl per 0.1 ml of whole blood 
to inhibit angiotensin converting enzyme activity and angiotensinases. The inhibitor 
consisted of 0.05 g 1 -10 phenanthroline monohydrate (0.025 map) (Sigma, UK) 
dissolved in 400 µl absolute ethanol and added to 0.464 g EDTA disodium salt (0.125 
mol/1) (BDH Analar Laboratory Supplies, Poole, UK) and made up to 10 ml with 
water. Blood was then spun immediately at 4000 g for 10 minutes at 4 °C and plasma 
stored at -70 °C before assay. Plasma was passed through an extraction step using Sep - 
pak C18 cartridges previously washed with 5 ml methanol and 5 ml distilled water439 
Plasma samples were then loaded and passed through the columns at a pressure of 10 
psi. Ang II was eluted from the columns with 80% methanol in distilled water and the 
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extracts were dried under air and redissolved in Tris buffer (50 mmol/1, pH 7.5) 
before RIA. 
Duplicate standard curves for Ang II were prepared from a stock solution of 
Val5 angiotensin II amide ( "Hypertensin ", Ciba, Sussex, UK) at concentrations of 
100, 50, 25, 12.5, 6.25, 3.12, 1.56 and 0 pg in 200 µl Tris buffer (50 mmol/1 pH 
7.4). 400 µl of Tris/HC1 buffer (50 mmol/1 pH 7.4) was added to each of the plasma 
extracts which were thoroughly mixed, centrifuged (3000 rpm, 5 °C, 10 minutes) and 
then 100 µl of extract was pipetted into duplicate tubes. Mg II antiserum (BPU) (100 
1.11 of 1:30,000) was added together with 50 pl 1251 Iles Ang II (Dupont) to both 
extracts and standards. Tubes for total counts were prepared from Tris buffer (100 µl) 
and Ang II label (50 µl). After thorough mixing, all tubes were placed in a fridge for 
18 hours at 4 °C. Bound and free label were separated using dextran- coated charcoal. 
Dextran T70 (0.282 g, Pharmacia) was dissolved in 50 ml of Tris/HC1 buffer pH 7.4. 
Norit SX -1 charcoal (15 g) was added to 1.35 1 of Tris/HCl buffer pH 7.4, dissolved 
on stirring, mixed with the Tris /dextran and stored at 5 °C before use. Cold 
dextran/charcoal (1 ml) was added to all tubes which were then centrifuged (3000 
rpm, 5 °C, 10 minutes) and the supernatant discarded. The radioactivity present in the 
charcoal pellet (free fraction) was counted in an automatic 'y- counter (LKB model 1260 
gamma counter), the standard curve computed and hence values extrapolated for the 
plasma extracts. After adjusting for sample dilution, recovery and plasma volume final 
plasma concentrations were obtained in pg/ml. 
Aldosterone was assayed from serum (obtained from whole blood spun at 
4000 g for 10 minutes at 4 °C) by N Burns and Dr B Williams (Department of 
Medicine, Western General Hospital, Edinburgh) by the method described 
previously441. 50 pl of plasma or 50 µl of standard (concentration range 0.06 to 32 
nmo1/1) were incubated in triplicate for 18 hours at 4 °C with 200 µl of phosphate citrate 
buffer (pH 4, 0.05% bovine serum albumin) containing the radio -label 125I- 
iodohistamine- aldosterone -3- mono -oxime and antisera (402L) in a final dilution 
1:60,000. Standards were made up in charcoal stripped rat plasma. Free and bound 
radiolabel were also separated using dextran- coated charcoal, and the free fraction was 
quantitated using an LKB model 1260 gamma counter. Intra- and inter -assay 




Immunohistochemistry was performed on kidney using a polyclonal rabbit 
anti -mouse renin antibody (given by Dr D Campbell, Melbourne, Australia). Formalin 
fixed, paraffin embedded tissues were used, prepared as detailed earlier. Three µm 
sections were cut using a microtome (Anglia Scientific 0325), floated on to Superfrost 
microscope slides (Menzel -glaser, Germany) and baked for 5 minutes. Paraffin wax 
was then removed by 2 minute immersion of slides in serial baths containing 
Histoclear (3 baths), 100 %, 95 %, 70 %, and 50% ethanol and finally distilled water. 
The slides were dried and wax was used to encircle the tissue section. Blocking 
solution (phosphate buffered saline (PBS) /5% goat serum) was layered on and left for 
one hour in a moist box containing PBS buffer. The blocking solution was aspirated 
off, and rabbit anti -mouse renin antibody was applied at a dilution of 1:2000 in 
PBS /2% goat serum for overnight incubation at 4 °C in a moist box. The primary 
antibody was omitted for control sections which were processed in parallel. Three 2- 
minute washes with PBS /2% goat serum were followed by a 10 minute incubation 
with PBS /2% goat serum with 2% hydrogen peroxide to quench endogenous 
peroxidase activity. Three 2- minute washes with PBS /2% goat serum were then 
followed by incubation for 30 minutes with biotinylated goat anti -rabbit antibody 
(1:200) (VectastainTM, Vector Laboratories Inc., Burlinghame, CA, USA) in PBS /2% 
goat serum. After four washes with PBS, an immunoperoxidase detection system 
(VectnstainTM Elite ABC kit) was used in which a complex was formed between avidin 
DH (1:100) and biotinylated horse -radish peroxidase H (1:100) in PBS binding to the 
biotin of the secondary antibody. After incubation for 20 minutes at room temperature, 
further washes with PBS were followed by application of the chromogen 
diaminobenzidine tetrahydrochloride (DAB) dissolved in PBS and filtered through a 
0.2 tm syringe filter, and hydrogen peroxide (3 111/m1 of 30 %). A red -brown 
precipitate was formed by reaction with peroxidase on standing for 1 -5 minutes. This 
was terminated by washing with UHP water and subsequently the slides underwent 
serial dehydration through graded alcohols and clearing with Histoclear before 
mounting. Counterstains were not applied. 
Minimal background staining which was limited to red cells was encountered 
on using this antibody and secondary detection system. On omitting the primary 
antibody, no staining was seen. 
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2.5 Endothelin in malignant hypertension 
(I) RNase protection assays for endothelin mRNA on whole rat kidney . 
Animals 
Male heterozygotes, hemizygous for the mouse Ren -2 transgene were bred and 
maintained as previously described. Hypertensive HanRen2/Edin - -, HanRen2/Lew - -, 
and non- transgenic, normotensive EdinSD were used (see Fig 3.1.1 for explanation of 
nomenclature). 
Malignant hypertension was identified on the basis of clinical features as 
described in chapter 3 which include weight loss, apathy, fitting and which were 
confirmed by histopathological examination as previously described. Four groups of 
8 -10 week old rats were studied: (1) HanRen2 /Edin -- with malignant phase 
hypertension (n =11), (2) age- matched HanRen2/Edin -- with benign hypertension but 
no signs of malignant phase (n =6), (3) HanRen2/Lew -- with benign hypertension 
(n =4), and (4) normotensive EdinSD (n=4). Animals were briefly anaesthetized by 
2% halothane anesthesia and killed by cervical dislocation. Kidneys were quickly 
dissected out, snap frozen in liquid nitrogen, and stored at -70 °C before RNA 
extraction. 
RNA extraction 
Total RNA was extracted from whole kidney for use in an RNase protection 
assay for endothelin mRNA quantification. At sacrifice, one kidney was immediately 
dissected out and the capsule removed, blotted dry, snap frozen in liquid nitrogen and 
stored at -70 °C until RNA extraction was performed. A phenol/guanidium thiocyanate 
method was used as previously described442. Where appropriate, solutions used in 
RNA work were DEPC (diethylpyrocarbonate) treated as per standard protocols` 43, 
but at a concentration of 0.01 %. 
Approximately one sixth kidney from each animal was homogenized in 4 ml of 
RNAzo1TM B (Biotecx Laboratories, Inc. Texas, USA) in a Falcon 2059 tube on ice 
using a Polytron homogenizer. Four hundred j.il of chloroform were added, mixed and 
left to stand on ice for 5 minutes. After centrifugation (3200 rpm at 4 °C for 5 min) the 
upper phase was aspirated. An equal volume of isopropanol was added, tubes were 
mixed by inversion and left to stand at 4 °C for 60 minutes to allow RNA to precipitate. 
After centrifugation at 10,000 rpm for 15 minutes at 4 °C (Beckman Centrifuge, SS34 
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rota), the RNA pellet was washed with 70% ethanol (in DEPC treated water), mixed 
and spun for a further 15 minutes. After removal of ethanol, the dry pellet was 
resuspended in 100 R1 of DEPC water. RNA concentration was quantified by 
spectrophotometry at wavelength 260 nm (Pharmacia LKB Ultrospec Plus). Integrity 
of extracted RNA was checked on ethidium bromide stained 1% agarose gels 
visualizing 5s, 18s and 28s ribosomal bands. 150 Rg of total RNA was re- precipitated 
in 1 /10th volume 3 mol/1 sodium hydroxide and 2.5 volumes of 100% ethanol and 
stored at -70 °C for RNase protection assay for endothelin mRNAs. 
Endothelin RNase protection assay 
The RNase protection assays for rat ETs -1, -2 and -3 were kindly performed 
by Dr J D Firth, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford 
according to the method previously reported414 In brief, uniformly labeled antisense 
RNA transcripts were generated by in vitro transcription using SP6 polymerase 
(Amersham) and a32P -GTP (410 Ci/mmol/1, Amersham). In each case the riboprobe 
template contained genomic sequence which included a part of exon 2 of the gene of 
the relevant ET, which is the region coding for the mature peptide. For analysis of 
mRNA, precipitated total RNA from coded samples, were dissolved in hybridization 
buffer (80% formamide, 40 mmol/1 PIPES, 400 mmol/1 sodium chloride, 1 mmol/1 
EDTA pH 8) and RNA concentration determined by absorbance measurement at 260 
nm using a DU -62 spectrophotometer (Beckman Instruments Inc.). One Rg of RNA 
extracted from the human cell line K562, containing abundant a- globin mRNA, was 
added to 30 Rg of rat kidney RNA in a final volume of 501.11. RNA was denatured at 
90 °C for 10 minutes. Hybridization was performed overnight at 60 °C with 2.5x105 
cpm of the appropriate ET probe and 2.5x105 cpm of a probe specific for human a- 
globin. A comparison of the recovery of a- globin mRNA from individual samples 
allowed a correction to be made for any variation in efficiency of processing and gel 
loading. After hybridization, RNase digestion was carried out at 37 °C for 30 minutes 
by the addition of 350 Rl of solution containing 40 Rg/ml RNase A (Boehringer), 10 
mmol /1 Tris (pH 7.5), 5 mmol /1 EDTA and 300 mmolll NaCl. This reaction was 
terminated by the addition of 60 Rl of proteinase K (1 mg/ml) with 3% SDS and 
further incubation for 30 minutes at 30 °C. Phenol -chloroform and then chloroform 
extractions were performed and the RNA fragments precipitated with 2.5 volumes of 
absolute ethanol. Precipitated RNA was dissolved in 51.1.1 of 80% formamide running 
buffer, and the reaction mix electrophoresed on a denaturing 8% polyacrylamide gel. 
After electrophoresis the gels were dried and subjected to autoradiography at -70 °C, 
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following which the autoradiographs were aligned with their corresponding gels and 
the protected ET and a- globin mRNA bands excised. These were then counted using 
a flat -bed liquid scintillation counter (1205 Beta Plate TM, Pharmacia -Wallac OY, 
Turkey, Finland). Results were expressed as cpm (mean ± SD) after (a) subtraction of 
background (cpm derived from counting a sample containing no RNA) (b) correction 
for recovery of a- globin mRNA in individual samples (which did not vary over a 
range of more than 15% on any gel), and (c) correction for the cpm obtained from 
three external standards run on each gel. These external standards - containing 15 µg, 
30 tg and 60 tg from a pool of RNA derived from the kidneys of normal SD rats - 
were required because the cpm obtained from any particular gel depended not only on 
the samples themselves, but also on the activity of the particular batch of probe used, 
which was made freshly each week. 
Statistical analysis was initially performed using the Kruskal- Wallis test one 
way ANOVA, corrected for ties, to test the null hypothesis that there was no 
difference between the four groups. Where statistically significant differences were 
found, a Mann -Whitney U test, also corrected for ties, was applied between pairs of 
groups to identify where such differences lay. The p -value indicating statistical 
significance was taken to be < 0.05. 
(II) Effects of an Endothelin antagonist, Bosentan, on transition from benign to 
malignant phase hypertension. 
Animals 
Male HanRen2 /Edin -- were housed as described above in groups of three or 
four and fed a diet (0.32% sodium, Harlan -Olac, Bicester, Oxford) from weaning at 
25 days. They were randomly assigned to a treatment group (n = 17), given Bosentan 
(Hoffman la Roche, Basle, Switzerland) at a dose of 100 mg/kg/day and a control 
group (n = 17) given the same diet without added Bosentan. The drug was thoroughly 
mixed with powdered foodstuff in aliquots of 1.75 g/kg. Correct dosage was verified 
by periodic weighing of both rats and food intake. Both groups had tap water ad 
libitum to drink. MH was defined as present on development of clear signs of the 
syndrome as previously described, together with light microscopic examination of 
renal tissue confirming the presence of fibrinoid necrosis and myointimal proliferation. 
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Blood pressure measurement 
In order to determine the effect of Bosentan on BP in conscious transgenic 
Ren -2 rats, an additional group of 11 male rats (body weight 340 to 435g) had 
transmitters (TA11PA -C40) implanted under anaesthesia for telemetric recording of 
continuous arterial pressure as previously described in section 2.2 (I). At least two 
weeks after surgery, they were administered single doses of Bosentan 1(X) 
mg/kg/day, dissolved in 5% gum arabic (Fisons, Loughborough, UK) by gavage. 
Three rats were given further single doses of up to 175 mg/kg a week later to ensure 
that any increase in dose would not affect BP. MBP was recorded for 24 hours prior 
to and 48 hours after dosing in conscious unrestrained animals, and comparisons 
made between MBP at equivalent times of the day to correct for circadian 
rhythm444,445. 
During the study of chronic Bosentan treated versus untreated groups, systolic 
blood pressure (SBP) and heart rate (HR) were measured weekly in anaesthetized rats 
using the indirect tail cuff plethysmographic method (see section 2.2(11)). Five 
readings of SBP were obtained at each time point and a mean recorded for the 
individual animal. Body weight was measured weekly. Statistical comparison between 
groups was performed by Student's t test, with p <0.05 taken to be significant. 
Effects of exogenous Endothelin 
The effect of exogenous endothelin in treated and control animals was 
examined in order to show that treatment with Bosentan given mixed in food had 
effectively blocked endothelin receptors. On completion of the study at 105 days of 
age, random surviving Bosentan treated (n =3) and untreated animals (n=4) underwent 
BP recording by direct carotid pressure monitoring (see section 2.2 (III)). The internal 
jugular vein was cannulated for intravenous administration of porcine big -Endothelin 
(Sigma, UK) at a dose of 0.3 nM/kg in 0.9 %NaCl/0.l% BSA at a final volume of 
0.5m1/kg. After a stable baseline BP had been achieved, big -ET was given and the BP 
response was recorded over the following 60 minutes. 
(III) Effects of chronic Bosentan treatment on development of LVH 
In conjunction with the above experiment, HanRen2/Edin -- rats underwent 
measurement of LVMI using echocardiography using the method described in section 
2.3 (II) at 25 days of age and from surviving rats at 60 days of age. Results obtained 
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from treated and untreated control groups, were compared by Students t -test at 25 and 
60 days of age with p <0.05 taken to be significant. 
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CHAPTER 3 
Characterization of a malignant hypertensive phenotype 
3.1 Introduction 
The transgenic rat line TGR(mREN2)27 was initially bred at the University of 
Heidelberg where the transgene was introduced into F1 embryos from a SD/WKY 
cross267. A colony of TGR(mREN2)27 was subsequently bred and maintained by 
back -crossing of transgene positive rats onto SD, referred to here as Hannover SD 
(HanSD), at the Central Institute for Laboratory Animal Breeding, Hannover, 
Germany. This strain has been well characterized producing a phenotype of severe, 
but benign hypertension as described in section 1.7. HanSD male rats homozygous 
for the Ren -2 transgene (HanRen2 /HanRen2) were maintained on ACE inhibitors to 
control BP for breeding purposes. In order to develop a colony of rats hemizygous for 
the transgene at the Centre for Genome Research in Edinburgh, SD rats were obtained 
from N.I.M.R. Mill Hill, England, and established in Edinburgh (referred to as 
EdinSD) and these were then used to cross with homozygous HanRen2/HanRen2 to 
obtain F1 hybrids HanRen2/Edin - -, hemizygous for the Ren -2 transgene (see Fig 





Parental strain Parental strain 
HanRen2/HanRen2 
Heterozygous for HanSD or EdinSD 
derived alleles. 
Hemizygous for the Ren -2 transgene. 
Homozygous for HanSD derived alleles. 
Homozygous for the Ren -2 transgene. 
Fig 3.1.1 illustrates examples of the nomenclature that have been used to describe the genotype of rats 
used in the following studies. Parental strains are depicted as Edin for EdinSD, Han for HanSD and 
Lew for Lewis. Ren2 refers to the presence of the Ren -2 transgene, -- indicates absence of the 
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transgene. The term hemizygous refers only to the transgene, while heterozygous refers to all other 
alleles. 
3.2 Description of the change in phenotype 
HanRen2/Edin -- rats developed hypertension as previously described, but they 
exhibited an unexpected increase in mortality, with death occurring in a significant 
proportion of the animals by 100 days of age. It was observed that they became 
lethargic, adopting a characteristic hunched and apathetic posture with piloerection, 
though a smaller proportion exhibited signs of irritability and aggression. On occasion 
there were signs of neurological involvement manifesting as unilateral myoclonic 
seizures, hemiparesis or hemiplegia or with signs of retinal haemorrhage appearing as 
a darkened eye. Invariably weight loss occurred over a period of one to five days, 
together with evidence of a diuresis indicated by increased soiling of bedding. 
Fig 3.2.1 
130 Fig 3.2.1 shows the change in body 
weight (BW) taken as a change in the 
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%BW relative to the BW at the time of 
110 T death (arbitrarily set at 100 %). Data is 
100 expressed as group mean (t standard 
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deviation). Males and female rats were 
included, and the age at death varied from 
80 49 days to 105 days which will both 
70 contribute to the variance of the data. 
-25 -20 -15 -10 - 
Days before death 
A group of 91 male and female rats were initially studied with body weight 
(BW) recorded every two days and it was observed that development of the above 
fatal syndrome occurred in 51 individuals and was heralded by a weight loss ranging 
from 0% to 29.7% of maximum BW attained (Matt Sharp, Donald Ogg - personal 
communication). Fig 3.2.1 shows the percentage change in BW in these 51 rats over 
the 24 days prior to developing terminal features of the syndrome. 
These observations prompted the following questions; what was the nature of 
the phenotypic change in this transgenic hypertensive rat line giving rise to an 
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unexpected increase in mortality? Why was it occurring and in particular was it related 
to a change in environment or was it an effect resulting from a change in the 
background strain in which the Ren -2 transgene was operating? 
To address the potential environmental factors, a review of the conditions 
under which rats were kept in Heidelberg and in Edinburgh was made and apart from 
a small difference in the dietary sodium content with German rat chow containing 
0.2% sodium as opposed to 0.32% in Edinburgh, conditions were otherwise the 
same. Animals were housed in groups in both centres and kept to a 12:12 hour 
light/dark cycle, with controlled temperature (18 to 20 °C) and humidity (45 to 65%). 
The possible effects of a small change in dietary sodium intake on the development of 
hypertension and mortality rate were tested, and to examine whether genetic factors 
might be operating, three separate crosses were established, in which HanSD male 
rats, homozygous for the Ren -2 transgene (HanRen2 /HanRen2), were crossed with 
non -transgenic EdinSD, HanSD and Lewis females. The genotypes of resulting 
progeny, hemizygous for the Ren -2 transgene, were therefore described as 
HanRen2 /Edin - -, HanRen2 /Han -- or HanRen2 /Lew -- respectively. The three 
heterozygote crosses were then compared with reference to mortality, physiological 
and pathological findings. 
Rats were maintained in conditions described above, housed in groups of 
either three males or four females and were not used for any other experimental 
purposes to ensure that potential stress effects were minimised. Though pathological 
examination of tissues was not performed on all affected cases, characteristic 
pathological changes were found in tissues of all cases examined, namely 
HanRen2 /Edin -- (n =31) and HanRen2/Han-- (n =7) which were randomly selected 
from those exhibiting typical phenotypic features (see section 3.3). 
Table 3.2.1. 
Heterozygote cross Genotype of Incidence of Malignant hypertension 
Flhybrid Male Female 
HanRen2 X Edin SD HanRen2/Edin -- 86/117 (73.5 %) 83/158 (52.5 %) 
HanRen2 X Han SD HanRen2/Han -- 7/39 (18 %) 2/44 (4 %) 
HanRen2 X Lewis HanRen2/Lew -- 0/35 (0 %) 0/31 (0 %) 
Table 3.2.1 shows the incidence of the phenotype (percentage) occurring by 100 days of age in the 
three heterozygote crosses, both for males and females, while maintained in identical conditions. 95% 
confidence limits were calculated for the incidence in each cross - for HanRen2/Edin -- males 65.7 - 
81.3%, and for females 44.7- 60.3 %; and for HanRen2/Han -- males 6 -30% and for females 0 -10%. 
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The age range at which male and female HanRen2/Edin -- rats developed 
irreversible features of the phenotype is shown in Fig 3.2.2. The age ranges at which 
HanRen2/Han -- males (n =7) developed the phenotype was 56 to 87 days (median 70 
days and mean 69.6 ± SD 12.0 days) while HanRen2/Han -- females (n =2) developed 
characteristic features at the ages of 58 and 80 days (data not shown). 
Fig 3.2.2 
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Fig 3.2.2 shows the age at 
death for male (A) and 
female (B) rats, against the 
number of animals. 
Out of 117 male 
HanRen2/Edin -- rats, 86 
had died by 100 days, and 
92 died in total over a 
range of 33 to 113 days. 
The median age at time of 
death was 62 days, with a 
mean of 62.2 days ± SD 
12.7 days. 
Out of 158 female 
HanRen2/Edin - -, 83 had 
died by 100 days and 91 
died in total over a range 
31 to 115 days. The 
median age at time of death 
was 62 days, mean of 65.1 
days ± SD 15 days. No 
significant gender 
differences were observed 
for the age at onset of the 
syndrome or death. 
3.3 Characterization of the change in phenotype. 
A post -mortem study was performed on an initial series (n =197) of transgenic 
heterozygote animals HanRen2 /Edin - -, HanRen2/Han- -, HanRen2/Lew -- and non - 
transgenic strains (EdinSD and HanSD) who had been maintained with free access to a 
normal diet (sodium content 0.32 %) and tap water and were housed in groups of three 
(males) or four (females). At four, six and eight weeks of age (n= 3 -8 per group) 
tissues were taken from age matched, healthy males from each heterozygote cross. 
They were anaesthetized with 6% halothane, killed by cervical dislocation and tissues 
were removed for weighing and histological examination as described earlier. A 
random selection of animals who had spontaneously developed clinical features as 
described above, including sudden weight loss, apathy or signs of cerebral irritation 
also underwent post -mortem examination after sacrifice (n =38). Kidney, heart, brain, 
aorta and superior mesenteric artery were removed; kidneys, whole heart and left 
ventricle were weighed and all tissues were fixed in 4% formal saline, embedded in 
paraffin wax blocks, sectioned and stained with H &E, MSB, PAS, EVG and LFB 
where appropriate as described earlier. 
3.3.1 Pathology 
Macroscopic findings 
In general affected animals showed evidence of marked tissue dehydration. The main 
findings on macroscopic examination were seen in the kidneys with evidence of 
superficial petechial haemorrhage to varying degrees in the majority of affected 
animals. Haematuria was noted in some cases and in two animals examined (one 
HanRen2 /Edin -- and one HanSD), unilateral or bilateral hydronephrosis was 
observed. Apart from these individuals, no other abnormalities were observed 
macroscopically in kidneys from healthy transgenic or non -transgenic SD. There was 
no significant difference in size between kidneys from the three different transgenic 
heterozygotes and pooled non -transgenic SD males at four, six and eight weeks of age 
(Table 3.3.1). 
With regard to the cardiovascular system, left ventricular hypertrophy (LVH) 
was apparent in both affected animals and in healthy hypertensive transgenic animals. 
Quantification of LVH was performed in healthy HanRen2/Han - -, HanRen2 /Lew - -, 
HanRen2/Edin -- and non -transgenic SD male rats at four, six and eight weeks of age 
(i.e. up to the age of expected onset of weight loss and phenotypic change). The 
indices of change in left ventricle (LV) weight measured were: (1) whole heart weight 
85 
to 100g body weight ratio (HW/BW), (2) LV weight to 100g BW ratio (LV/BW) and 
(3) LV to heart weight ratios (LV /HW) (Table 3.3.2). 
Table 3.3.1 












HanRen2/Han-- 6 0.55 ±0.03 3 0.46 ±0.03 8 0.45 ±0.02 
HanRen2/Lew -- 3 0.56 ±0.04 5 0.50 ±0.03 5 0.45 ±0.03 
HanRen2/Edin -- 4 0.55 ±0.01 5 0.47 ±0.03 6 0.43 ±0.05 
SD 8 0.53 ±0.03 6 0.44 ±0.03 8 0.40 ±0.04 
Changes in kidney weight (KW) where KW equals the mean of the weights of the two kidneys and is 
depicted as a ratio to body weight (BW) at 4, 6 and 8 weeks of age. No statistically significant 
difference was found between the four groups. 
Table 3.3.2 
Strain 
Age 4 weeks 
n HW /BW 
mean ± SD 
LV /BW 
mean ± SD 
LV /HW 
mean ± SD 
HanRen2/Han -- (TH) 6 0.44 ± 0.02 0.33 ± 0.01 0.75 ± 0.02 
HanRen2/Lew -- (TL) 3 0.45 ± 0.03 0.32 ± 0.01 0.72 ± 0.05 
HanRen2/Edin -- (TE) 5 0.48 ± 0.03 0.37 ± 0.01 0.80 ± 0.03 
SD 8 0.44 ± 0.03 0.33 ± 0.02 0.79 ± 0.05 
6 weeks 
HanRen2/Han -- (TH) 3 0.51 ± 0.05 0.39 ± 0.03 0.76 ± 0.4 
HanRen2/Lew -- (TL) 5 0.56 ± 0.03 0.43 ± 0.04 0.75 ± 0.04 
HanRen2/Edin -- (TE) 5 0.50 ± 0.03 0.41 ± 0.03 0.84 ± 0.02 
SD 6 0.37 ± 0.01 0.30 ± 0.02 0.80 ± 0.04 
8 weeks 
HanRen2/Han -- (TH) 8 0.48 ± 0.05 0.38 ± 0.02 0.78 ± 0.06 
HanRen2/Lew -- (TL) 5 0.49 ± 0.05 0.40 ± 0.02 0.84 ± 0.02 
HanRen2/Edin -- (TE) 6 0.50 ± 0.03 0.41 ± 0.03 0.84 ± 0.02 
SD 8 0.34 ± 0.02 0.26 ± 0.01 0.78 ± 0.04 
Changes in heart weight (HW) and LV weight as ratios to Body weight (100g) (BW) and changes in 
LV/HW ratio with age in three transgenic heterozygotes crosses and in normal Sprague -Dawley 
controls. Data shown as mean ± standard deviation (SD). 
86 
LVH was apparent in all three transgenic heterozygotes with statistically 
significant increases in both LV /BW and HW/BW ratios relative to normotensive 
pooled SD controls at six and eight weeks of age. However, no significant difference 
was seen between the three transgenic groups. Looking at LV/HW ratios, significant 
differences were elicited between HanRen2 /Edin -- and both HanRen2 /Han -- and 
HanRen2/Lew -- at four and six weeks, though the significance of this is not clear, 
since the ratios observed in normotensive SD were comparable to those seen in 
HanRen2 /Edin - -. However by eight weeks of age LV /HW ratios were significantly 
increased in both HanRen2 /Edin -- and HanRen2/Lew -- compared to SD (Fig 3.3.1). 
Fig 3.3.1 
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A. Total ventricular tissue (wet weight) expressed as a ratio to 100g body weight (13W) for rats aged 4, 
6 and 8 weeks. Group means (± SD) for HanRen2/Han-- (TH), HanRen2/Edin -- (TE), HanRen2/Lew -- 
(TL) and pooled EdinSD and HanSD (SD) are shown. * indicates a significant difference (p<0.05) 
between the group indicated and all other groups after Bonferroni correction for multiple comparison. 
B. LV tissue (wet weight) expressed as a ratio to 100g body weight in groups TH, TL, TE and SD as 
above. * indicates a significant difference (p <0.05) between the group indicated and all other groups 
after Bonferroni correction for multiple comparison. 
C. LV weight expressed as a ratio to total heart weight, both measured as wet tissue weights for 
groups as above. t indicates a significant difference between TE and both TH and TL groups but not 
SD, after correction for multiple comparison. tt shows a significantly decreased LV/HW ratio at 8 
weeks for SD compared with all three transgenic groups after correction for multiple comparison. 
In some affected animals, there was evidence of superficial cortical 
haemorrhage seen as petechiae over the surface of the cerebral hemispheres. No other 
specific abnormality were detected. Of note, no evidence of macroscopic hepatic or 
splenic pathology was found in any of the groups of animals studied. 
Microscopic findings 
Renal: 
In all affected cases studied, a similar pathology was found. H &E stained 
sections (3 pm) cut through the long axis of the kidney were examined under light 
microscopy. The main finding was of interlobular and afferent arteriolar damage with 
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evidence of myo- intimal proliferation and fibrinoid necrosis in all affected cases (Fig 
3.3.2 A to J). Together with deposition of fibrinoid, there was evidence of endothelial 
cell swelling and disruption, mild inflammatory cellular infiltrates and thromboses 
within the arterial lumens leading to virtual or complete occlusion. No evidence of 
significant peri- vascular inflammatory infiltration was found. MSB stains also 
demonstrated fibrinoid (Fig 3.3.2, G &H). In larger vessels e.g. renal artery and 
arcuate vessels, medial hypertrophy was seen though there was usually no marked 
difference between affected animals and healthy age- matched hypertensive animals, 
but in some cases fibrinoid deposits were seen in the media of larger vessels (Fig 
3.3.2 J). In some cases, longitudinal sections through an interlobular artery would 
demonstrate the patchy nature of fibrinoid necrosis (not shown). 
Glomeruli in the majority of affected animals appeared to be mainly unaffected 
(Fig 3.3.2 G). In a few cases afferent arteriolar fibrinoid necrosis was associated with 
either fibrinoid necrosis or collapse of a glomerular tuft (Fig 3.3.2 H). . There was no 
evidence of mesangial proliferation and only occasional small and early crescent 
formation. Fibrin deposition was occasionally seen in Bowman's space. There was 
minimal tubular damage in the majority of cases with symptoms, but in both older 
affected animals and healthy transgenic hypertensive rats ( >12 weeks old), features of 
tubular atrophy and glomerulosclerosis were seen and on rare occasions these were 
coincident with evidence of fibrinoid necrosis (Fig 3.3.2 B). 
The overall impression arising from the histological examination of renal tissue 
from affected animals was that the changes were compatible with malignant phase 
hypertension (MH) and secondly, that the described lesions were of relatively acute 
onset and of a similar age suggesting that onset of, or transition to, MH was recent, 
with insufficient time to elapse for secondary ischaemic changes such as glomerular 
sclerosis and tubular atrophy to develop in the majority of cases. 
Myocardium: 
Three µm sections through left and right ventricular myocardium were 
examined after staining with H &E and PAS stains, and findings are illustrated in Fig 
3.3.3 (A to H). LVH was apparent on light microscopy with cellular hypertrophy 
rather than hyperplasia observed when compared with non -transgenic controls, though 





Fig 3.3.2 A - J are all photomicrographs from 3 µm sections of renal tissue fixed in 4% formalin 
before sectioning, staining and mounting. 
A Section taken from a non- transgenic HanSD rat showing a normal afferent arteriole and 
glomerulus (H &E X250). 
B Hypertensive damage in a HanRen2/Edin -- rat showing evidence of fibrinoid necrosis, with 
chronic hypertensive renal damage consisting of glomerulosclerosis (gs), arterial medial wall 




C Fibrinoid necrosis of an afferent arteriole from a HanRen2/Edin -- (H &E X250) 
D Myo- intimal proliferation and fibrinoid necrosis affecting afferent arterioles supplying two 




E Myo-intimal proliferation (H &E X250). 
F Longitudinal section through an inter -lobular artery showing fibrinoid necrosis, with 




G Fibrinoid necrosis of afferent arterioles, while glomeruli appear undamaged (MSB X250). 




Glomerulosclerosis with complete hyalinisation of a single glomerulus. Adjacent normal 
glomerulus for comparison (H &E X250). 
Fibrinoid necrosis affecting a larger artery in cross -section, principally with fibrinoid 
deposition in the sub -endothelial region, and also within the media. Significant luminal 






Fig 3.3.3 A -H are all taken from sections of myocardium from transgenic rats. Tissues were fixed 
with 4% formalin before sectioning, staining and mounting. 
A An acute myocardial infarct (microscopic) is shown by the relative pallor of the 
cardiomyocytes, vacuolation and loss of cell borders together with evidence of haemorrhage 
within the infarct. Normal cardiomyocytes surround the infarct (H &E X100). 
B A microscopic infarct showing evidence of an early healing response with inflammatory 




C Photomicrograph shows the concomitant presence of three microscopic myocardial infarcts of 
differing age within the same section. The upper (top right) infarct is acute with no evidence 
of a healing response, while the lower (bottom left) shows granulation tissue. (H &E X40). 
D A more advanced stage in the healing process of an individual infarct is shown by the 




E Typical perivascular fibrosis (PAS X100). 




G Normal cardiac arteriole from a non -transgenic Lewis rat (H &E X100). 
H Cardiac arteriole, from a rat who had malignant hypertension, showing features typical of 
fibrinoid necrosis (H &E X250). In some cases myo-intimal proliferation (not shown here) 
was also observed. 
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In both HanRen2/Edin -- and HanRen2 /Han- -, microscopic infarcts were found 
in LV myocardium (Fig 3.3.3 A to D). Acute lesions appeared as groups of infarcted 
cells with pale cytoplasm, vacuolation and indistinct cell membranes. Small 
haemorrhages were occasionally noted within infarcted areas. Lesions of varying age 
were seen with both foci of granulation tissue and fibrosis existing in the same slide as 
an acute microinfarct (Fig 3.3.3 C). This suggested that such lesions were not a 
terminal event, but underwent a healing response with inflammatory cell infiltration, 
the appearance of granulation tissue and ultimately healed leaving focal areas of scar 
tissue (Fig 3.3.3 D). On occasion, but not in all cases, microinfarcts appeared to be 
associated with fibrinoid necrosis of small cardiac arterioles (Fig 3.3.3 H). They were 
sited throughout the thickness of the LV and septal myocardium, but were not clearly 
seen in the free wall of the RV. Microinfarcts were found in sick animals but also in 
apparently healthy heterozygotes. No such lesions were observed in HanRen2 /Lew -- 
or in non -transgenic strains. 
Fig 3.3.4 
4 - 
3 - 0 
2 
1 - 00 00 
00 00000 
0 00 000 00000 
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Number of individual 
microinfarcts seen in one 3 
pin section through mid -LV 
of hearts from age -matched 
HanRen2 /Edin -- (n =14), 
HanRen2/Han -- (n =13) and 
HanRen/Lew -- (n =14) males. 
Each point represents the 
score for an individual 
animal. 
The incidence of microscopic myocardial infarcts was quantified by looking at 
H &E sections (3 µm) from randomly selected animals taken from the three transgenic 
groups aged eight weeks; HanRen2 /Edin -- (n =14); HanRen2 /Han -- (n =13) and 
HanRen2/Lew -- (n =14). One 3 µm section, taken through the long axis of the LV 
including the apex was examined under light microscopy (X100) in a systematic 
fashion while blinded to the origin of the slide. Looking at all fields, the number of 
distinct micro -infarcts of any stage was counted, and the results are depicted in Fig 
3.3.4. This showed that myocardial microinfarcts were more common in 
HanRen2 /Edin - -, with individual animals tending to show more frequent lesions, but 
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lesions were found both in animals exhibiting the described clinical features but also in 
apparently healthy animals. 
Using a crude index of pulmonary oedema as measured by water content as a 
percentage of lung wet tissue weight, affected animals were evaluated for evidence of 
LV failure and the results are depicted in Fig 3.3.5. No significant difference was seen 
in the lung water content between normotensive SD controls, healthy hypertensive 
transgenic rats with benign hypertension and rats with clinical and pathological 







MH BH NT 
Lung water content as a percentage of total lung 
tissue (wet) weight from age -matched (8 -10 week) 
transgenic heterozygotes exhibiting clinical 
features of MH (n =21) confirmed on renal 
histology; healthy, hypertensive, transgenic 
heterozygotes with benign hypertension (BH) 
(n =15); and normotensive SD (NT) (n =8). 
Cerebrum: 
Petechial haemorrhages were seen over the cortical surface of the cerebral 
hemispheres in a number of animals showing features of MH. In one rat, evidence of 
previous cerebral cortical ischaemia or infarction was observed with neuronal loss and 
gliosis (Fig 3.3.6 A). Coronal sectioning at the level of the mid -brain revealed 






A Section taken through the cerebral cortex of a HanRen2/Edin -- rat which showed evidence of 
previous cortical ischaemia (arrowed) where there was a marked loss of neuronal tissue and a 
fibrillary gliosis (H &E X40). 
B Areas of cerebral haemorrhage within the thalamus adjacent to the IHrd ventricle. Area of 
recent infarction (arrowed) (H &E X100). 
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Mesenteric vessels: 
No evidence of mesenteric ischaemia or infarction was apparent at the 
macroscopic level and on sectioning of superior mesenteric artery, no clear evidence of 
any characteristic pathology was seen in rats with MH. Though hypertensive 
transgenic heterozygotes showed evidence of some medial wall thickening compared 
to non- transgenics, this was not marked within the age range of rats studied (up to 
eight weeks), but in a series of sixteen week old transgenic heterozygotes medial 
hypertrophy was more apparent. This was not increased in rats showing features of 
MH, nor was there any evidence of fibrinoid necrosis or myo- intimal proliferation. 
Aorta: 
Within the age range of animals studied there were no specific features 
observed to be characteristic of the malignant phase. With increasing age, transgenic 
heterozygotes of all three crosses showed some increased reduplication of the elastic 
laminae (not shown). 
3.4 Blood Pressure 
The above findings have described a phenotypic change with mortality of 
affected animals associated with clear pathological features of MH on light microscopy 
of renal tissue. It was therefore of interest to look at changes in BP over the course of 
development of the syndrome. 
Established methods of BP measurement in rats have usually relied on 
measures that require either anaesthesia, tethering or restraint and even with training 
and acclimatization to conditions, such methods clearly induce stress and elevation of 
BP422. In the context of studying a phenotype which might involve an accelerated 
phase rise in BP it was important to avoid inducing this prematurely or artificially. It 
was therefore decided to employ a method that required minimal handling of rats, did 
not require anaesthesia or restraint and allowed continuous recording of BP. 
Telemetric BP recording (Data Sciences International, St Paul, MN, USA) had many 
of these advantages and after recovery from surgical implantation (see section 2.2), 
data from unstressed animals could be collected on a continuous basis. 
Telemetric implants (TA11PA -C40) were implanted by aseptic technique under 
halothane anaesthesia as described previously, into male transgenic heterozygotes 
HanRen2/Edin -- (n =10), HanRen2 /Han -- (n =6), HanRen2 /Lew -- (n=4), and non - 
transgenic control strains EdinSD (n =3), HanSD (n =3) and Lewis (n=4). Data was 
collected from 46 to 95 days of age, commencing from three days after surgical 
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implantation, with SBP, MBP, DBP and HR recordings made every 10 minutes and 
30 minute averages stored for later analysis as described in section 2.2. It was 
observed that variable damping of pulse pressure occurred in some cases and therefore 
for the purposes of this study, only MBP values were analysed. Animals were housed 
singly in regular plastic cages with free access to a normal diet (0.32% sodium) and 
tap water. 
MBP over time in both the transgenic stains and non -transgenic controls is 
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Fig 3.4.1 shows MBP 
recorded by telemetry. 
Group mean and SEM are 
shown every three days for 
clarity. Where error bars 
are not seen, they were 
smaller than the symbol 
used. Closed symbols 
represent transgenic 
heterozygotes, open 
symbols represent non -TG 
Age (days) strains 
HanRen2/Edin-- Edin--/Edin-- -0- 
HanRen2 /Han-- Han- -/Han-- -0- -a- 
HanRen2/Lew -- -A-- Lew -- /Lew -- 
HanRen2 /Edin -- males showed significantly higher MBP from 52 to 60 days 
of age compared to the other two heterozygous Ren -2 crosses HanRen2 /Han -- and 
HanRen2 /Lew -- (p<0.01), but on attaining the plateau phase, MBP in both 
HanRen2/Han -- (169 ± 11.9 mmHg) and HanRen2 /Lew -- (177.3 ± 4.1 mmHg) were 
not significantly different to the MBP found in 60 day old HanRen2/Edin -- (180.7 ± 
10.0 mmHg) (Fig 3.4.1). Beyond age 60 days, group means for HanRen2/Edin -- are 
not shown as seven out of ten rats developed features of MH over the ensuing period. 
Early manifestations of MH in the HanRen2 /Edin -- group before 60 days of age may 
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not have been clinically apparent but may have been associated with the beginning of 
an accelerated phase rise in MBP. This could result in the average MBP in apparently 
healthy HanRen/Edin -- to appear artificially elevated. This is supported by observed 
traces where some (Fig 3.4.2) affected animals exhibited a steeper rise during the 
period of developing hypertension. In the terminal phase all showed a striking 
accelerated rise in MBP (Fig 3.4.3). Only a single HanRen2/Han-- rat developed MH 
on telemetry (Fig 3.4.4). 
In five rats on telemetry, who developed MH and where the natural course of 
events was allowed to progress, the mean rise in MBP over the terminal six hours was 
72 mmHg (range 65 to 75 mmHg). It was apparent that those rats which exhibited a 
steeper rise in MBP had a shorter life expectancy (Fig 3.4.5). Histopathological 
examination in all such cases confirmed the presence of fibrinoid necrosis in renal 
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Fig 3.4.2 shows representative traces of MBP recorded by telemetry. 
A. HanRen2/Han-- showing development of benign hypertension (BH) characterized by a rise in MBP 
to a plateau phase by 70 days of age. In contrast a steeper rise in MBP was seen from a 
HanRen2/Edin- rat who developed features of MH at 58 days. 
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Terminal accelerated phase from the 
HanRen2/Han -- male aged 81 days 
that developed MH. MBP is shown 
over the last 40 hours to illustrate 
the steep rise occurring in the 
terminal six hours. Such a rise was 
also observed in 5 HanRen2JEdin -- 
rats on telemetry where MH was 
allowed to progress without 
intervention. 
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Mean BP 
Diastolic BP 
Telemetric recording of SBP, MBP and DBP from a HanRen2/Han -- male rat that developed features 
of MH. Interestingly, this rat showed evidence of an earlier accelerated phase in BP from which it 
made an apparent recovery before developing a second accelerated phase at 81 days of age. (SBP and 
DBP are also shown to demonstrate the progressive damping that occurred with time with narrowing 







35 40 45 50 55 60 65 
Age (days) 
Rat (age at death) 
-0-- 4317 (58) t 4316 (61) --- 4313 (66) - 0- 4301 (66) 
4315 (66) 
4314 (69, B) 
4299 ( -) 
4300 ( -) 
Twenty -four hour average MBP is shown every three days for individual HanRen2/Edin -- males on 
telemetry. Data from two additional animals, 4318 and 4319, were not shown in this figure as they 
both developed catheter haemorrhage at 61 and 62 days respectively. Rat 4314 developed haemorrhage 
from the catheter at 69 days (B). 4299 and 4300 did not develop features of MH. Traces are shown up 
till three days before MH to avoid inclusion of any terminal accelerated phase in a calculated 24 hour 
mean for MBP. 
The results from this study have suggested that in association with the 
pathological changes, an accelerated rise in BP occurred in affected animals, further 
providing support for a diagnosis of MH. Interestingly, though higher BP at a 
younger age appeared to be a marker for developing MH, absolute BP levels were not 
the sole factor precipitating transition to the malignant phase. This was clearly 
demonstrated by the fact that both HanRen2 /Han -- and HanRen2 /Lew -- strains 
developed levels of MBP by 70 days comparable to those found in HanRen2 /Edin -- of 
a younger age who were about to develop MH. 
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3.5 Effects of small changes in dietary salt intake on the phenotype 
It was of interest to identify whether any small variation in dietary sodium 
might account for the variation in the phenotype. Firstly, it had been identified that the 
sodium content of the diet fed to a colony of HanRen2/Han-- in Heidelberg, Germany 
contained a slightly lower sodium (0.2 %), and no significant mortality had been 
observed in this colony up to at least five months of age. On the basis of earlier studies 
where transgenic Ren -2 rats had not been shown to alter their BP significantly in 
response to a change from a low to a high sodium intake291, small changes in dietary 
sodium intake were not expected to significantly affect BP. More marked sodium 
depletion, induced by diuretics and a low sodium diet, have been shown to lower BP 
in transgenic Ren -2 rats280, but it could also be argued on the basis of the current 
understanding of MH, with activation of the renin -angiotensin system (RAS), that a 
relative degree of salt depletion might result in increased basal activity of the RAS. 
This could increase the likelihood of transition to MH. This study was designed 
specifically to exclude any potential contribution that small variations in dietary sodium 
intake might make to the increased incidence of mortality in the Ren -2 heterozygote 
colony (HanRen2 /Edin --) in Edinburgh compared to the colony of HanRen2 /Han-- 
originally bred and maintained in Heidelberg. 
Accordingly, a parallel study was performed on HanRen2 /Han males 
maintained on 0.32% (n =6) and 0.2% (n =6) sodium diets from weaning. Progeny 
from two litters both derived from the same homozygous transgenic father were 
randomly allocated into two groups. They had free access to diet and drinking water 
and were housed singly. HanRen2/Lew male progeny were similarly obtained from 
the same father and given 0.32% (n =4) and 0.2% (n =5) sodium diets in parallel. MBP 
was recorded continuously from 45 days by radiotelemetry. 
The incidence of MH, confirmed by histopathological examination in the four 
groups was recorded. Twenty -four hour MBP for each rat was derived as described 
previously from values obtained every 30 minutes, and group means on the two 
sodium diets were compared by unpaired t test (Fig 3.5.1). Though small but 
statistically significant differences were seen between the two sodium diets, at age 75 
days in HanRen2/Han -- and at age 66, 69 and 72 days in HanRen2/Lew - -, this did not 
appear to be responsible for the change in phenotype. Only one HanRen2 /Han-- rat 
developed MH while on a 0.32% Na diet. As regards HanRen2/Edin -- rats, weaning 
onto the lower sodium diet was not protective. Though blood pressure was not 
measured in this group, it was observed that of a litter of eight animals on a low salt 
diet, six developed features of MH. In conclusion, after excluding other potential 
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environmental contributions to the change in phenotype on breeding HanRen2lEdin -- 
at the Centre for Genome Research, results have suggested that dietary differences 
were unlikely to be responsible. In the light of the striking differences in the incidence 
of the phenotype when all animals have been maintained under identical conditions, 
even within the saine room, the evidence would point to genetic factors conferring 
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A. Mean blood pressure in 
HanRen2 /Han -- males on a 
0.32% (n =6) and 0.2% (n =5) 
sodium diet. Results are shown 
as group means and error bars 
represent SD. A statistically 
significant difference in MBP 
was observed on Day 75 alone. 
1/6 HanRen2 /11an -- on 0.32% 
and 0/5 on 0.2% diets developed 
MH. 
B . Mean blood pressure in 
HanRen2/Lew -- males on 0.32% 
and 0.2% sodium diets. There 
was a small but significant 
increase in MBP at age 66, 69 
and 72 days of age. No rats from 
either group developed MH. 
3.6 Renal function 
In untreated MH progressive uraemia and renal failure is a common terminal 
event. This may be a consequence of the afferent vascular pathology leading to a 
reduced renal blood flow and glomerular filtration rate as discussed in Chapter 1. 
More accurate methods of determining renal plasma flow in rats have usually 
employed clearance studies using inulin or para- aminohippuric acid (PAH), but in this 
model performing such studies in rats exhibiting features of MH was neither practical 
nor humane. It was therefore decided to simply measure plasma urea and creatinine 
levels both in transgenic heterozygote groups (HanRen2/Han - -, HanRen2 /Lew - -, 
HanRen2/Edin --) and their non -transgenic (HanSD, Lewis and EdinSD) controls (Fig 
3.6.1). Blood was obtained as described in the Section 2.3 (1). Animals were all on 
telemetry to allow concurrent recording of BP. In addition blood was also obtained 
from non -telemetered HanRen2 /Han - -, HanRen2/Lew, HanRen2/Edin - -, and pooled 
SD controls as well as HanRen2/Edin -- with clinical features of MH which was later 
confirmed on histological examination of renal tissue (Table 3.6.1). This was to 
ensure that the presence of the implant did not significantly alter renal function and to 
allow determination of renal function in animals of four and six weeks of age. 
This was felt to be a reasonable assessment of gross changes in renal function 
prior to, and on developing MH, in the knowledge that neither dietary protein intake 
nor muscle mass should significantly differ between groups up until the terminal 
stages. In the later stages of MH, with the observed diuretic phase and body weight 
loss, degrees of salt/water depletion together with anorexia were likely. Increased 
protein catabolism at the time of MH could result in increased plasma creatinine. Blood 
samples were taken from rats showing clinical features of MH, and on subsequent 
histological examination varying degrees of severity of pathology were apparent 
indicating that samples were being obtained at varying stages through the natural 
course of MH. 
Results obtained therefore showed a marked variance in the measured urea and 
creatinine, and the small size of the groups may have resulted in many changes not 
reaching statistical significance. Levels of plasma urea and creatine measured in the 
telemetered rats (Fig 3.6.1) did not show significantly higher levels than the non - 
telemetered group (Table 3.6.1) indicating that the presence of the implant did not 
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Fig 3.6.1 shows plasma urea (mmol/1) and creatinine (µmol/1) for transgenic and non- transgenic 
control strains D. Blood was obtained by retro- orbital bleed into tubes containing lithium heparin, 
from rats whose BP was monitored continuously by telemetry. Assay methods were as described 
previously (section 2.3). Plasma urea and creatinine values are shown for HanRen2/Han-- (n =6) and 
HanSD (n =3) in A and B respectively; HanRen2/Lew -- (n =5) and Lewis (n =4) are shown in C (urea) 
and D (creatinine); and HanRen2/Edin -- (n =9) and EdinSD (n =4) values are shown in E (urea) and F 
(creatinine). Only one series of blood samples was taken from HanRen2/Edin -- (aged 61 days) as all 
(except two) rats developed MH in the following 7 days. (Plasma urea was not measured in Edin SD 
aged 124 days). 
Table 3.6.1 
RAT STRAIN 4 weeks 6 weeks 8 weeks 12 weeks 
HanRen2 /Han-- Urea 5.8±0.9 3.8±0.6 5.02±0.7 9.84±2.5 
(n =5) Creatinine 32.6±6.5 25.6±4.4 36.8±6.01 57.4±22.6 
HanRen2/Edin -- Urea 4.5 ±0.78 6.2 ±0.97 9.2±3.7 - 
(n=5) Healthy Creatinine 26.8±2.6 30±5.5 42.8±3.3 *t - 
HanRen2/Edin-- Urea - - 24.9 ±43.7 - 
(n=8) with MH Creatinine - - 111.9 ±59# - 
HanRen2/Lew-- Urea - - - - 
(n=5) Creatinine 27.6±3.6 19.8±2.5 27.4 ±3.4 - 
SD (n =5) Urea 6.6 ±0.64 5.8±0.9 4.8 ±0.75 6.5±0.4 
Creatinine 31.2±9.4 30±3.5 29.9±6.2 36±4.4 
Table 3.6.1. shows mean (± SD) of plasma urea(mmol/1) and creatinine (µmol/1) in different 
transgenic and non -transgenic groups. Blood samples were taken at sacrifice by LV puncture in 
anaesthetized animals and assays were performed as previously described. Rats were not on telemetry. 
Data was not available for plasma urea from HanRen2/Lew -- rats. Values for plasma urea and 
creatinine are shown for HanRen2/Edin -- (aged 57.6±4.9 days) with clinical features of MH (confirmed 
on histological examination) for comparison with other groups. Statistical significance was checked 
by unpaired t -test applied to creatinine levels firstly between aged matched groups and secondly 
between 4 weeks with 6, 8 and 12 weeks within groups where appropriate. Correction for multiple 
comparisons were made. *Plasma creatinine in 8 week old HanRen2/Edin -- was significantly greater 
than in SD (p= 0.008); t creatinine in 8 week old HanRen2/Edin -- was significantly higher than in 4 
week old rats (p<0.001). # Creatinine levels were significantly higher in HanRen2/Edin -- with Mil 
compared with all other age -matched groups (p<0.05) 
112 
A trend of increasing plasma urea and creatinine with age is observed in the 
three transgenic F1 hybrids, while the non -transgenic strains do not show any 
significant trend. Over the age range studied, no statistically significant change in 
creatinine was seen in any of the crosses except for HanRen2/Han -- aged 12 weeks 
and healthy HanRen2 /Edin -- aged 8 weeks. A striking difference is seen for 
HanRen2/Edin -- with MH (plasma urea 24.9 ± 43.7 mmoUl; plasma creatinine 111.9 
± 59.3 .tmo1/1) compared both with aged matched healthy HanRen2/Edin -- (p= 0.046), 
and with other strains (p<0.05). Statistical comparisons were not made between 
values for urea, as it was felt that interpretation of the values was complicated in MH 
by concomitant salt/water depletion and a large variance in the measurement was 
apparent. 
In conclusion, in MH varying degrees of renal failure were apparent. The 
variance in measurements seen in this group may in part be due to the fact that samples 
were collected from animals showing features of MH but who were inevitably at 
different stages through the natural course of the condition. Within the age range of 
animals studied, only HanRen2 /Edin -- showed a significant rise in plasma creatinine 
with age. This rise appeared to occur between 6 and 8 weeks of age and may be 
relevant to understanding why this hybrid was at increased risk of developing MH. 
Alternatively, this group of apparently healthy animals may have included a proportion 
who were already beginning to develop MH and so values measured from an 
apparently healthy group may have been artefactually increased. 
3.7. Renin -angiotensin system 
Activation of the kidney RAS has been well described both in humans and 
animal models of MH342,340,346,155. The hypertensive Ren -2 transgenic rat line 
appears to have an Ang II dependent form of hypertension as discussed in Chapter 1. 
However there may be inappropriate Ang II activity in the kidney of Ren -2 rats 
accounting for an increased pre -glomerular vascular resistance2M, despite reportedly 
suppressed renal tissue renin content267,270. Circulating plasma renin has been 
thought to be primarily transgene derived, while the majority of kidney renin present 
may be derived from endogenous rat renin gene expression which is suppressed 
owing to increased BP288. 
It was therefore interesting to determine what changes in circulating plasma 
renin, Ang II and aldosterone content occurred on transition to the malignant phase 
and secondly to observe what response occurred in the JGA cells of transgenic Ren -2 
rats with MH. 
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Plasma renin, Ang II and aldosterone were measured by RIA by methods 
previously described in Chapter 2. Blood samples were obtained either by retro- orbital 
bleeding or by cardiac puncture from rats which had been briefly anaesthetized with 
halothane in oxygen, and assay were performed as described in section 2.4. Healthy 
HanRen2/Edin - -, HanRen2 /Han - -, HanRen2/Lew - -, pooled non -transgenic controls 
(SD and Lewis) and HanRen2/Edin -- with MH were used. All rats were seven to nine 
weeks of age, male and maintained on the same diet and in the same conditions. 
Fig 3.7.1 
A. Plasma renin B. Ang II C. Aldosterone 
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Fig 3.7.1 shows plasma renin concentration (PRC), Ang II and aldosterone, measured in the three 
hemizygous Fl hybrids, non- transgenic SD/Lewis and in MH. For HanRen2/Edin -- n= 15, 11, 14 for 
each assay respectively; HanRen2/Han-- n= 19, 11, 30 ; HanRen2/Lew, n= 14,12,19; pooled non - 
transgenic strains n= 18, 14, 13 (results were pooled having established that there was no significant 
difference between the strains) and for MH n= 14, 11, and 15 respectively. Results are shown as group 
means ± SD. Significant increases in PRC* (p<0.008), Ang IIt (p<0.04) and aldosterone§ (p<0.004) 
were seen in the MH group compared to the other 4 non -malignant groups by unpaired t -test with 
Bonferroni correction for multiple comparison. 
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Results showed that amongst healthy, non -malignant transgenic male rats of 
seven to nine weeks of age PRC, Ang II and aldosterone levels were not significantly 
suppressed in comparison to the non -transgenic, normotensive rats (Fig 3.7.1). A 
small increase was seen in healthy HanRen2/Edin -- group relative to other transgenic 
heterozygotes but statistically significant differences were not observed. An increased 
variance in HanRen2 /Edin -- may in part be due to the fact that, of this group a 
proportion would have been expected to develop MH in the following days. Two 
animals did develop MH within three days of being classified as being "healthy" while 
others developed MH at later stages. 
This data does conflict with earlier reports of suppressed PRC in transgenic as 
opposed to non -transgenic strains. Recently a study has been performed to look at 
changes in plasma renin, plasma prorenin, adrenal and kidney tissue renin, plasma 
angiotensinogen and changes in SBP with increasing age (over a range of 25 to 75 
days) in HanRen2/Han-- and HanSD controls (M Veniant, C Whitworth, J Ménard et 
al - submitted for publication). Data showed that while adrenal renin content increased 
from 25 to 75 days of age in transgenic rats to levels 16 fold higher than in HanSD, 
kidney renin content at 25 days in HanRen2 /Han-- was slightly, but not significantly 
lower than that in HanSD and fell with increasing age and increasing BP to levels 
approximately 15% of those seen in HanSD by 75 days of age. In keeping with the 
results reported here, plasma renin levels in HanRen2/Han-- were significantly higher 
than those found in non -transgenic HanSD rats at age 65 to 75 days. Prorenin levels 
remained several fold higher in transgenics than in HanSD through out the age range 
studied. Using a ratio of Ang I generation in vitro at pH 8.5 and 6.5, it appeared that 
adrenal renin and circulating plasma renin were transgene (mouse) derived while renal 
renin was primarily of rat origin. This study supported the findings reported here for 
the three hemizygous F2 hybrids who showed plasma renin values to be similar to or 
slightly higher than those in non -transgenic control strains. 
Striking and highly significant increases in circulating PRC, Ang II and 
aldosterone were observed in the MH group (Fig 3.7.1). The results suggest that in 
this model on transition from benign hypertension to MH, activation of the RAS 
occurs. Immunohistochemistry was therefore performed using a polyclonal anti - 
mouse renin antibody and an avidin- biotin horse radish peroxidase secondary 
detection system on 3 µm formalin fixed kidney sections. The methods were as 
described in section 2.4. Primary antibody was omitted to verify that there was no 
background staining in sections processed in parallel. Sections were taken from 
healthy HanRen2/Han -- (n =8) HanRen2/Lew -- (n =4), control HanSD and EdinSD 
(n=4) and rats with MH (n =10). Light microscopy of sections showed staining at the 
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afferent arterioles in the vicinity of the vascular pole of glomeruli in all sections from 
non - transgenic strains (Fig 3.7.2). Markedly increased staining was seen in transgenic 
rats with MH (Fig 3.7.2 B) and this staining was seen to extend to smaller renal 
arterioles. More frequent and heavier staining of the vascular poles was apparent in the 
MH compared to healthy hypertensive transgenic heterozygotes. Some sections were 
obtained from rats that had been on telemetry and it was observed that relatively 
increased staining was seen in those transgenic heterozygotes that tended to have a 
lower BP compared to others. Staining in healthy transgenic heterozygotes was scanty 
(Fig 3.7.2 A) and less intense than that observed in non -transgenic EdinSD and 
HanSD supporting previous findings of reduced renal renin content in Ren -2 
transgenic heterozygotes269. 
In conclusion in MH there appears to be increased circulating plasma renin, 
Ang II and aldosterone and this may in part be due to activation of the renal RAS 
which is normally suppressed in Ren -2 transgenic heterozygotes with BH. As the 
antibody used does not differentiate between mouse and rat renin, it has not been 
possible from this experiment to differentiate rat from mouse renin. It is possible that 
both may contribute to the increased staining observed at the vascular poles, but as 
other experiments have shown by the pH profile of in vitro Ang I generation that rat 
derived renin is the primary renin in Ren -2 transgenic kidneys (Veniant, Whitworth, 
Ménard et al - manuscript submitted), it would appear likely that it is primarily the 
endogenous renin gene that is being activated in response to the transition to MH. One 
approach would be to use a specific ribonuclease protection assay that can differentiate 
and quantify rat Ren from mouse Ren -2 mRNA on total RNA extracted from 




Immunohistochemistry was performed using a polyclonal anti-mouse renin antibody with an avidin- 
biotin horseradish peroxidase secondary detection system on 4% formal saline fixed kidney sections. 
A Staining at the vascular pole of glomeruli was scanty in healthy hypertensive transgenic 
Ren-2 rats. Photomicrograph (X 630) shows the vascular pole (not counter-stained) of an 
individual glomerulus. 
B In contrast the staining seen at the vascular poles from transgenic rats with features of MH 
was frequent and more dense. Photomicrograph (X 400) shows an example of a glomerulus 
with the arteriole staining for renin. 
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3.8 Blood films 
A process of intravascular haemolysis has been well described in MH and is a 
common component of the clinical presentation, though it tends to be less florid than 
that found in conditions such as HUSIF'IY (haemolytic -uraemic syndrome/thrombotic 
thrombocytopenic purpura) which may be accompanied by severe hypertension363- 
365. It has been suggested that the haemolysis may in part be due to the concomitant 
uraemia365, while others have suggested that it is a primary process which itself 
induces vascular wall damage initiating the transition to MH331. 
It was therefore decided to specifically look for evidence of microangiopathic 
haemolytic anaemia (MAHA) in transgenic rats with MH, in healthy hypertensive age - 
matched littermates of those with MH who might be considered as pre- malignant and 
in normotensive SD at age seven to nine weeks. Blood was obtained either by retro- 
orbital bleed or by direct cardiac puncture under halothane anaesthesia. 
A reticulocyte count was determined as a percentage of red cells from all films. 
The normal range for reticulocyte counts in male Alderley rats (aged 26 weeks) was 
0.5 to 2.7 %. SD may have a different normal range. Haemolysis was defined as 
present when there was evidence of spherocytes, microspherocytes and red cell 
fragments, and films were scored blind on a grade of 0 to + ++ (Table 3.8.1). In 
addition, burr cells were also noted in the films of some rats with MH. Four of the 
samples were taken from rats who were on telemetry but it was clear that the intra- 
aortic catheter did not induce intravascular haemolysis. Examples of a blood film 
(Wrights stain) from a normal SD and one from a rat with MH showing evidence of 
haemolysis is shown in Fig 3.8.1. 
The results clearly demonstrated that with MH, there were features of 
microangiopathic haemolysis, namely red cell fragmentation with spherocytes and 
microspherocytes. Reticulocyte counts ( %) in rats with MH (mean ± SD) were 
11.2 ±2.5% which were significantly higher (p= 0.003) than those found in age - 
matched transgenic littermates (6.22 ±1.1 %). It could not be confirmed that the latter 
group were truly pre- malignant as blood was obtained at the time of sacrifice, and on 
pathological examination features of florid fibrinoid necrosis were not seen. However 




HanRen2 /Edin ID Comments Haemolysis Reticulocyte 
count 
Malignant 4313 on telemetry + ++ 13.6% 
4644 - + ++ 10.6% 
4666 - + ++ 13.2% 
4756 - ++ 7.4% 
5061 - + ++ 11.2% 
Pre- malignant 4299 on telemetry 0 4.7% 
4300 on telemetry 0 6.3% 
4643 on telemetry 0 5.6% 
5067 - 0 7% 
5063 - 0 7.5% 
Edin SD 1 - 0 3.5% 
2 - 0 2.4% 
All rats were male. Four were on telemetry as indicated. "Malignant" hypertension was defined as 
present when affected rats had both clinical features of the syndrome, and evidence of fibrinoid necrosis 
on histology of renal tissue as described earlier. Potentially "pre -malignant" rats were age -matched 
litter -mates of HanRen2/Edin -- rats with MH, and blood was taken on the same day as their affected 
brothers with MH. Two non -transgenic EdinSD rats aged 8 weeks were also included for analysis. 
Haemolysis was scored blind to the status of the rat on a 0 to + ++ scale, with the presence of 






Blood films were both spread and stained with Wright's stain before photographing at X 630. 
A A film, taken from a healthy HanRen2/Edin - -, showing normal red blood cell morphology. 
B Film taken from blood obtained from a HanRen2/Edin -- rat with clinical and pathological 
signs of malignant hypertension. It shows an increased reticulocyte count (rt), 
microspherocytes (ms), red cell fragments and occasional Burr cells (b). 
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3.9 Conclusions 
The results reported here have characterized a rat model of MH where a 
spontaneous transition from BH to MH has occurred without the need for dietary, 
pharmacological or surgical manipulation. Features included an accelerated phase rise 
in MBP with increments of 70 mmHg over the terminal hours. Classical pathological 
changes affecting the kidney were seen with florid fibrinoid necrosis and myo- intimal 
proliferation. Surprisingly few secondary ischaemic changes were seen involving 
glomeruli or tubules suggesting that the duration of severe vascular damage was 
relatively short. In keeping with the renal pathology, affected rats developed acute 
renal failure with a rising plasma urea and creatinine. 
Evidence of activation of the RAS was seen with increased levels of circulating 
plasma renin, Ang II and aldosterone in MH compared to BH. Increased staining of 
afferent arterioles occurred at the vascular poles of glomeruli in affected rats 
suggesting that activation of the renal RAS occurred in this transgenic rat as seen in 
other models of MH155. 
Pathological changes were not limited to the kidney. Transgenic heterozygotes 
developed progressive LVH with statistically significant changes relative to non - 
transgenic SD present by six weeks of age. In sixteen week old Ren -2 heterozygotes, 
cardiac hypertrophy and reduced LV compliance has been previously reported with 
evidence of increased peri- vascular fibrosis, but not interstitial fibrosis290. 
Multiple cardiac micro -infarcts were found in HanRen2 /Edin -- and in 
occasional HanRen2 /Han - -. These were occasionally seen to be associated with 
fibrinoid necrosis of cardiac arterioles, but were also observed in rats that did not have 
features of florid renal fibrinoid necrosis. Such lesions have been previously reported 
in SHR -SP maintained on 1% NaC1 drinking solution362,446. SHR -SP maintained on 
water also show an expected increase in myocardial fibrosis with perivascular, 
interstitial and focal distributions. It has been suggested that perivascular and 
interstitial fibrosis may be induced by exudation of growth factors, possibly secondary 
to increased vascular wall permeability447, but the nature of focal fibrosis has been 
less well characterized. It would seem likely that focal infarction is responsible. In 
SHR of over eight months of age, foci of old and new necrosis and fibrosis have been 
described448. The aetiology of these microinfarcts in this strain with their likely 
sequelae of focal fibrosis is not clear. 
Observations from this study have suggested that fibrinoid change in small 
cardiac arterioles may be contributory. Both Ang II and aldosterone have been 
implicated as growth factors which, via induction of proto- oncogenes, may be 
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involved in the process of development of LVH and in remodeling in response to 
hypertension and endothelial damage203,194,195,207,208_ Elevated circulating Ang II 
levels, either of endogenous or exogenous origin, have also been implicated in causing 
focal cardiac myonecrosis and fibrosis449, and may be relevant in this model. 
Continuous ECG recording (two lead) was performed in two HanRen2 /Edin -- 
animals. Implants (TA11CTA -F40) were surgically implanted into 40 day old male 
rats under halothane anaesthesia with placement of the electrodes at the right shoulder 
and left groin. Both rats developed MH, and it was observed in one of the two rats 
that, over the last 24 hours before death, an increasing frequency of ventricular extra - 
systoles and self -terminating runs of ventricular tachycardia were observed leading to 
ventricular fibrillation (data not shown). Though preliminary, this suggests that 
ventricular arrhythmias may well originate from such foci of necrotic and fibrotic 
myocardium and warrants further investigation. Angina has been reported to be a rare 
symptom in MH 306,302, and the clinical picture in humans is likely to be strongly 
influenced by the presence of coronary vascular disease. It is not known however 
what the incidence of sudden death or documented ventricular tachyarrythmias are in 
patients with MH. 
The reasons why HanRen2 /Edin -- are more at risk of developing MH are not 
clear from these physiological studies. They do appear to have a slightly higher MBP 
than the other two hemizygous crosses from 52 to 60 days of age, but this finding 
may be confounded by inclusion of rats in the initial stages of an accelerated phase in 
this group. Certainly absolute BP levels alone are not crucial to precipitating the 
change from BH to MH, as HanRen2 /Han -- and HanRen2 /Lew -- hybrids reached 
comparable BP levels to HanRen2 /Edin -- after a lag phase of approximately 10 days. 
Transgene dosage effect has been linked to inducing MH, and it has been reported 
previously that untreated homozygous Ren -2 rats have a higher incidence of death269. 
Histopathological examination of tissues from homozygous transgene positive rats, 
not maintained on a converting enzyme inhibitors, did reveal fibrinoid necrosis of 
comparable severity. However for the three F1 hybrids examined here who exhibited a 
clear difference in incidence of the phenotype of MH, no change in either transgene 
copy number or transgene insertion site can account for the variation as homozygotes 
from the same transgenic line TGR(mREN2)27 were used for breeding purposes. 
Hemizygotes derived from the line TGR(mREN2)26 and EdinSD did not 
develop MH, but they are less hypertensive compared to TGR(mREN2)27 derived 
hemizygotes. Hypertensive transgenic rats have been made using a transgene construct 
(a1AT- REN2), comprising the al -antitrypsin promoter fused to Ren -2 cDNA, 
introduced into EdinSD rat embryos, and resulted in expression of Ren -2 primarily in 
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liver. MH has occurred in a significant proportion of the progeny and has been 
confirmed by histopathological examination of renal tissue. These transgenic rats have 
very elevated circulating prorenin levels, but no significant difference in plasma renin 
was found in transgene positive rats compared to non -transgenic littermates. Active 
Ren -2 derived renin was found in plasma indicating that activation of transgene 
derived prorenin was occurring outwith the liver (D Ogg, personal communication) 
450,451. Another group have now reported the early death of some animals from a 
group of hemizygous Ren -2 rats on a SD background associated with severe arterial 
and arteriolar changes including fibrinoid necrosis. The origins of their SD colony 
were not published/52. 
Thus experiments have suggested that environmental factors are not 
responsible for the differing incidence between the three transgenic, hemizygous F1 
hybrids, but that the EdinSD rat may exhibit an increased predisposition to develop 
MH. The relatively narrow age range at which these animals develop MH is 
interesting. Survivors beyond 100 days infrequently develop either clinical or 
pathological features of MH. This might suggest that the vasculature in younger rats 
has had less time to develop structural adaptations to the increase in pressure and this 
may be relevant to understanding the pathogenesis of the transition to MH. It is 
possible that the reduced incidence seen in HanRen2/Han -- and HanRen2/Lew -- is due 
to the small lag phase of rise in BP, and therefore that a higher BP at a younger age 
may be a marker of increased risk of transition to MH. 
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CHAPTER 4 
Transition to Malignant hypertension may have a genetic basis 
4.1 Introduction 
In Chapter 3 the studies have clearly indicated that genetic factors appeared to 
be important in increasing the likelihood of transition from benign hypertension to 
malignant phase in the three heterozygote crosses. Subtle dietary differences did not 
appear to be important. If a genetic factor or factors were important then this might 
point towards a putative triggering factor that is acting in conjunction with elevated BP 
to induce development of the vascular damage and activation of the renin -angiotensin 
system. In the light of the clear distinction between the HanRen2 /Edin -- and 
HanRen2 /Lew -- crosses in terms of incidence of the malignant phenotype it was 
decided to design an analytical cross to further ascertain whether a genetic factor or 
factors was important. 
4.2 Design of the analytical cross 
A breeding programme was instituted with the aim of segregating alleles 
derived from EdinSD rats. The design of the cross is illustrated in Fig 4.2.1 
Fig 4.2.1 
HanRen2/HanRen2 T Edin--/Edin-- 
HanRen2/Edin-- HanRen2/Edin-- Edin--/Edin-- 
(Han,Edin)Ren2 /(Han,Edin)Ren2 
Gamete p(E) =50 %, p(H) =50% 
Zygote 
Lew -- /Lew -- 
Edin--/Lew-- 
p(E)=50%, p(L)=50% 
(Han,Edin) Ren2/(Edi n,Lew)-- 
(EE, HE, EL, HL) 
p(E)=75% 
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Fig 4.2.1 shows the analytical cross designed to segregate EdinSD derived alleles. Crosses are depicted 
by their assumed genotype. At the gamete stage from the male side, it can be assumed that there is a 
50% probability of an EdinSD (E) and 50% probability of Hannover SD (H) derived allele. On the 
female side, there is a 50% probability of an EdinSD (E) and a 50% probability of a Lewis (L) allele. 
Therefore in the progeny depicted (Han,Edin)Ren2/(Edin,Lew)--, the possible alleles at any one locus 
may be EE, HE, EL or HL giving an overall 75% likelihood of the presence of an EdinSD derived 
allele. The limited number of crosses reduces the likelihood of recombination events occurring. 
4.3. Methods 
Male F1 progeny defined as (Han,Edin)Ren2 /(Edin,Lew) -- (n =73) were bred 
from three (Han,Edin)Ren2 /(Han,Edin)Ren2 males and eight Edin -- /Lew -- females. 
The (Han,Edin)Ren2 /(Han,Edin)Ren2 males in this study were confirmed to be 
homozygous for the transgene after the progeny of three litters were tested for the 
presence of the transgene by Southern blotting of tail DNA. Such homozygous males 
were maintained on Lisinopril (25 mg/1 drinking water) to control BP for the purposes 
of breeding. After mating the females were removed and not exposed further to ACE 
inhibitors or other drugs. They were raised on a standard diet (sodium 0.32 %) with 
tap water ad libitum to drink and housed in groups of three. 
Systolic blood pressure (SBP) was measured by tail cuff plethysmography 
under light halothane anaesthesia in all 73 rats at age 52 days and in a sub -group of 28 
rats, SBP was measured at 35 days, 42 days and 52 days. All animals were examined 
for development of features suggestive of MH and diagnosis was confirmed post- 
mortem by histological examination of 3 Jim sections of kidney stained with H &E and 
mounted. Surviving animals were sacrificed at age 130 days, and renal histological 
examination performed. X2 analysis was used to compare the incidence of MH in the 
male Fl progeny with HanRen2 /Edin -- as well as comparing expected penetrance in 
the progeny on the assumption of a one, two or three gene model. A p value of <0.05 
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Fig 4.4.1 shows a frequency distribution for the age at death of 43 (Han,Edin)Ren2 /(Edin,Lew) -- 
males raised on a normal sodium diet. Median age was 66 days (range 53 to 117 days). Seventy -three 
rats were studied. 
Forty -three (41 by 100 days of age) of the original seventy -three rats 
subsequently developed the terminal clinical features suggestive of MH, and on renal 
histological examination the presence of fibrinoid necrosis was apparent in forty -two 
of these animals (Table 4.4.1). Those animals that did not develop clinical features of 
MH and survived to the end of the study period were deemed to have BH. The age 
range at which rats died from MH is shown in Fig 4.4.1. 
The median age was 66 days, range 53 to 117 days which was very 
comparable to the age range seen for male HanRen2 /Edin -- (median 57 days, range 
33 -103 days). Therefore, the penetrance of the malignant hypertensive phenotype in 
this cross was taken to be 42/73 or 57.5% (95% confidence limits 45.9 - 69.5 %453) 
This was significantly different to the incidence observed in HanRen2 /Edin -- 73.5% 
(95% confidence limits 65.7 - 81.3 %) by X2 analysis (X2= 5.181, df =1, p <0.05). 
SBP in those that subsequently went on to develop MH was compared to 
those with benign hypertension and the results are shown in Fig 4.4.2. SBP was not 
significantly different in those that developed MH at 52 days of age compared to those 
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with BH. No significant difference was seen in the 42 day old group (of 28 rats, 13 
went on to develop MH, 15 rats had BH). However in the 35 day old group there was 
a small but significant difference with a higher SBP in those that ultimately developed 
MH (141.9 ± 20.1 mmHg) compared to those who persisted with BH (124.1 ± 17.8 
mmHg). 
From 52 days of age, at least 27 rats went on to develop and die from MH 
over the following 18 days, and therefore a number of these might have been expected 
to have been entering the accelerated phase at that time. Recording SBP by tail cuff 
plethysmography under anaesthesia, unlike telemetry, might in some way have 
masked this effect. The results do however suggest that there was little difference in 
SBP between those developing MH and those with simple BH at that age. 
In this study, the probability of at least one EdinSD- derived allele being 
present at any one locus is 0.75. On making the assumption that a putative EdinSD 
derived MH gene might act in a dominant fashion, the expected penetrance in the 
(Han,Edin)Ren2 /(Edin,Lew) -- males would be a product of 0.75 times the observed 
penetrance (73.5 %) in HanRen2 /Edin -- where there is an EdinSD derived allele at all 
loci. This would give an expected penetrance of 55.1% (95% confidence limits 49.3 - 
61%) which was close to that observed (57.5 %). If two genes were involved, the 
probability of EdinSD derived alleles being present at both loci is 9/16 or 0.562. The 
expected penetrance would therefore be 41.3% (95% confidence limits 36.9- 45.7 %). 
Two genes could not be excluded with the numbers of rats used in this study. 
Over the 95% confidence range, X2 ranged from 2.028 to 6.18 for 1 degree of 
freedom and therefore p ranged from 0.01 to >0.05. Three genes could be excluded, 
the expected penetrance being 27/64 or 0.422 of 73.5% which equals 31.0% (95% 
confidence limits 27.7- 34.3 %). X2 ranged from 7.972 to 11.706 giving a p value of 
<0.01 
In conclusion, these results most strongly supported a monogenic model 
where the effects of the expression of a single gene acting in conjunction with 
hypertension leads to transition into MH, but two genes could not be excluded. One 
potential source of error would be the effects of delayed penetrance. In all groups the 
majority of affected rats have developed the malignant phenotype by 100 days of age, 
but in this study two rats developed MH at 103 and 117 days of age and they have 
been included in the analysis. Secondly some surviving rats (n =8) exhibiting no 
clinical features suggestive of MH nevertheless had histological signs of myo- intimal 
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The penetrance in the HanRen2/Edin -- cross was 73.5 %. This therefore raises 
the question as to why the remainder did not develop MH. Certainly it appeared that 
some litters of HanRen2 /Edin -- tended towards almost 100% penetrance while others 
had a lower penetrance with the overall incidence of MH being taken to be 73.5% with 
described confidence limits. The SD rat is an out -bred strain and thus it would be 
wrong to assume that all rats might carry the responsible gene. This might help to 
explain the lower penetrance in the HanRen2/Han -- which is also a SD strain together 
with the finding of MH in other SD strains crossed with transgenic Ren -2 
homozygotes 452. In the (Han,Edin)Ren2 /(Edin,Lew) -- cross it was important to note 
that litters derived from all three transgenic homozygotes also gave varying levels of 
penetrance of the malignant phenotype (see Table 4.4.1). 
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Table 4.4.1 
ID Father Mother Age Histology 
5560 A2333 4336/7/8 66 1 
5561 A2333 4336/7/8 73 1 
5562 A2333 4336/7/8 - 3 
5563 A2333 4336/7/8 62 1 
5564 A2333 4336/7/8 117 1+3 
5565 A2333 4336/7/8 59 1 
5566 A2333 4336/7/8 80 1 
5567 A2333 4336/7/8 58 1 
5568 A2333 4336/7/8 62 1 
5569 A2333 4336/7/8 70 1 
5570 A2333 4336/7/8 - 4 
5571 A2333 4336/7/8 - 3 
5572 A2333 4336/7/8 64 1 
5573 A2333 4336/7/8 - 1* 
5574 A2333 4336/7/8 66 1 
5575 A2333 4336/7/8 - 3 
5732 A2333 4338 70 1 
5733 A2333 4338 103 1 
5734 A2333 4338 53 1 
5848 A2333 4337 - 1* 
5850 A2333 4337 59 1 
5851 A2333 4337 59 1 
5852 A2333 4337 - 1* 
5853 A2333 4337 55 3t 
5854 A2333 4337 - 1* 
5855 A2333 4337 62 1 
5856 A2333 4337 - 1* 
5857 A2333 4337 57 1 
5858 A2333 4336 - 2 
5859 A2333 4336 68 N/A 
5860 A2333 4336 73 1 
5861 A2333 4336 - 1* 
5862 A2333 4336 - 3 
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5863 A2333 4639 86 1 
5864 A2333 4639 - 2 
5865 A2333 4639 - 3 
5866 A2333 4639 81 1 
5867 A2333 4639 - 4 
5868 A2333 4639 - 2 
5869 A2333 4639 - 4 
5870 A2333 4639 - 2 
5576 C2337 4333/4/5 62 N/A 
5577 C2337 4333/4/5 61 1 
5578 C2337 4333/4/5 66 1 
5579 C2337 4333/4/5 82 1 
5580 C2337 4333/4/5 67 1 
5581 C2337 4333/4/5 70 1 
5582 C2337 4333/4/5 68 1 
5583 C2337 4333/4/5 70 1 
5584 C2337 4333/4/5 - 2/3 
5585 C2337 4333/4/5 - 3 
5871 C2337 4335 - 2 
5872 C2337 4335 56 N/A 
5873 C2337 4335 - 1* 
5874 C2337 4335 - 3 
5875 C2337 4335 92 1 
6136 C2337 4334 65 1 
6137 C2337 4334 - 1* 
6138 C2337 4334 56 1 
6139 C2337 4334 - 3 
6140 C2337 4334 60 1 
6141 C2337 4334 - 2 
6142 C2337 4334 - 3 
6143 C2337 4333 - 2 
6144 C2337 4333 - 1* 
6145 C2337 4333 - 3 
6146 C2337 4333 91 1 
6426 C2339 4333 67 1 
6427 C2339 4333 72 1 
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6428 C2339 4333 67 1 
6429 C2339 4333 58 N/A 
6430 C2339 4333 73 1 
6431 C2339 4333 65 N/A 
n=73 n=42 
+ I t 
Table 4.4.1 shows litters born from 3 males A2333, C2337 and C2339 and 8 females 4333 -4339, and 
4639. Rats (5560 -5575) were derived from three litters by A2333 out of the three females (4336, 
4337, 4338) and it was not possible to separate the litters. Similarly 5576 -5585 were derived from 
three litters by C2337 out of females (4333, 4334, 4335). Otherwise all litters were maintained 
separately until ear tagged and weaned and thereafter adults were kept in cages of three. The age at 
death is shown. Histological grading of kidney sections was performed, while blind to the clinical 
status of the rat, and is shown as 1. severe, acute fibrinoid necrosis; 2. sub -acute fibrinoid change; 3. 
chronic hypertensive vascular wall thickening and secondary ischaemic change; 4. no abnormalities 
detected. *indicates where there was severe acute fibrinoid necrosis, but no clinical evidence of MH. 
tindicates one animal who died but did not have histological evidence of fibrinoid necrosis or other 
pathological features of MH on the kidney section studied. The proportion of progeny who derived 
from A2333 developing MH was (22 +1t) /41; from C2337 14/26 and C2339 6/6. 
4.5 Preliminary mapping studies of the MH gene. 
If it were possible to identify a genetic marker that was in linkage 
disequilibrium with the phenotype of MH, then by reverse genetics it might be 
possible to identify the gene responsible, its function and hence the pathophysiology 
behind the development of MH. Having established an apparent genetic predisposition 
to MH, it was decided to perform a preliminary study using the above F2 hybrids 
(Han,Edin)Ren2 /(Edin,Lew) -- to determine the feasibility of mapping a putative MH 
gene or genes. Primers flanking polymorphic microsatellites (mainly CA repeat 
sequences) were obtained from Dr H Jacob (MapPairsrm (Rat), Cardiovascular 
Research Centre, Massachusetts General Hospital, Massachusetts, USA) and 
following PCR and gel electrophoresis (8% sequencing gel) of the PCR products, the 
F2 hybrids were genotyped. 
At the time of sacrifice, either on exhibiting clinical features of MH or at the 
end of the study period as described above, the spleen was dissected out, snap frozen 
in liquid nitrogen and stored at -70 °C for later DNA extraction. For those rats who 
were found dead, a small sample of tail was taken post -mortem to obtain DNA. Tail 
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DNA was also taken from an additional five HanSD, five EdinSD, five Lewis rats and 
from male A2333 and females 4666, 4667, 4668 and 4639. 
This preliminary study was restricted to the 41 male progeny derived from 
A2333. Informative primers were identified as being able to differentiate Lewis, Edin 
SD and HanSD alleles. Out of 150 loci tested, 30 primer pairs were found to be 
informative distinguishing three alleles L, E and H respectively and were therefore 
used to genotype the F2 hybrids derived from A2333. Examples of results obtained 




Phenotype Genotype (A) Genotype (B) 
Lewis - 1 3 11 
A2333 2 3 1 2 
4336 - 1 2 1 3 
4337 - 1 2 1 3 
4338 - 1 2 1 3 
4639 - 1 2 1 3 
5560 M 1 3 1 2 
5561 M 2 3 1 1 
5562 - 1 3 1 3 
5563 M 2 3 1 2 
5565 M 2 3 2 3 
5566 M 2 3 1 3 
5567 M 1 3 2 3 
5568 M 2 3 11 
5569 M 2 2 1 1 
5570 - 1 3 2 3 
5571 - 2 2 1 2 
5572 M 1 2 1 1 
5573 - 1 3 1 3 
5574 M 2 2 2 3 
5575 - 1 2 1 3 
5732 M 1 3 1 1 
5733 M 1 3 2 3 
5734 - 2 3 2 3 
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5848 - - - - 2 3 
5850 M 1 2 1 1 
5851 M 1 3 1 1 
5852 - 1 3 1 2 
5853 M 2 2 1 2 
5854 - 2 2 1 2 
5855 M 1 3 1 3 
5856 - 2 3 1 3 
5857 M 1 2 1 3 
5858 - 2 3 2 3 
5859 M 2 2 1 2 
5860 M 1 3 1 1 
5861 - 1 3 1 3 
5862 - 1 2 1 1 
5863 M 1 2 1 1 
5864 - 1 3 1 1 
5865 - 2 2 1 3 
5866 M 1 2 
5867 - 1 2 2 3 
5868 - 1 2 1 2 
5870 - 2 3 11 
Table 4.5.1 illustrates the results obtained from two informative primer pairs A and B. In each case 
three alleles have been identified (1, 2 or 3). 
Table 4.5.2 
Primer Pair Genotype Phenotype 
M/- 
A 1/2 5M,4- 
A 2/3 5 M, 4 - 
A 2/2 4 M, 3 - 
A 1/3 7 M, 6- 
B 1/1 9M,3- 
B 1/2 4M,4- 
B 2/3 4M,5- 
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Table 4.5.2 illustrates the analysis of results. Using primer pair A there was random inheritance of 
the determined genotypes with either the phenotype M of malignant hypertension or - indicating 
benign hypertension. With primer pair B, there was a deviation from random inheritance with an 
excess of the alleles 1/1 in the group with MH, but this did not reach a statistically significant LOD 
score. 
It was shown that there were not sufficient animals in this study to obtain 
statistically significant evidence of linkage disequilibrium, but that further work 
utilising this technique might potentially demonstrate linkage of a marker with the 
phenotype. The relatively small number of informative markers available at the time of 
the study reduced the likelihood of a positive result, but further work will undoubtedly 
benefit from the increased number of genetic markers available. 
4.6 Conclusions 
The study described in this chapter has lent further support to the earlier results 
suggesting that the development of MH in transgenic Ren -2 hybrids is in part 
genetically determined. Previously it was noted that a higher MBP in telemetercd 
HanRen2/Edin -- heterozygotes from 52 - 60 days of age was present relative to the 
other two heterozygote crosses (Fig 3.3.1), but in this study of 
(Han,Edin)Ren2 /(Edin,Lew) -- hybrids, SBP both at 42 and 52 days of age did not 
show any clear difference between those destined to develop MH and those who 
persisted with BH. The method used for measurement of BP may be relevant. 
Measuring SBP by tail cuff plethysmography under halothane anaesthesia may mask 
some early changes in BP which are related to the development of MH. There is a 
suggestion from the results shown in Fig 3.3.1 that HanRen2 /Edin -- do have a higher 
MBP at a younger age and with the results shown here of a significantly higher SBP 
at 35 days of age in (Han,Edin)Ren2 /(Edin,Lew) -- hybrids who developed MH, 
elevated BP at a younger age may in some way be a marker of a predisposition to 
develop MH. 
The incidence of the MH phenotype in the (Han,Edin)Ren2 /(Edin,Lew) -- F2 
cross most strongly supports a monogenic model, though with the limitation of the 
number of rats used two genes could not be excluded. It is possible that a genetic 
marker might ultimately be found which shows linkage disequilibrium with the trait of 
malignant hypertension. It would therefore be interesting in the event of such a marker 
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being found, through reverse genetics, to identify the functional effects. One might 
hypothesize that altered function or permeability of the endothelium or an altered 
response of some other component of the arterial wall might be responsible. 
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CHAPTER 5 
The role of endothelin in the transition from benign to malignant phase 
hypertension 
5.1 Introduction 
The transition from benign to malignant phase hypertension involves a 
pressure induced natriuresis and diuresis, an accelerating rise in BP, myointimal 
proliferation and fibrinoid necrosis particularly affecting afferent arterioles and 
interlobular arteries in the kidney306 In addition as discussed in Chapter 1, there is 
evidence that activation of the renal renin- angiotensin system (RAS) occurs, which 
may in turn contribute to the vicious circle of increasing BP and vascular damage341- 
343,358. However the factors which initiate the transition from benign to malignant 
phase hypertension remain to be identified, together with their relationship with the 
onset and progression of the resulting pathological damage. Male HanRen2/Edin -- rats 
derived from crossing homozygote TGR(mREN2)27267 with EdinSD have been 
shown to have an increased predisposition to MH, while HanRen2 /Lew -- derived 
from crossing with the Lewis strain developed only benign hypertension (BH). 
Studies described in Chapter 4 have suggested, on the basis of a genetic cross 
designed to segregate EdinSD derived genes, that a genetically determined factor 
acting in addition to but independent of BP, was important in initiating this transition. 
As discussed in section 1.9, a candidate that might be involved in the endothelial 
response to hypertension and hence might be a determining factor in the initiation of 
MH, is endothelin. It was decided to use this transgenic rat model of MH to 
investigate such a role in the pre -malignant phase and in established MH. 
It was decided to look firstly for changes in renal expression of ET -1, -2, and 
-3 mRNA levels in rats with MH compared to those with benign hypertension or 
normotension using appropriate transgenic heterozygote crosses and EdinSD controls. 
To determine whether there was any pathological role for ET, the effects of chronic 
administration of the non -specific ET receptor antagonist Bosentan (4 -tert -butyl - N - 
(6-(2-hydroxy-ethoxy) - 5 - (2- methoxy -phenoxy) - 2, 2' - bipyrimidin -4 -y1) - 
benzene sulfonamide)454 on HanRen2 /Edin -- was studied. The methods used are 
described earlier in section 2.5. 
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5.2 Results 
Four groups of 8 to 10 week old rats were studied: (1) HanRen2/Edin -- with 
malignant phase hypertension (n =11) where malignant hypertension was identified on 
the basis of the previously described appearances of weight loss, apathy, fitting and 
confirmed by histopathological examination, (2) age- matched HanRen2/Edin -- with 
benign hypertension but no signs of malignant phase (n =6), (3) HanRen2/Lew -- with 
benign hypertension (n =4), and (4) normotensive EdinSD (n=4). 
On total RNA extracted from kidney tissue as described earlier, RNasc 
protection assays for ET -1, ET -2 and ET -3 mRNA were performed using human a- 
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Fig 5.2.1 is a scatter plot of cpm quantifying ET -1 (A) and ET -3 (B) mRNA for individual rats. Four 
age -matched groups were studied; A - HanRen2/Edin -- with malignant phase hypertension; B - 
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RNase protection assays were performed for ET -1, ET -2 and ET -3 mRNA on total RNA extracted 
from kidneys snap frozen at sacrifice. A shows an autoradiograph of a gel after hybridization with 
probes specific for ET -1 and human a- globin, while B shows an autoradiograph of a gel after 
hybridization with probes specific for ET -3 and human a- globin as described in section 2.5. 
Lane M indicates RNA markers; Lanes 1 - 3 EdinSD; Lanes 4 - 7 and 9 - 12 (indicated by the 
black bar) I IanRen2/Edin -- with MI-1; Lane 8 HanRen2/Lew --; Lanes 13 - 16 HanRen2/Edin -- 
with BH (indicated by the shaded bar); Lane 17 no RNA for background and Lanes 18 - 20 external 
standards using pooled RNA from SD rats. 
After excision of the protected fragments, the results were expressed as counts 
per minute (cpm) after correction for efficiency of processing, gel loading and 
background activity and results from individual animals are shown in Fig 5.2.1 A and 
B. Example autoradiographs are shown in Fig 5.2.2 A and B respectively. Both ET -1 
mRNA and ET -3 mRNA were detected with the RNase protection assays, but ET -2 
mRNA was not detected in kidney tissue from any of the four groups studied. 
ET -1 mRNA levels differed significantly between the four groups (Kruskal- 
Wallis one way ANOVA corrected for ties; X2 = 11.757, df = 3, p = 0.008). For 
HanRen2/Edin -- with clinical signs and histopathological evidence of malignant phase 
hypertension (MH), the mean (± SD) was 81.8 ± 24.7 cpm, compared with age - 
matched HanRen2 /Edin -- with benign hypertension (BH) at 49.5 ± 19.1 cpm, 
HanRen2 /Lew -- with BH at 37.2 ± 15.7 cpm or normotensive SD with 36.2 ± 6.8 
cpm. On comparing groups using a Mann -Whitney U test (corrected for ties) 
HanRen2 /Edin -- with MH had significantly higher levels of ET -1 mRNA compared 
with either HanRen2/Edin -- with BH (Z statistic = -2.3, p = 0.02), HanRen2 /Lew (Z 
statistic = -2.49, p = 0.013) or Edin SD (Z statistic = -2.3, p = 0.019). 
Differences in ET -3 levels detected between the four groups did not quite 
attain statistical significance (Kruskal- Wallis, X2 = 7.810, df = 3, p= 0.0501), though 
lower levels were observed to occur in MH kidney (9.15 ± 5.7 cpm) compared with 
the control groups; HanRen2/Edin -- with BH (16.2 ± 7.5 cpm), HanRen2 /Lew -- with 
BH (12.9 ± 1.1 cpm), or normotensive EdinSD (20.9 ± 10.0 cpm). 
It therefore appeared that increased renal ET -1 mRNA levels were present on 
transition to the malignant phase. In order to determine whether this increase in renal 
ET -1 mRNA had an important role in the initiation of, or the transition to MH, it was 
decided to administer a non -specific endothelin antagonist, Bosentan to the susceptible 
group, HanRen2 /Edin - -. It was important to exclude any anti- hypertensive effect of 
the drug which could have also reduced the incidence of MH. 
Average MBP, recorded over equivalent 12 hour periods to correct for the 
effects of diurnal variation, were compared before and after administration of 
Bosentan by gavage to transgenic Ren -2 rats on telemetry. No significant effect on 
MBP, either within the first 12 hours or from 12 to 24 hours after a single dose was 
administered, was observed (Fig 5.2.3 A). A repeat dose given one week later to four 
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Fig 5.2.3 A shows MBP (mean ± SD) pre -dose and post -dose comparing equivalent periods of the day 
for male rats (n =11) given Bosentan 100 mg /kg by gavage. MBP was recorded by telemetry in 
conscious unrestrained rats as previously described. Two example traces are shown in B where 
recording over a 72 hour period shows no significant hypotensive effect of the non -specific El' 
antagonist administered at the arrowed time point. 
Male HanRen2/ Edin -- rats were therefore housed in groups of three or four 
and fed a normal sodium diet from weaning at 25 days and randomly assigned to 
either a treatment group (n = 17), given the non -specific endothelin receptor antagonist 
Bosentan or a control group (n = 17) given the same diet without Bosentan added. 
MH was defined as present on development of clear signs of the syndrome, together 
140 
with light microscopic examination of renal tissue confirming the presence of fibrinoid 
necrosis and myointimal proliferation. SBP, heart rates (HR) and body weights were 
regularly recorded in both groups through -out the treatment period as described in 
section 2.5. No effect on SBP (measured by tail cuff plethysmography in 
anaesthetized rats), HR or gain in body weight was observed in rats up to fifteen 
weeks of age (Fig 5.2.4). 
Fig 5.2.4 
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A. Systolic blood pressure (SBP) 
was measured by tail cuff 
plethysmography in anaesthetized 
rats. Group means are shown with 
error bars representing one SD. 
indicate Bosentan treated rats (n = 
17) and indicate control untreated 
rats (n = 17) at the start of the 
study. 
B shows heart rate (mean ± SD) for 
treated and untreated controls. I leart 
rate was measured at the time of 
SBP recording by tail cuff 
plethysmography in anaesthetized 
rats. 
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C shows body weight (mean ± 
SD). Both treated and untreated 
groups received the same powdered 
rat diet. Bosentan was mixed into 
the diet in the treated group. There 
was no evidence of a difference in 
food intake between the two groups 
In this study, there was no statistically significant difference in the survival 
curves between the two groups, with 9/17 (53 %) control animals and 11/17 (65 %) 
treated animals developing MH (Fig 5.2.5) with the pathological features of MH 
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Survival curve compares Bosentan 
treated D and untreated control 
rats, with the period of treatment 
indicated by the bar. Necropsy was 
performed after death and MII 
confirmed on histopathological 
examination of kidney tissue. 
To make any conclusions from this study, it was important to verify that, both 
the dose of endothelin antagonist used, and the method of administration had achieved 
blockade of ET receptors. As described in section 2.5, three treated survivors and four 
untreated survivors, while still on their assigned diet, were given intravenous big -ET 
(0.3 nmol/Kg). If there had been adequate receptor blockade, it was anticipated that 
the hypertensive response elicited by big -ET would be abolished. The maximal 
increase in MBP occurring during the subsequent 60 minute period in untreated rats 
ranged from +24.5% to +42.4 %, but in the Bosentan treated rats, an increase in MBP 
of between only 0% and +5.6% was observed. This indicated that, at the dose of 
Bosentan used and with the method of delivery, adequate blockade of ET- receptor 
mediated systemic vasopressor effects had been achieved (Fig 5.2.6). In addition, 
there was no evidence to suggest that tachyphylaxis had occurred during chronic 
treatment leading to inadequate blockade of the ET receptors. 
Fig 5.2.6 
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Response to porcine big - 
ET (0.3 nmol /kg IV). 
Percent change in MBP is 
shown, with the pre - 
dosage MBP standardized 
to 100. MBP was recorded 
in anaesthetized rats by 
continuous direct intra- 
arterial monitoring. 
Measurements are shown 
at 5 minute intervals for 
individual animals; 
Bosentan treated as open 
symbols and untreated 
controls as closed 
symbols. 
5.3 Effects of Endothelin receptor blockade on development of left ventricular 
hypertrophy 
The effects of ET -1 have been shown to be both pro -mitogenic as well as 
hypertensive as discussed previously370. It was therefore of interest to ascertain 
whether the development of LVH in hypertensive transgenic rats could be diminished 
by the chronic administration of the endothelin antagonist Bosentan. In the course of 
the above experiment, male HanRen2 /Edin -- rats underwent echocardiographic 
determination of the left ventricular mass index (LVMI) at 25 days of age, immediately 
before randomisation to treatment with Bosentan (n =13) or control diet (n =14). This 
was repeated in healthy, surviving animals at 60 days of age (treated n =12, untreated 
n =9). Echocardiography was performed as previously described in section 2.3 (II). 
Three measurements of the left ventricular posterior wall thickness, end -diastolic 
diameter and interventricular septal thickness were obtained and the means used to 
determine the LV mass index (LVMI). The results are shown in Fig 5.3.1. Though a 
significant increase in LVMI occurred in both treated and untreated groups, there was 











Fig 5.3.1 shows left ventricular mass index (LVMI) at 28 and 60 days of age in Bosentan treated and 
untreated control rats. Mean LVMI and SD are shown. A significant increase in LVMI occurred over 
the time period in both groups (p<0.001 by unpaired t test) but there was no significant difference 
between the treated and untreated groups at either 28 days (p= 0.887) and at 60 days (p= 0.167). 
In conclusion, though ET has been demonstrated to exhibit pro- mitogenic 
effects in vitro, in this in vivo situation there was no attenuation in development of 
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LVH in response to hypertension in the face of chronic endothelin receptor blockade. 
Because some rats developed MH in both groups before the second echocardiographic 
determination of LVMI, it is possible that this might have affected the group 
comparisons but it seems unlikely that the findings would have been significantly 
altered. 
5.4 Discussion 
The identification of a genetic susceptibility to malignant phase hypertension in 
transgenic Ren -2 rats led to the question as to what factor(s) additional to high blood 
pressure might be responsible for initiating the transition to malignant phase 
hypertension. A few studies have suggested that transgenic Ren -2 rats may have 
altered endothelial function. It has been reported that an in vitro ring segment 
preparation taken from left anterior descending coronary arteries of 12 week old 
HanRen2/Han-- showed almost no contractile response to the NO synthase inhibitor 
L- arginine N- nitro -L- arginine methyl ester (L -NAME) compared to the response seen 
in 6 week old transgenic rats or in 12 week old HanSD and this suggested that there 
was an attenuated basal release of NO in older transgenic rats. However the 
endothelial -dependent relaxation response to the nitrovasodilator 3- morpholino- 
sydnonimine (linsidomine) and the vasoconstrictor response to potassium chloride 
was similar in 6 and 12 week old transgenic and non -transgenic rats, with no 
significant differences observed between the four groups455 Impaired basal NO 
activity in older transgenic rats might result in increased susceptibility to vasospasm 
and thrombotic events. However a significant and acute hypertensive response was 
elicited on giving L -NAME (75 mg/kg) to male HanRen2 /Han-- rats aged 15 weeks 
(n =3) on telemetry (data not shown). 
A role for endothelin has also been suggested on the basis of its potent 
vasoconstrictor effects, particularly on the kidney, and pro -mitogenic effects. 
Induction of endothelin expression within vascular endothelial cells occurs in response 
to low levels of shear stress, and in response to mediators such as thrombin, and Ang 
1I37° which could be involved in the process of MH. Recently it has been reported that 
the effects of pressure alone, without inducing shear stress, on cultured human 
umbilical vein endothelial cells resulted in an increase in ET -1 release via a mechanism 
involving protein kinase C and phospholipase C456 Elevated plasma immunoreactive 
ET -1 levels have been reported in two experimental rat models of malignant 
hypertension, following deoxycorticosterone acetate (DOCA) -salt administration to 
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spontaneously hypertensive rats (SHR) and chronic administration of caffeine to two - 
kidney, one clip rats420 
The short half -life of plasma endothelin, low circulating plasma levels and lack 
of evidence for endothelin storage have supported an autocrine or paracrine role for 
this peptide and this has made interpretation of plasma endothelin levels difficult374. In 
the DOCA -salt hypertensive rat, increased ET -1 gene expression has been reported, 
together with evidence of increased ET -1 peptide from acid extracts of thoracic aorta 
and mesenteric vessel wall tissue. However there was no difference in circulating ir- 
ET-1 levels between DOCA -salt hypertensive rats and their normotensive 
controls391,392. In contrast, the same authors reported finding a statistically significant 
increase in plasma it -ET -1 in 16 week old SHR compared to age -matched 
normotensive WKY, but a significantly lower total it -ET -1 content was found in acid 
extracts of SHR thoracic aorta segments and a small, but statistically insignificant, 
reduction was found in mesenteric vessel wall compared to those found in WKY391. 
Measurements of tissue endothelin mRNA levels were therefore felt to be a better 
reflection of the activity of the ET system. 
In this study the kidney was specifically studied in view of its known 
involvement in the pathogenesis of MH. RNase protection assays were used which 
could clearly differentiate between ET -1, ET -2 and ET -3 mRNA. The significant 
finding was of an increase in ET -1 mRNA expression in kidneys taken from rats with 
MH. Interestingly there was a tendency towards a reciprocal relationship between 
expression of ET -1 and ET -3 which has previously been observed414, with lowest 
levels of ET -3 occurring in MH kidneys. However the differences in ET -3 mRNA 
between groups did not reach statistical significance. ET -2 was not detected in rat 
kidney, as previously reported414 The results here have shown that increased renal 
expression of ET -1 mRNA is associated with the development of MH in concordance 
with the findings in other rat models of MH. It was important however to identify an 
active role for ET in MH, as an increase in ET -1 may simply have been an 
epiphenomenon reflecting endothelial cell damage. 
To examine this possibility, the effect of pharmacological manipulation of the 
ET system on the development of MH was studied. ET -A receptors preferentially bind 
ET -1 compared to the other isoforms, have a high efficacy and mediate vasoconstrictor 
effects, though the relative contribution of the ET -A and ET -B receptors to 
vasoconstriction may depend on the vascular bed studied. ET -B receptors show equal 
affinity for all three isoforms and have been linked to the formation of nitric oxide and 
prostacyclin374. It may be that changes in the ratio of ET -1 to ET -3, highest in MH, 
are relevant as they may reflect an imbalance between local vasoconstrictor and 
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vasodilator effects. In this study, the effects of the non -specific ET antagonist 
Bosentan, were examined in the MH model using a dose (100 mg/kg/day) which had 
previously been demonstrated to effectively block both ET -A and ET -B mediated 
vasoconstrictor effects454. It was important to exclude any anti -hypertensive effects of 
the antagonist which might reduce the risk of transition to MH. As such, with either 
acute administration of Bosentan to conscious rats, who had BP monitored by 
telemetry or on chronic administration to rats where BP was assessed weekly by tail 
cuff plethysmography, there was no anti -hypertensive response to the ET antagonist. 
This suggested that maintenance of blood pressure in transgenic Ren -2 rats was not 
mediated in the 'benign' hypertensive state by either ET receptor. 
It was also verified that at the end of the eleven week period of chronic oral 
administration of the antagonist, adequate receptor blockade and hence abolition of a 
systemic hypertensive effect from exogenous administration of porcine big -ET (0.3 
nmol/kg) had been achieved. It may still be possible that intra -renal ET receptor 
antagonism might not be complete, despite abolition of a systemic hypertensive 
response to exogenous big -ET. 
Chronic administration of the ET receptor antagonist did not significantly alter 
the incidence of MH, basal SBP, HR or gain in body weight. Though untreated 
HanRen2/Edin -- rats did develop MH slightly earlier than those in the Bosentan treated 
group, the age at onset for both groups did not differ significantly from the age range 
(median age 62 days, range 33 -113 days) in which a larger group (92/117) of 
untreated rats developed the syndrome (see Fig 3.2.1). 
In summary, this study has clearly demonstrated increased ET -1 mRNA 
expression in the kidney on transition to MH in the hypertensive transgenic 
HanRen2/Edin -- cross. In an age- matched group of healthy HanRen2 /Edin -- which 
might be considered as potentially pre -malignant, there was no significant difference in 
ET -1 mRNA levels relative to the non -susceptible cross HanRen2 /Lew -- with 
equivalent BP. The non -selective ET receptor antagonist, Bosentan did not 
significantly reduce the incidence of MH and this suggested that, in this model, the 
pathophysiological effects of endothelin are not involved in either initiating the 
transition from BH to MH or in the progression of the natural course of MH. 
Increased renal ET -1 mRNA expression may occur as a result of endothelial cell 
damage or ischaemia or simply by the effects of exposure to pressure, shear stress, 
Ang II or thrombin. 
It has also been demonstrated in this hypertensive rat model that endothelin 
receptor blockade does not attenuate the development of LVH. A similar finding was 
reported by Li et al (1994) who gave Bosentan (100 mg/kg/day) to DOCA -salt rats for 
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three weeks commencing from the time of surgery. No difference in heart weight/body 
weight ratio was seen between the treated and untreated groups despite there being a 
small but significant reduction in SBP in the Bosentan treated DOCA -salt rats. 
Interestingly Bosentan treatment did reduce the increment in mesenteric artery medial 
wall thickness and wall to lumen ratio that occurred over the same period393 ET 
peptides have been shown to have pro -mitogenic effects in vitro and it remains 
possible that a small contribution to the development of LVH is mediated by 
endothelin but as such it was too small to detect in these in vivo experimental models 
over the time scale used. Alternatively ET peptides may not be involved in either a 




Essential hypertension remains a major cause of morbidity and mortality in the 
world. In developed nations, it has recently been estimated that 24 - 30 % of all U.S. 
citizens over 18 years of age are hypertensive, and of them only 45% are adequately 
treatedl. Hypertension remains one of the main reasons for initiating life -long medical 
therapy with resulting cost implications, in order to reduce both target organ damage 
and associated morbidity and mortality. Despite the fact that an elevated BP has been 
recognised as a risk factor for a number of cardiovascular, cerebrovascular and renal 
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conditions, a clear understanding the causes of high BP in the majority of cases with 
essential hypertension has not been found. In Chapter 1, a review of the evidence was 
presented suggesting that genetic factors may be important. By using "reverse 
genetics ", identifying abnormal genes has led to improvement in the understanding of 
the aetiology of hypertension arising from some single gene defects, but the genetic 
basis of essential hypertension remains to be described. However, it is important to 
recognise that the finding of linkage between a polymorphism lying close to a 
candidate gene and hypertension does not imply causality. Secondly the contribution 
of environmental influences to elevation of BP, particularly those operating in utero, 
may be hard to quantify. 
The ability to study the contribution of individual candidate genes to a 
phenotype by transgenesis has resulted in some interesting models of monogenic 
hypertension, and in the case of the TGR(mREN2)27 hypertensive rat, this has led to 
much interest being focused on extra -renal RAS activity and the role of prorenin in the 
genesis of hypertension. 
Having the ability to recognise which hypertensive individuals are at risk of 
developing clinically significant target organ damage would be a useful adjunct to the 
management of hypertensive patients. To date recognised cofactors likely to increase 
the risk of cardiovascular, cerebrovascular or renal complications include cigarette 
smoking, diabetes mellitus, hyperlipidaemia and a family history of cardiovascular 
disease. More recently it has become recognised through using techniques such as 
linkage analysis, that genetic risk factors for target organ damage arising from 
hypertension exist. Specifically the ACE DD genotype has been shown to be an 
independent risk factor for LVH, cardiomyopathies and myocardial infarction. 
Malignant phase hypertension, arising as a complication of either essential or 
secondary hypertension, has undoubtedly reduced in incidence over the last 40 years 
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probably as a result of improved treatment and control of BP. While the classical 
pathological findings have been previously described in detail, the reasons why a 
transition from benign to malignant phase hypertension occurs have remained 
unknown. Animal models have depended on either surgical, pharmacological or 
dietary manipulation to induce the transition to the malignant phase. 
Once in the malignant phase of hypertension, studies have clearly implicated 
involvement of the RAS. MH is proportionately a more common complication of high 
renin hypertension such as renal artery stenosis than of low or normal renin 
hypertension. The frequent finding of elevated plasma renin, Ang II and aldosterone in 
affected individuals, even when they had a low renin hypertension prior to developing 
MH, has led to the suggestion that many of the pathological manifestations may be a 
consequence of high circulating Ang II. This was supported again by the ability to 
induce many of the ,features of MH simply by infusing Ang II into rats350 The known 
physiological actions of Ang II and the often dramatic response to ACE inhibitors 
would support a pivotal role for this peptide in MH. It would be very interesting to 
ascertain whether the incidence of MH developing in essential hypertensives with 
poorly controlled BP differs between those receiving an ACE inhibitor and those on 
other anti -hypertensive therapy such as calcium channel antagonists. Blockade of Mg 
II receptors at sub -hypotensive doses has been shown to reduce the development of 
fibrinod necrosis in SHR -SP354 and it is likely that inhibition of tissue ACE activity 
even at doses that do not lower systemic BP may be protective. 
It is not clear however, how the transition from a state of hypertension and 
RAS suppression converts to a state of hypertension and RAS activation with sodium 
retention, vasoconstriction, increasing BP, renal afferent vascular pathology and 
progressive renal failure. It has been suggested, mainly on circumstantial evidence, 
that an initial pressure diuresis and natriuresis might be important in leading to a state 
of relative sodium depletion and hence RAS stimulation. This is supported by the 
clinical findings of postural hypotension and extra -cellular fluid depletion in some 
affected patients together with the ability to lower BP in some patients with MH 
simply by infusing isotonic saline360 
It was therefore of considerable interest that a heterozygous cross, transgenic 
for the mouse Ren -2 transgene, (HanRen2 /Edin --) exhibited a tendency for the 
spontaneous transition from benign hypertension to MH with many of the classical 
described features. By utilising telemetry, an accelerated phase rise in BP in the 
terminal stages was demonstrated. This was associated in many cases with clinical 
signs of salt/water depletion associated with a significant loss in body weight in 65% 
of cases. Behavioural changes included adoption of a hunched and apathetic posture, 
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seizures or agitation and these may have been indicative of a hypertensive 
encephalopathy. Biochemical evidence of acute renal failure was present. The classical 
pathological feature of fibrinoid necrosis was invariably present, though within 
individual arterial sections, the patchy nature of such vascular pathology was 
observed. A microangiopathic haemolytic anaemia was seen in the malignant phase. 
Classically the TGR(mREN2)27 rat line has been thought of as having 
hypertension with a low circulating plasma renin and reduced renal renin content 
relative to non -transgenic controls267. Evidence reviewed in Chapter 1 would suggest 
that the elevation of BP is however mediated by Ang II, derived from extra -renal 
sources with the adrenal and/or vascular wall being implicated. With development of 
MH, dramatic increases in circulating plasma renin, Ang II and aldosterone were seen. 
Immunohistochemistry suggested that there was increased renin protein in the kidney 
of transgenic rats with MH. It is not clear whether the renin is derived from transgene 
or endogenous gene expression, as the renin antibody used did not differentiate mouse 
from rat renin. Treatment of heterozygous Ren -2 transgenic rats with Lisinopril has 
been recently shown to increase renin activity in the kidney in a dose -dependent 
manner. Using RNase protection assays, the authors were able to show that both 
endogenous renin gene expression and to a lesser extent transgene expression 
increased in response to ACE inhibition457. In addition expression of the transgene in 
the adrenal gland was also seen to occur in response to ACE inhibition457. Further 
work is required to clarify this, but one might hypothesize that the increase in kidney 
renin may be both endogenous and transgene derived in origin. In any case unlike rat 
models with high renal renin hypertension such as 2K -1C rats, MH appears to be 
developing on a background of renal RAS suppression leading to the expected 
changes of renal afferent arteriolar pathology and renin synthesis and release. Changes 
in Ren -2 transgene expression in other tissues including adrenal in rats with MH were 
not looked for in this study, and it remains possible that a contribution to the increase 
in plasma renin in MH comes from altered transgene expression in extra -renal sites. 
The development of the MH syndrome in affected HanRen2 /Edin -- animals 
occurred within a relatively narrow age range (mean age 62 days ±12.7 days for 
males, 65 ± 15 days for females). Surviving rats thereafter developed pathological 
evidence of target organ damage with progressive glomerulosclerosis and left 
ventricular hypertrophy269, but beyond 120 days of age there was no significant 
incidence of MH. 
Studies were performed to clarify why HanRen2 /Edin -- were at increased risk 
of MH relative to either HanRen2 /Han -- and particularly to HanRen2 /Lew - -. No 
environmental agent was identified, with small variations in dietary sodium intake 
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being specifically excluded as a contributory factor in view of the difference in the 
diets available to transgenic rats originally maintained in Germany. The influence of 
additional "hypertensinogenic" genes interacting with the physiological effects of the 
transgene expression appeared unlikely as there was no clear difference in BP between 
non -transgenic EdinSD and HanSD. Lewis rats being inbred, were both smaller and 
had a slightly lower BP. However on comparing the transgenic heterozygote crosses, 
BP in HanRen2/Edin -- did appear to be significantly higher between 52 and 60 days 
of age. The rate of rise in BP in the susceptible cross was not steeper than the 
relatively less susceptible or resistant HanRen2 /Han-- and HanRen2 /Lew crosses, but 
it remains possible that a higher BP at a younger age is important. This observation 
was repeated in the later study looking at (Han,Edin)Ren2 /(Edin,Lew) -- crosses 
where a higher BP at 35 days of age was the only significant difference between rats 
who ultimately developed MH and those that did not. 
Early descriptions of MH prompted Volhard and Fahr and later investigators to 
suggest that the pathological damage might be initiated by vascular spasm leading to 
endothelial and sub- endothelial ischaemia leading in turn to extravasation of plasma 
proteins and the deposition of fibrinoid316,317. One might hypothesize that younger 
rats exposed to higher arterial pressures have had a relatively shorter time to allow 
vascular remodeling and that structural adaptation may be important in protecting the 
blood vessel wall from an insult that precipitates transition to MH. This is interesting 
in the light of the observation that relatively younger patients present with MH 
compared to the age distribution for hypertension in the population3°6. It is clear that 
absolute BP level was not important, both on the basis of the study (Chapter 3) 
comparing the three heterozygote crosses and more definitively in the later study 
(Chapter 4) looking at (Han,Edin)Ren2 /(Edin,Lew) -- rats where there was no 
significant difference in BP between affected and unaffected rats beyond 42 days of 
age. It would therefore be interesting to attempt to delay the rise in BP in the 
susceptible HanRen2 /Edin -- cross, perhaps by a limited period of anti -hypertensive 
treatment from 30 to 40 days of age. If this then reduced or abolished the tendency to 
MH, then this would be a clear pointer towards high BP at a relatively young age 
being of aetiological importance. 
No clear differences were elicited between the three heterozygote crosses when 
studied in the pre -malignant/benign hypertensive state in terms of base -line renal 
function or plasma RAS activity. Secondly there was no significant difference in the 
development of another marker of target organ damage, namely LVH. 
The study that specifically looked at rats on telemetry, and their subsequent 
development of MH compared three heterozygote crosses where all Fl progeny were 
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derived from the same homozygous HanRen2 /HanRen2 father. Transgene copy 
number and insertion sites would not be altered in the three crosses, but it is 
theoretically possible that other strain dependent factors might alter levels of transgene 
expression262 or function and this was not specifically looked at in the course of these 
studies. 
Kincaid -Smith suggested that "malignant hypertension may be determined by 
some new and unknown factor in addition to high BP "306 and reported in a later paper 
of the considerable overlap that exists in actual BP between those with MH and those 
with BH368. In this thesis, a genetic susceptibility to MH in a hypertensive transgenic 
rat model has been demonstrated and from the data presented in Chapter 4, this 
appears to be conferred by one or possibly two loci. The number of rats bred in the 
analytical cross designed to segregate EdinSD alleles together with the number of 
available genetic microsatellite markers was not adequate to identify significant 
linkage. With the availability of increasing numbers of markers, this aspect should be 
re- addressed. 
Another group has reported features suggestive of MH in a colony of Ren -2 
transgenic rats crossed with SD rats452. The SD is not inbred and other groups have 
also found higher death rates from MH than was observed here amongst 
HanRen2 /Han -- heterozygote crosses (H Montgomery, London - personal 
communication). The responsible loci may not be limited to EdinSD. 
It is therefore possible that genetic factors determine the risk of transition to 
MH from BH in humans and identification of the locus(ci) might lead to an 
understanding of the trigger factor. Various postulated hypotheses have included 
altered vascular reactivity leading to vasospasm and ischaemia. This might not be the 
primary trigger, but could simply be an effect of it and hence identifying a responsible 
gene would be a major step forward. Even though the relative clinical importance of 
MH declines with the decreasing incidence of the condition, it is possible that the 
aetiology may be relevant to a number of related conditions. Examples include 
scleroderma renal crisis, haemolytic -uraemic syndrome /thrombotic thrombocytopenic 
purpura, and acute vascular rejection of renal transplants. 
On the basis of the known pathophysiology of MH and the evidence in the 
literature of the role of endothelins in various pathological conditions (reviewed in 
Chapter 1), it was decided to ascertain whether endothelins might have a role in MH. 
They had been implicated by previous investigators because of reported increased 
levels of plasma it -ET -1 in animal models of MH420. It was recognised that increased 
ET -1 synthesis occurred in response to hypoxia, low levels of shear stress, thrombin 
and Ang II. In turn, ET -1 acting as a powerful vasoconstrictor with pro -mitogenic 
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activity could induce some of the physiological and pathological changes seen in MH. 
The studies described in Chapter 5 found that despite there being evidence of a 
significant increase in ET -1 mRNA expression in kidney from rats with MH, no clear 
role for ET -1 could be identified on the basis of the lack of effect of the combined ET- 
A and ET -B receptor antagonist in preventing transition from BH to MH. 
ET -1 has been implicated in a number of pathological states and in many of 
these cases a clear role needs to be identified for the peptide. There are examples in the 
literature of situations where measurements of ET -1 peptide have not shown a good 
correlation with either vascular wall ET -1 content or ET -1 mRNA levels391 The short 
plasma half -life and the lack of evidence of any storage of ET -1 outwith the posterior 
pituitary has suggested that this peptide is likely to work in a paracrine or autocrine 
fashion. In conditions such as myocardial infarction and reperfusion injury, pre - 
eclampsia or cyclosporin- induced nephrotoxicity where endothelial cell ischacmia and 
damage are likely, it may well be that the appearance of increased circulating levels of 
ET may be an epi- phenomenon reflecting cell damage rather than being intrinsic to the 
pathological process. Other mediators of endothelial function and vascular reactivity 
could be relevant and it would be of interest for example, to look for differences in 
basal NO activity and NO synthase gene expression in vascular wall tissue between 
the the relatively susceptible HanRen2/Edin -- and resistant HanRen2/Lew -- crosses. 
The HanRen2 /Edin -- cross appears to be good model of malignant or 
accelerated phase hypertension in that it arises spontaneously exhibiting many of the 
features seen in the human condition. It therefore offers a valuable model to look for 
the factors that initiate onset of MH, which may be potentially relevant to other 
conditions with a similar pathology. The work presented has suggested that in this 
case, there may be a genetic factor operating in addition to high BP which confers an 
increased susceptibility to MH. 
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The role of transgenesis in investigating the 
cardiovascular system 
Caroline E. Whitworth and John J. Mullins 
AFRC Centre for Genome Research, University of Edinburgh, Edinburgh, Scotland, UK 
introduction 
An increasing understanding of the genetic factors and 
of the molecular mechanisms that contribute to cardio- 
vascular disease has led to new avenues for interven- 
tion. As a consequence of finding genetic loci linked 
to phenotypes and disease patterns, attention is being 
directed towards the regulation and function of candi- 
date genes. This can be done at a physiological level by 
monitoring, for example, plasma renin levels or blood 
pressure, and at a molecular level, by identifying the 
sites and levels of mRNA expression. These two ap- 
proaches may be effectively combined with the use 
of transgenesis to investigate the expression of specific 
genes and their effects on physiological processes. 
Within the limits of this review, we propose to concen- 
trate on three areas of transgenic research: 
Investigations into the renin -angiotensin system 
(RAS) in hypertension 
Lipids and apolipoproteins in atherogenesis 
Approaches towards understanding cardiomyo- 
cyte cell biology and cardiac disease 
Generation of transgenics 
A transgene may be defined as a gene or gene con- 
struct which has been introduced into the germ line. 
This DNA may originate from the same species or may 
be constructed from a combination of DNA elements 
from different species. After being integrated into the 
germ line it will, under normal circumstances, be inher- 
ited in a Mendelian fashion. Transgenic animals may be 
generated through the 'addition' of transgenes by sev- 
eral methods [1), including the direct microinjection of 
DNA into the pronuclei of one -cell embryos in vitro 
or by using retroviral vectors in the pre -implantation 
embryo and their subsequent re- introduction into a 
foster mother (Fig. 1). By such an approach the ef- 
fects of specific RNA molecules and/or polypeptides 
may be addressed in the whole animal. In addition, 
genetic regulatory elements can be studied using 're- 
porter' gene constructs which are typically designed 
to express a heterologous and conveniently assayable 
enzymatic activity [2,3). Successive series of such gene 
constructs can yield valuable information concerning 
the location and interaction of regulatory sequences 
controlling, for example, cell -specific or developmen- 
tally regulated gene expression. In certain cases such 
reporters can be assayed colorimetrically or fluorimet- 
rically (e.g., the Escherichia coli Lac Z gene coding for 
ß- galactosidase which produces a blue colour on stain- 
ing with X -gal (5-bromo-4-chloro-3-indolyl-13-n- galac- 
tosidase) providing a variety of experimental possibil- 
ities. 
Microinjection, cell transfection, retroviral infection 
and direct injection 
Fig. la. Fertilized oocytes from superovulated females. Microinjec- 
tion of DNA into pronucieus of fertilized oocyte. Returned to pseu- 
dopregnant foster mother. b. Retroviral infection of 4-cell embryo. c. 
Introduction of DNA constructs into embryonic stem cells in culture 
results in random integration or homologous recombination. Identi- 
fication of appropriate transformation is followed by microinjection 
of cells into a blastocyst and re- implantation into foster mother. d. 
Retroviral infection of embryo. 
A second route to the generation of transgenic animals 
(presently limited to the mouse), involves the use of 
embryonic stem cells which can be maintained and 
genetically manipulated in vitro, before being used 
to develop viable animals (Fig. 1). Through the use 
Abbreviations 
Al-angiotensin I; All-angiotensin II; ACE -angiotensin converting enzyme; apo- apolipoprotein; 
HDL- high -density lipoprotein; IDL- intermediate -density lipoprotein; MI.-low-density lipoprotein; 
Lp(a)- lipoprotein (a); MLC- myosin light chain; MT1- metallothionein promoter; RAS- renin angiotensin system; 
SHR- spontaneously hypertensive rat; SV40- simian virus 40; TGR(hAOGEN)- transgenic rats carrying human angiotensin gene; 
TGR(hREN) -transgenic rats carrying human renin gene; VLDL- very -low- density lipoprotein. 
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of such cells the ablation or modification of a gene is 
possible. In contrast to the microinjection of single -cell 
embryos, such an approach provides the ability to tar- 
get alterations to specific chromosomal sites thereby 
providing a greater measure of experimental preci- 
sion. To a large extent, however, the two techniques 
complement each other and are valuable for address- 
ing different questions. Such methods can be used to 
verify that a particular gene, implicated with a dis- 
ease on epidemiological grounds, is actually causative. 
In cardiovascular medicine, polygenic conditions with 
environmental influences, for example hypertension 
and atherosclerosis, contribute largely to the present- 
ing pathology. Transgenesis, using the whole animal 
as an in -vivo preparation, is a powerful tool for study- 
ing the interaction of specific genes with both genetic 
background and environment. 
The RAS in hypertension 
Essential hypertension has no defined phenotype but 
is a quantitative trait. Net blood pressure is a con- 
sequence of interactions between an individual's ge- 
netic make -up, diet and environment. Early research 
was based on descriptions of physical and biochemi- 
cal measurements of the phenotype and of the effects 
of pharmacological or surgical intervention. Over the 
past 5 years, molecular studies have opened up the 
field with animal models of genetic hypertension help- 
ing to identify chromosomal loci which might harbour 
candidate genes [4]. Selective breeding from initially 
normotensive rat populations has led to the derivation 
of the spontaneously hypertensive rat (SHR), stroke - 
prone SHR [5], salt -sensitive Dahl rat, and the Milan 
hypertensive strain. An inherent disadvantage of these 
models is that selective breeding causes not only the 
segregation of genes relevant to the phenotype but also 
concurrent segregation of the vast majority of irrelevant 
genes. In addition, molecular divergence of supposed 
inbred populations complicates the study of genotypic 
differences between hypertensive and normotensive 
populations [6-81. 
In spite of these caveats, a number of candidate genes 
have been identified. Linkage studies in crosses be- 
tween stroke -prone SHRs and normotensive Wistar- 
Kyoto controls suggested that a locus on rat chro- 
mosome 10 close to the angiotensin converting en- 
zyme (ACE) gene may contribute to regulation of blood 
pressure in salt- loaded stroke -prone [9',101 SHRs, but 
no linkage between human essential hypertension and 
the human ACE locus has been found [11,121. A dele- 
tion polymorphism of the ACE gene (DD) has been 
linked with increased risk of myocardial infarction 
[13'1, parental history of myocardial infarction [141, 
idiopathic and ischaemic dilated cardiomyopathy [151 
and hypertrophic cardiomyopathy [161. Inheritance of 
a DNA restriction fragment length polymorphism mark- 
ing the renin gene from SHR, as opposed to the 
renin gene from normotensive Lewis rats, is associ- 
ated with a higher blood pressure in F1 progeny [171. 
Similarly, a renin gene restriction fragment length poly- 
morphism from the Dahl salt -sensitive rat cosegregates 
with higher blood pressure [181. No overwhelming evi- 
dence of linkage of human essential hypertension and 
renin polymorphisms have been found to date [19,201. 
Linkage of a molecular variant of the angiotensinogen 
gene, associated with increased plasma angiotensino- 
gen levels, has been found in essential hypertensive 
individuals from two populations [211 and in individu- 
als with pre- eclampsia [22,231. Such genetic evidence 
implicating the RAS in both human and animal hyper- 
tension, together with the known physiological effects 
of the RAS (Fig. 2) has made this system an attractive 
area for study using transgenic methods. 
Transgenic models 
Introduction of the mouse Ren 2 renin gene and flank- 
ing sequences into the rat, resulted in severe hyper- 
tension and target -organ damage [24,251. Expression 
of the transgene was found to be high in the zona 
glomerulosa and outer zona fasciculata of the adrenal 
gland [26,271. Low plasma and kidney renin concen- 
trations and high plasma prorenin were seen, with 
suppression of endogenous rat renin expression oc- 
curring in a blood- pressure dependent fashion [26 -281. 
Blood pressure could be reduced by ACE inhibition or 
by angiotensin II (AIL) antagonists [24,29,301 suggest- 
ing that an overactive RAS could contribute to the 
severe hypertension in spite of the apparently low 
plasma renin concentrations. The role of local tissue 
and extrarenal RAS activity compared with circulat- 
ing plasma RAS activity has been an important issue 
since the efficacy of ACE inhibitors in treating essen- 





Proximal tubular sodium reabsorption 
Angiotensin I Glomerular efferent artriolar constriction 
Enhanced sympathetic drive 
ACE 
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Fig. 2. Physiological actions of the RAS. 
Genetic polymorphisms have been iden- 
tified at the angiotensinogen, renin and 
angiotensin converting enzyme loci. RAS, 
renin -angiotensin system. 
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tial hypertensive individuals with low plasma renin 
concentrations was shown. In this transgenic model, 
the role of the adrenal gland has been of particular 
interest because of the high adrenal transgene expres- 
sion. Adrenalectomy experiments in transgene- positive 
animals have suggested that the elevated prorenin and 
hypertension may result from transgene expression in 
this organ [251, but how this leads to a rise in blood 
pressure is not clear. There is some evidence of in- 
creased adrenal mineralocorticoid production [31,321, 
but insufficient to account for the rise in blood pres- 
sure. Evidence of activation of a vascular RAS in 
TGR(mREN2)27 came from finding mRNA in vascu- 
lar tissue [26,33], and from studies of angiotensin I (AI) 
and All release from perfused hind -limb preparations 
where levels were found to be significantly higher in 
transgenic rats compared with Sprague -Dawley con- 
trols [33]. Prior nephrectonty reduced the release of 
angiotensins from Sprague -Dawley hind limbs but not 
from TGR(mREN2)27 animals. 
A hypertensive phenotype was similarly generated af- 
ter microinjection of the rat angiotensinogen gene into 
the mouse germ line [34.1. Three transgenic lines were 
established with elevated blood pressure, the presence 
of rat angiotensinogen and increased plasma All be- 
ing found in two of the lines. In a third transgenic 
line (#92) elevated plasma All levels appeared to be 
insufficient to cause hypertension. Using a different 
approach in which the mouse metallothionein pro- 
moter (MT1) was fused to the rat angiotensinogen 
coding region, Ohkubo et al. [351 were able to in- 
duce expression of rat angiotensinogen in response 
to heavy metals, i.e., ZnSO4 treatment. In this study 
no difference in blood pressure levels was reported; 
however, plasma levels of angiotensinogen were ap- 
proximately half those reported above [34.1. 
Mice carrying a rat renin transgene under the control 
of MT1 also remained normotensive, in spite of evi- 
dence of rat renin production in mouse liver [351, 
presumably as a consequence of species differences 
in substrate specificity as rat renin has been shown 
not to cleave mouse angiotensinogen in vitro [361. Such 
biochemical differences can clearly affect the interpre- 
tation of transgenic experiments. Hypertension was 
seen in double transgenic mice carrying both the rat 
renin and the rat angiotensinogen transgenes, and was 
responsive to ACE inhibition [351. 
Using a human genomic renin transgene, Takaori et al. 
[371 generated three lines of transgenic mice of which 
one line showed elevation of both plasma renin and 
prorenin with 80% of human renin in transgenic mouse 
plasma in the form of prorenin. Transgene expression 
was predominantly seen in the kidney and sodium de- 
pletion studies indicated that plasma renin levels were 
increased as would be expected. No elevation of blood 
pressure was reported, again, presumably because of 
species specificity of the cleavage reaction. When the 
identical transgene was introduced into the rat germ 
line [38] (see below) the kidney, although a major 
site of expression, was not the site of maximal trans- 
gene expression. Some caution must therefore be ex- 
ercised when interpreting the results of cross- species 
transgenic experiments. 
Transgenic rats carrying both the human renin 
[ TGR(hREN)] and angiotensinogen ITGR(hAOGEN)1 
genes have been established [381. In TGR(hREN) 
plasma, human renin and prorenin were found, al- 
though the level of renin was 12 -times higher than 
is normally seen in humans. Parameters of the rat 
RAS were unaffected by the presence and activity of 
human transgenes, implying that human renin did not 
act on rat angiotensinogen in vivo. TGR(hAOGEN) an- 
imals showed elevated plasma angiotensinogen rang- 
ing between two- and 40 -fold higher than in nor- 
mal human plasma with expression of the transgene 
occurring mainly in liver. As expected, the endoge- 
nous rat RAS was unaffected. No animals from either 
transgenic strain were spontaneously hypertensive, nor 
were double -transgenic progeny from a preliminary 
test cross. A hypertensive response was elicited by in- 
fusing rat renin or human renin into TGR(hAOGEN); 
Ro 42 -5892, a human renin -specific antagonist, low- 
ered blood pressure specifically in transgenic rats given 
human renin; while DUP 753, an All antagonist, low- 
ered blood pressure after infusion of either human or 
rat renin. Infusion of human renin into transgene -neg- 
ative animals had no hypertensive effect. In contrast, 
however, and in a different type of study, Tornita et al. 
[391 observed transient hypertension and evidence of 
cleavage of rat angiotensinogen after the direct trans- 
fer of the human renin gene into rat liver using a Sendai 
virus (HVJ)- liposome carrier. This elevation in blood 
pressure was responsive to the human -specific renin 
inhibitor FK 906. 
The vascular smooth cell response to hypertension 
The vascular wall response to hypertension, namely 
smooth muscle cell migration and remodelling, may 
be secondary to elevated blood pressure or in part a 
consequence of direct actions of mitogens [40). The 
promitogenic effects of All on smooth muscle cells, 
independent of vasopressor effects, have implicated 
the RAS system in pressure overload cardiac hypertro- 
phy, post -myocardial infarction ventricular remodelling 
and restenosis after balloon angioplasty or endarterec- 
tomy [41,421. Separating the contribution of these two 
potential components is difficult. Experiments using 
expression of simian virus 40 (SV40) large T antigen 
[431 under the control of the Ren 2 promoter as both a 
reporter and immortalization agent resulted in cellular 
transformation of renin expressing cells in transgenic 
mice. Marked proliferation of smooth muscle cells oc- 
cur within the media of arterial walls resulting in thick- 
ening and luminal narrowing. This transgenic model 
has normal blood pressure, although there was some 
evidence of plasma volume expansion. In addition to 
permitting the study of juxta- glomerular -like cells these 
animals may prove to be a useful model in helping to 
dissociate the vascular wall hypertrophic responses to 
hypertension and to RAS perturbation [44,451. 
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Lipids and atherogenesis 
Atherosclerosis, like essential hypertension, is a poly - 
genic disorder with environmental contributions. Fa- 
milial hypercholesterolaemia can result from defects 
in the low -density lipoprotein (LDL) receptor gene. 
The type of defect (deletion or missense mutation) 
in humans influences both plasma cholesterol and 
severity of coronary heart disease [46]. Attempts at 
gene therapy in animal models have included the in- 
troduction of functional human LDL receptor genes 
into Watanabe heritable hyperlipidaemic rabbits, us- 
ing retrovirus transduced hepatocytes which resulted 
in a transient reduction in serum cholesterol [471. Sim- 
ilarly, adenovirus- mediated gene transfer resulted in 
transient hepatic LDL receptor expression in normal 
mice lowering plasma cholesterol and the half -life of 
labelled LDL [481. Overexpiession of the human LDL 
receptor in transgenic mice, using 3 kb of the mouse 
transferrin promoter linked to a human LDL receptor 
minigene, resulted in either a 50% reduction in total 
plasma cholesterol (normal diet), or in an attenuated 
elevation of cholesterol levels (high -fat diet) compared 
with transgene- negative littermates. This was mainly 
achieved by reducing the rise in intermediate -density 
lipoprotein (IDL) and LDL fractions [491. 
Apolipoprotein (apo)E is a high affinity ligand for the 
LDL receptor and is found on chylomicrons, IDL, very- 
low- density lipoprotein (VLDL) and high- density lipo- 
protein (HDL) [50]. Three common structural alleles 
have been identified. ApoE -2, because of an amino 
acid substitution, has 2% of normal binding affinity 
for the LDL receptor and may account for altered post- 
prandial lipid clearance in 50% of the population. Type 
III or remnant hyperlipidaemia, affecting one in 5000 
individuals, is caused by homozygosity for the Apoe 
2 gene. In a few patients complete ApoE deficiency 
has been described. ApoE- deficient mice have been 
created by two groups using homologous recombina- 
tion, targeting the murine apoE gene [51",521. Such 
mice showed a five- to eight -fold increase in plasma 
cholesterol levels and two -fold rise in triglyceride on a 
normal mouse diet. On a high -fat diet (42% of calories 
as fat), a rise in plasma cholesterol to 1821 ± 395 mg/di 
occurred, mainly in the VLDL and IDL fractions, com- 
pared with 132± 18 mg/dl in non -transgenic rats [51]. 
Early atherosclerotic lesions were seen in both trans- 
genic models from 10-12 weeks of age. 
ApoA -I and apoA -II are the major lipoprotein compo- 
nents of HDL, which is thought to have a protective in- 
fluence. In a susceptible mouse strain (C57BL/6) given 
a high -fat diet, introduction of a human apoA -I trans- 
gene resulted in an increase in the HDL fraction, but 
no change in non -HDL fractions. Transgenic mice had 
a smaller fatty streak lesion area on the atherogenic diet 
compared with transgene negative controls [53,54.1, 
but introduction of a human apoA -II transgene into 
the apoA -I transgenics resulted in an increased sus- 
ceptibility to atherogenesis in spite of similar lipid 
profiles [551. Further work is needed to understand 
the in -vivo mechanisms behind the protective effect of 
HDL, apoA -I and the metabolic effects of apoA -II. 
Lipoprotein (a) [Lp(a)) consists of a particle simi- 
lar to LDL, namely phospholipids, cholesterol and 
apoB -100 which is linked to apo(a). Apo(a) is a gly- 
coprotein showing considerable size polymorphism 
(300-800 kD) and both size and sequence variations 
at the apo(a) locus may partly determine plasma lev- 
els [561. High levels of Lp(a) have been found to be 
an independent risk factor for myocardial infarction 
[571. Homology of amino acid sequence of 80% be- 
tween apo(a) and plasminogen has led to the sug- 
gestion that binding of apo(a) to fibrin as part of a 
wound healing response might result in the delivery 
of excess lipid to sites of damaged endothelium and 
alter fibrinolysis [581. In vitro, Lp(a) and apo(a) stimu- 
late proliferation of human aortic smooth muscle cells 
in a dose -dependent fashion [591. This is caused by in- 
hibition of plasminogen activation and hence in turn, 
reduced plasmin mediated -activation of transforming 
growth factor-0 (a potent inhibitor of smooth mus- 
cle cell proliferation). The absence of apo(a) from 
all species, apart from primates (and hedgehogs) has 
precluded the development of good animal models. 
Transgenic mice were made by the introduction of hu- 
man apo(a) complementary DNA fused to the mouse 
transferrin promoter directing expression principally to 
the liver which resulted in plasma apo(a) levels com- 
parable with human values [6011. Mean lipid staining 
lesion areas in aortas of transgene- positive animals on 
an atherogenic diet were significantly higher than those 
found in transgene -negative littermates or in transgene- 
positive animals on a normal diet. Infusion of human 
LDL into these transgenic mice resulted in association 
of human LDL and apo(a) in the plasma to form Lp(a), 
but such an association did not occur between mouse 
LDL or human HDL with apo(a) [611. 
These experiments have helped to establish that genes 
for apo(a), apoA -I, apoE and the LDL receptor, for ex- 
ample, can interact with diet to alter predisposition 
to atherosclerosis and support previous work where 
these genes were implicated simply on the basis of 
epidemiological associations. In addition, they offer an- 
imal models of a human disease which can be used for 
developing therapeutic strategies. 
Cardiomyocyte cell biology and cardiac disease 
Unlike skeletal muscle, cardiac cells do not possess 
a stem cell system which allows regeneration, so in- 
farction or disease leads to an irreversible loss. When 
undifferentiated skeletal myoblasts have been grafted 
by injection into ventricular myocardium of syngeneic 
mice, they ceased proliferation, adopted a phenotype 
of differentiated skeletal myocytes and survived for up 
to 3 months [62]. Whether contractility and appropri- 
ate electrical properties would be achieved with larger 
grafts is not certain. Targeting the SV40 T antigen to 
cardiac myocytes has enabled the generation of car - 
diomyocyte cell lines (ATI) which retain a proliferative 
capacity and a degree of differentiation [631, but the 
tumorigenic potential of these may preclude extensive 
transplantation studies. 
The role of transgenesis in investigating the cardiovascular system Whitworth and Mullins 5 
Understanding the control mechanisms that govern 
cessation of proliferation and differentiation in muscle 
cells may allow a means of inducing controlled prolif- 
eration of cardiomyocytes. In skeletal muscle, a family 
of myogenic transcription factors has been identified: 
myf5, MyoD, and myogenic regulatory factor 4 /her- 
culin/myf6. They share a basic helix- loop -helix pro- 
tein structure and are muscle -specific [64,651. Informa- 
tive cell culture experiments include the transfection of 
fibroblasts by a construct consisting of the MyoD gene 
fused to the hormone binding domain of the human 
oestrogen receptor gene [66] resulting in the oestrogen - 
inducible expression of skeletal muscle markers. In 
separate studies it has been shown that insulin -like 
growth factor -induced myogenesis in cultured myo- 
blasts could be inhibited by antisense oligomers to 
myf5 [67]. Transgenic mice with a null mutation of 
MyoD, following homologous recombination in em- 
bryonic stem cells, showed normal muscle cell de- 
velopment, though a possible compensatory increase 
in myf5 rnRNA did occur [681. In contrast, ablation of 
the my/5 gene by homologous recombination resulted 
in perinatal lethality caused by defect in rib formation 
and respiratory failure; however, the progeny appeared 
to have relatively normal skeletal muscle development 
[691. The mild skeletal muscle changes in these two 
gene knock -out strains perhaps suggest functional re- 
dundancy of individual myogenic transcription factors. 
Although progress has been made in the search for cis- 
acting transcriptional control elements, cardiac muscle - 
specific trans -acting factors have been difficult to iden- 
tify. In addition to the relatively well characterized 
atrial natriuretic factor gene [70], several other genes 
expressed in the heart have been studied in trans - 
genic animals. A promoter region in the human myo- 
globin gene, identified using a Lac Z reporter construct 
in mice, controls the changing spatial pattern of ex- 
pression of the myoglobin gene in the ventricle dur- 
ing murine embryogenesis 1711. The regulatory myosin 
light chain (MLC) -2 is normally found in both skele- 
tal slow twitch and cardiac muscle. It is postulated that 
trans-acting factors might bind to a 250 base pair frag- 
ment of the MLC -2v (ventricular) gene promoter and 
determine ventricular specification in the developing 
heart during murine embryogenesis 1721. Within this 
fragment a 28 base pair element (HF -1) confers car- 
diac specificity with point mutations at two sites (HF- 
la and HF -1b) significantly reducing MLC -2 promoter - 
luciferase fusion gene expression [731. A complemen- 
tary DNA coding for a C2H2 zinc finger protein that 
hinds to the HF -lb site has been isolated, and can 
activate transcription in vitro [74]. Clearly, significant 
steps still need to be made before a comprehensive 
understanding of cardiomyocyte development and dif- 
ferentiation is possible. 
Single gene defects are more amenable to transgenic 
investigation and such a candidate would be familial 
hypertrophic cardiomyopathy, an autosomal dominant 
condition with several identified mutations, mostly 
on chromosome 14q1, affecting the ß- cardiac myo- 
sin heavy chain gene [75 -771. While [3-- cardiac myo- 
sin heavy chain protein is found in both left and right 
ventricles and skeletal muscle, the pathology manifests 
principally in the left ventricle and interventricular sep- 
tum. The reasons for this are not clear, but cloning 
of the mutations and generation of transgenic mod- 
els might shed light on this. The incidental finding 
of a dilated cardiomyopathy occurring in transgenic 
mice expressing an Epstein -Barr virus protein (EBNA- 
LP), has resulted in a potential animal model of dilated 
cardiomyopathy [781. The v fps transgene (encoding a 
cytoplasmic protein - tyrosine kinase) in mice causes 
progressive cardiac fibrosis and variable hypertrophy 
with some secondary myocyte damage [791. Target- 
ing and knock -out of the transforming growth factor -111 
gene by homologous recombination in mouse resulted 
in a pancarditis and perivasculitis, but normal cardiac 
development [80]. 
Conclusions and future approaches 
Although technically possible, the production of trans- 
genic animal models of polygenic diseases remains dif- 
ficult without further information concerning the genes 
involved. The above examples illustrate the value of 
the techniques for investigation of individual genes 
and their interactions with the environment. Breed- 
ing of transgenic animals with various inbred or out - 
bred strains can introduce additional genetic factors 
which can modify a phenotype. Appropriate experi- 
ments such cross -breeding will enable complex genetic 
and physiological interactions to be studied. 
Gene ablation strategies are at present limited within 
the field of cardiovascular research because of the re- 
quirement for embryonic stem cell lines, which to date 
are only available for the mouse. Although some el- 
egant studies have been done, physiological investi- 
gations in this species are difficult because of size 
constraints. The development of embryonic stem cell 
technology in larger species will open up new possi- 
bilities including elucidation of abnormalities in genetic 
models of hypertension (e.g., the SHR) which may help 
in understanding human essential hypertension. 
Approaches using direct gene transfer in larger animals 
e.g., dogs, pigs [3,81] are increasing the scope for 
development of therapeutic strategies. In the future, 
genetic material, including gene constructs, oligonu- 
cleotides etc., might be introduced directly into car - 
diomyocytes or endothelial cells to improve contrac- 
tility, promote cellular regeneration or stimulate devel- 
opment of collateral blood flow to ischaemic regions 
[821. In certain situations transplantation of modified 
cells may be practical [831; however within the car- 
diovascular field, antisense methodology is the most 
likely technology to first reach clinical practice as 
promising results have been obtained in experimen- 
tal systems. Local delivery of antisense c -myb oligonu- 
cleotides has been shown to suppress intimai accumu- 
lation of smooth muscle cells after balloon angioplasty 
of carotid arteries in rats I84N1 and it is thought that 
this protooncogene is involved in the common path- 
way of mitogen- induced smooth muscle cell prolifera- 
tion. Practical problems with oligonucleotide delivery 
6 Annual of Cardiac Surgery 
and stability may limit applications but much effort is 
being placed at present to circumvent such difficulties. 
One exciting area of research which is likely to be- 
come increasingly important is the development of 
transgenic animals with a view to facilitating xeno- 
transplantation. In this area larger animals species such 
as the pig will certainly feature more prominently. So, 
the contributions of transgenic technology range from 
basic gene expression studies through to dissection of 
multigenic traits. It is safe to say that transgenic tech- 
nology is still going through rapid development, and 
over the course of the next few years ever -more use- 
ful methods for altering gene expression will become 
standard experimental and therapeutic tools. 
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Spontaneous development of malignant phase hypertension in 
transgenic Ren -2 rats 
CAROLINE E. WHITWORTH, STEWART FLEMING, ALLAN D. CUMMING, JAMES J. MORTON, 
NICOLA J.T. BURNS, BRENT C. WILLIAMS, and JOHN J. MULLINS 
Centre for Genome Research, Department of Pathology, and Department of Renal Medicine, University of Edinburgh; MRC Blood Pressure Unit, Western 
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Spontaneous development of malignant phase hypertension in trans - 
genic Ren -2 rats. Spontaneous development of malignant phase hyperten- 
sion in TGR(mREN2)27 heterozygotes occurs as a consequence of 
crossing TGR(mREN2)27 homozygotes with Edinburgh Sprague -Dawley 
rats. Similarities to human malignant phase hypertension are seen with an 
accelerated rise in blood pressure, fibrinoid necrosis of renal afferent 
arterioles, renal failure and evidence of renin -angiotensin system activa- 
tion. It appears that introduction of an additional genetic factor or factors 
into a monogenic model of hypertension results in malignant phase 
hypertension. 
Malignant hypertension (MH) is a rare but important compli- 
cation of human essential hypertension [1, 2]. Clinical markers of 
transformation to the accelerated phase include a rising blood 
pressure, presumed pressure diuresis, renal failure and develop- 
ment of grade III or IV retinopathy. Characteristic pathological 
changes in the renal vasculature occur including myointimal 
proliferation or `onion skinning' with endothelial swelling and 
fibrinoid necrosis [3, 4]. Activation of the renal renin -angiotensin 
system (RAS) is a presumed consequence of salt and water loss 
combined with afferent renal vascular pathology. This may serve 
to further increase blood pressure resulting in a vicious circle of 
progressive renal damage and rising blood pressure. 
Most animal models of MH to date have been limited by the 
need for dietary, surgical or pharmacological intervention to 
precipitate onset and this has made the study of both primary or 
initiating factors and secondary events operating in malignant 
hypertension difficult to study [5 -7]. 
The transgenic rat line TGR(mREN2)27 develops hyperten- 
sion as a consequence of introduction and expression of the 
mouse Ren -2 renin gene into the Sprague -Dawley (SD) rat [8]. 
Blood pressure rises to a plateau at 10 weeks of age and 
development of progressive left ventricular hypertrophy, arterial 
medial thickening and glomerulosclerosis occurs with increasing 
age [9]. Fibrinoid necrosis was not described in transgenic het - 
erozygotes. However, the underlying pathogenesis of the hyper- 
tension remains unclear. 
The breeding of a colony of TGR(mREN2)27 heterozygotes in 
Edinburgh using SD rats (Centre for Genome Research, Univer- 
sity of Edinburgh) was associated with the spontaneous onset of a 
© 1994 by the International Society of Nephrology 
phenotypic change with the occurence of a fatal syndrome at 50 to 
90 days of age. Features included a one to three day history of 
polyuria, weight loss, dehydration, apathy, piloerection, seizures 
and hemiplegia. Some similarities to human MH prompted this 
study to characterize this as a potential animal model and to 
identify whether environmental or genetic factors may be respon- 
sible. 
Methods 
Initially three transgenic heterozygote crosses were bred. Ho- 
mozygote TGR(mREN2)27 rats (TGR #27), derived from a Han- 
nover SD colony (Central Institute for Laboratory Animal Breed- 
ing, Hannover, Germany) were crossed with (1) SD (Edinburgh) 
obtained from the colony in the Centre for Genome Research, (2) 
SD (Hannover) from the Central Institute for Laboratory Animal 
Breeding (Hannover, Germany) and (3) Lewis rats from Harlan - 
Olac (Bicester, Oxford). 
All animals were housed in the same room with a 12:12 hour 
light -dark cycle, controlled temperature (18 to 20 °C), humidity 
(45 to 65 %), diet (0.32% sodium CRM diet, SDS, Witham, Essex, 
UK) and ad libitum tap water to drink. An alternative standard rat 
diet containing 0.2% sodium (CRM X) was prepared, and when 
used was given from weaning. 
Direct blood pressure monitoring using telemetry (Data Sci- 
ences International, St. Paul, Minnesota, USA) allowed continu- 
ous recording of mean blood pressure (MBP) in conscious, 
unrestrained male rats starting from 46 to 50 days of age following 
recovery from surgical implantation under halothane anaesthesia 
[10, 11]. Indirect measurement of systolic blood pressures (SBP) 
used a tail cuff plethysmography method (IITC Life Sciences) 
under light halothane anaesthaesia. Student's t -test was used for 
statistical analysis with a P value of less than 0.05 taken to be 
significant. 
Light microscopic examination of kidney, heart, brain and 
mesenteric artery was performed after fixation of tissues in 4% 
formal saline, wax embedding, sectioning (3 µm) and staining 
(hematoxylin and eosin, Martius Scarlett Blue, and periodic acid 
schiff stains). Renal function was assessed by plasma creatinine 
( Electro- nucleonics ®). Plasma renin activity (PRA), angiotensin 
II (Ang II) and aldosterone were assayed by specific radioimmu- 
noassay [12 -14]. Immunohistochemistry of fixed kidney sections 
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Table 1. The incidence of the MH phenotype in male and female 
transgenic heterozygotes maintained under the same environmental 
conditions and on the same diet 
Heterozygote cross Name 
Incidence of MH phenotype 
Male Female 
TGR#27-Edin SD TGR/Edin 86/117 (73.5 %) 83/158 (52.5 %) 
TGR#27-Han SD TGR/Han 7/39 (18 %) 2/44 (4 %) 
TGR#27-Lewis TGR/Lew 0/35 (0 %) 0/31 (0 %) 
was performed using a polyclonal rabbit anti -mouse renin anti- 
body, which cross reacts with rat renin (provided by Dr. D.J. 
Campbell, Melbourne, Australia). 
Results 
The occurrence of the MH phenotype in male and female trans - 
genic heterozygotes is given in Table 1, which shows a significantly 
higher incidence in TGR/Edin heterozygotes than either TGR/ 
Han or TGR/Lew heterozygotes. The median age at the time of 
death was 59 days (range 46 to 102 days). 
Continuous recording of blood pressure in conscious TGR/Han 
and TGR/Lew heterozygotes by telemetry showed development of 
hypertension with a characteristic rise to a plateau by 70 days of 
age with a MBP of 170 mm Hg (Fig. 1A). In contrast, those 
TGR/Edin (7 out of 10) and TGR /Han (1 out of 12) that 
developed MH while on telemetry showed a continuing increase 
in blood pressure, which culminated in a terminal accelerated rise 
of 67 to 75 mm Hg (mean 72 mm Hg) over six hours (Fig. 1B). 
MBP in pre -malignant phase TGR/Edin was significantly higher 
than either TGR/Han or TGR/Lew at 52 to 57 days of age, but by 
75 
days of age the MBP attained by TGR /Han and TGR/Lew hetero- 
zygotes was not significantly different to pre -malignant phase 
TGR/Edin (data not shown). 
All animals that exhibited signs of the MH phenotype were 
found to have pathological changes in the kidney. Figure 1C 
shows a kidney section from an 8- week -old hypertensive, but not 
malignant phase, transgenic rat kidney. In contrast, Figure 1D 
shows changes of MH. Fibrinoid necrosis was seen to principally 
affect afferent arterioles, interlobular arteries and occasional 
portions of glomerular tufts. Secondary ischemic changes were 
relatively rare, implying thgt such changes were acute. In addition 
proliferative myointimal changes with endothelial swelling and 
luminal thrombi were observed. More chronic hypertensive vas- 
cular and glomerular changes were not seen in the age range of 
the animals developing malignant phase hypertension. Small 
myocardial microinfarcts were seen in many TGR/Edin that 
developed MH, some in relation to fibrinoid changes within small 
cardiac arterioles. Cerebrovascular pathology was infrequent, with 
occasional infarction and hemorrhage. Minor thickening was seen 
in mesenteric artery wall, but there was no difference between 
malignant and non -malignant phenotypes. 
The MH phenotype was associated with varying degrees of 
renal failure with a mean creatinine of 111.9 µmol/liter in 
malignant TGR/Edin compared to 55 healthy age- matched hyper- 
tensive heterozygotes (range 22.4 to 60.4 µmol/liter, 95% confi- 
dence limits). No significant difference in renal function was 
observed between the transgenic heterozygote crosses prior to the 
development of MH. 
Significant elevation of PRA (29.1 ± 11.0 vs. 9.2 ± 8.3 ng Mg 
I /ml/hr), Ang II (829.5 ± 653.4 vs. 28.0 ± 25.2 pg/ml) and 
aldosterone (11.4 -!- 7.7 vs. 0.71 i- 0.97 nmol/liter) were seen in 
MH rats compared with age matched, non- malignant phase, 
hypertensive transgenic heterozygotes (Results shown as mean ± 
SD, N = 6 to 24 per group; P < 0.001). Immunohistochemical 
labeling of kidney sections using a rabbit anti -mouse renin 
antibody demonstrated a marked increase in renin staining at the 
vascular poles in malignant hypertensives (not shown). Staining of 
other renal structures was not found. 
A small reduction in dietary sodium (0.2% vs. 0.32 %) within the 
`normal' range was given from weaning to transgenic heterozy- 
gotes to mimic rat chow fed to original TGR /Han heterozygotes 
when first established and studied in Department of Pharmacol- 
ogy, University of Heidelberg, Germany [9]. There was a small 
reduction in MBP in telemetered TGR/Han and TGR/Lewis (Fig. 
2 A, B) which was only significant at 75 days in TGR /Han and 75 
to 81 days in TGR/Lew. No significant differences in the occur- 
rence of MH occurred, with one case in the TGR/Han group on 
0.32% sodium diet, but none in either TGR/Lew group. 
SBP measured by tail cuff plethysmography under light halo - 
thane anaesthesia in non -transgenic Edinburgh SD and Hannover 
SD (N = 6 to 14 per group) on a 0.32% Na diet from 4 to 12 weeks 
of age showed a lower SBP in Edinburgh SD from six weeks of age 
and slightly lower body weight (Fig. 2 C, D) 
Discussion 
The spontaneous occurrence of the MH phenotype in the 
transgenic rat line TGR(mREN2)27 is associated with evidence of 
classical pathological changes of fibrinoid necrosis and myo- 
intimal proliferation, renal failure, evidence of renal RAS activation 
and an accelerated rise in BP. Furthermore, the high percentage of 
male TGR/Edin affected offers a potentially valuable animal model 
in which to study MH, in particular the initiating and subsequent 
events. 
In this case transgenesis has created a monogenic model of 
hypertension in which additional interactions, either environmen- 
tal or genetic, have resulted in MH. What factors determine 
susceptibility in humans are poorly understood. Cigarette smoking 
[15, 16], oral contraceptive use [17] and HLA type have all been 
implicated [18]. Environmental factors were questioned in view of 
the change in phenotype on breeding TGR #27 heterozygotes in 
Edinburgh as compared to Heidelberg. Analysis of rat chow 
revealed a slightly higher sodium content in `Scottish' rat chow, 
but a comparison of the two diets did not significantly affect either 
blood pressure or survival. No other environmental differences 
such as temperature, humidity profiles or lighting times were 
found to explain the phenotypic change. Furthermore, the high 
incidence of MH in TGR/Edin compared with TGR/Han and 
TGR/Lew when maintained in identical conditions and on the 
same diet suggested that environmental factors were not crucial. 
It is likely that genetic diversity within the SD strain, which is 
outbred, explains the difference between Hannover and Edin- 
burgh strains. The finding of a lower SBP in Edinburgh SD 
compared with Hannover SD rats argues against additional 
`hypertensive' genes contributing to the MH phenotype. 
Neither the rate of rise in blood pressure nor absolute BP 
appear to be important in determining the risk of onset of 
malignant phase hypertension, but higher BP at a younger age 
may be important in these rats. The continuing rise in BP during 












A Non -malignant phase 
50 55 60 65 70 75 80 85 90 95 100 
Age, days 
B Malignant phase 
300 - 
250 - 







0 10 20 
Time, hours 
30 40 
Fig. 1. Two examples of continuous recording of'MBP by telemetry show in (A), 'normal' hypertension reaching a plateau phase of 170 mnt Hg in a TGRIHan, 
and in (B), the terminal 40 hours of a 79 day old TGR/Edin with MH demonstrating the accelerated phase with a rise of 75 mm Hg in six hours. (C) A light 
micrograph showing a normal glomerulus, afferent arteriole and interlobular artery (IA) from a non -malignant phase transgenic heterozygote. (D) 
Myointimal proliferative changes (arrowed) and fibrinoid necrosis of interlobular arteries from a TGR /Edin with MH. (H &E stain x100) 
the accelerated phase may be due to loss of autoregulatory 
mechanisms and the development of a high renin hypertension. 
Initial characterization of the TGR(mREN2)27 rat line has 
suggested that the hypertension may be Ang II dependent [19], 
though there is evidence that altered adrenal steroid metabolism 
may he important [20, 21]. Certainly transgenic rats with estab- 
lished hypertension have evidence of a suppressed kidney RAS 
[8]. In the malignant phase, activation of the renal RAS was seen 
with increased immunohistochemical staining of the afferent 
arteriole at the vascular pole. By the method used, we have not 
differentiated mouse from rat renin, but would expect that as a 
consequence of the relatively low level of transgene expression in 
the kidney [8], that it is predominantly endogenous rat renin 
which is expressed in the malignant hypertensive transgenic rat 
kidney. 
In conclusion, we believe that this may be a valuable animal 
model in which it may be possible to identify factors, either 
genetic or environmental, that contribute to the development of 
malignant phase hypertension. It suggests that the target organ 
damage resulting from hypertension in this case may in part be 
dependent on the interaction of additional genetic factors. 
Reprint requests to Dr. C.E. Whitworth, Centre for Genuine Research, 
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Fig. 2. MBP (inm Hg) measured by telemetry in (A) TGR /Han (N = 6, 5) and (B) TGR /Lew heterozygotes (N = 4, 5) on 0.32% () and 0.2% () sodium diets, 
respectively. Results are shown as mean ± SD for each group. MBP for each animal is taken as the mean over the 24 hour period (recordings at 10 min intervals). 
*Significant difference (P < 0.05) in MBP arising between 0.32% and 0.2% sodium diets. (C) SBP (mm Hg) of Edinburgh SD ( ) and Hannover SD ( ) rats 
from 4 to 12 weeks of age measured weekly by tail cuff plethysmography under light halothane anaesthesia; * *SBP for Han SD > Edin SD (P < 0.05); (D) 
body weight. 
References 
1. KINCAID -SMITH P, MC'MICHAEL J, MURPHY EA: The clinical course 
and pathology of hypertension with papilloedema (malignant hyper- 
tension). Quart J Med 27:117 -153, 1957 
2. HOUSTON MC: Pathophysiology, clinical aspects, and treatment of 
hypertensive crises. Prog Cardiovasc Dis 22:99 -148, 1989 
3. WILSON C, BYROM FB: Renal changes in malignant hypertension. 
Lancet 1:136 -I39, 1939 
4. KINCAID -SMITH P: Renal pathology in hypertension and the effects of 
treatment. Br J Clin Phaumacol 13:107 -115, 1982 
5. BYROM FB: The nature of malignancy in hypertensive disease. Evi- 
dence from the retina of the rat. Lancet 1:516 -520, 1963 
6. LOHMEIER TE, TILLMAN L.I, CARROLL RG, BROWN AJ, GUYTON AC: 
Malignant hypertensive crisis induced by chronic intrarenal norepi- 
nephrine infusion. Hypertension 6:I.177- 1.182, 1984 
7. GAVRAS H, BRUNNER HR, LARAGH JH, VAUGHAN ED, Koss M, COTE 
1532 Whitworth et al: Malignant hypertension in transgenic rats 
LT, GAVRAS I: Malignant hypertension resulting from deoxycortico- 
sterone acetate and salt excess. Circ Res 36:301 -309, 1975 
8. MULLINS JJ, PE.I hRS J, GANTEN D: Fulminant hypertension in transgenic 
rats harbouring the mouse Ren -2 gene. Nature 344:541 544, 1990 
9. BACHMANN S, PETERS J, ENGLER E, GANTEN D, MULLINS J: Trans- 
genic rats carrying the mouse renin gene -Morphological character- 
ization of a low -renin hypertension model. Kidney Int 41:24 -36, 1992 
10. LANGE J, BROCKWAY B, AZAR S: Telemetric monitoring of laboratory 
animals: An advanced technique that has come of age. Lab Animal 
20:28 -33, 1991 
11. BIDANI AK, GRIFFIN KA, PICICEN M, LANSKY DM: Continuous tele- 
metric blood pressure monitoring and glomerular injury in the rat 
remnant kidney model. Am J Physiol 265:F391 F398, 1993 
12. MORTON JJ, WALLACE ECH: The importance of the renin -angiotensin 
system in the development and maintenance of hypertension in the 
two kidney one clip hypertensive rat. Clin Sci 64:359 -370, 1983 
13. MORTON JJ, WEBB DJ: Measurement of plasma Angiotensin II. Clin 
Sci 68:483 -484, 1985 
14. DAVIES E, ROSSITER S, EDWARDS CRW, WILLIAMS BC: Serotoniner- 
gic stimulation of aldosterone secretion in the rat in vivo: Role of the 
renin -angiotensin system. J Endocrinol 130:347 -355, 1991 
15. ISLES C, BROWN JJ, CUMMING AM, LEVER AF, MCAREAVEY D, 
ROBERTSON JS, HAWTHORNE VM, STEWART GM, ROBERTSON JWK, 
WAPSHAW J: Excess smoking in malignant -phase hypertension. Brit 
Med J 1:579 -581, 1979 
16. PATEL R, ANSARI A, GRIM C: Prognosis and predisposing factors for 
essential hypertension in predominantly black patients. Am J Cardiol 
66:868 -869, 1990 
17. HODSMAN GP, ROBERTSON JIS, SEMPLE PF, MACKKAY A: Malignant 
hypertension and oral contraceptives: Four cases, with two due to the 
30 µg oestrogen pill. Eur Heart J 3:255 -259, 1982 
18. FORSBERG B, Low B: Malignant hypertension and HLA antigens. 
Tissue Antigens 22:155 -159, 1983 
19. HILGERS KF, PETERS J, VEELKEN R, SOMMER M, RUPPRECHT G, 
GANTEN D, LuFr FC, MANN JFE: Increased vascular angiotensin 
formation in female rats harboring the mouse Ren -2 gene. Hyperten- 
sion 19:687 -691, 1992 
20. SANDER M, BADER M, DJAVIDANI B, MASER -GLUTH C, VECSAI P, 
MULLINS J, CANTEN D, PETERS J: The role of the adrenal gland in 
hypertensive transgenic rat TGR(mRen2)27. Endocrinology 131:807- 
814, 1992 
21. Lo M, MEDEIROS I, MULLINS J, GANTEN D, BARRES C, CERUTTI C, 
VINCENT M, SASSARD J: High blood pressure maintenance in trans - 
genic mREN -2 vs. Lyon genetically hypertensive rats. Am J Physiol 
265:R180 R186, 1993 

Kidney International, Vol. 47 (1995), pp. 529 -535 
A genetic model of malignant phase hypertension in rats 
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A genetic model of malignant phase hypertension in rats. A genetic 
model of malignant phase hypertension in rats is described which closely 
parallels the natural history of untreated human malignant phase hyper- 
tension. Although the factors initiating transition from essential hyperten- 
sion to the accelerated phase in humans remain unknown, we report the 
characteristics of a genetically determined and reproducible phenotype 
which was found to result from a cross between hypertensive transgenic 
Ren -2 rats and normotensive Sprague -Dawley (Edinburgh) rats. Male Fl 
hybrids developed malignant phase hypertension with a penetrance of 
73.5% (95% confidence limits 65.7 to 81.3 %) by 100 days of age. 
Phenotypic features included an accelerated rise in blood pressure, 
fibrinoid necrosis, activation of the renal renin -angiotensin system and 
microangiopathic hemolytic anemia. In an analytical cross no significant 
difference in blood pressure was observed between malignant phase and 
non -malignant phase animals prior to transition, implying that a factor in 
addition to hypertension appears necessary for inducing transition to the 
malignant phase phenotype. Segregation of the malignant phenotype 
suggested that susceptibility is determined by at most two genetic loci. 
It is estimated that between 1 and 2% of essential hypertensives 
develop malignant phase hypertension precipitated by a sudden 
rise in blood pressure [1]. This incidence has been reduced from 
previous levels by improved management of essential hyperten- 
sion [2], but if untreated the mortality from this complication 
remains extremely high with a one year survival of less than 10% 
[3]. The pathological changes affecting the vasculature in malig- 
nant hypertension have been well described and include a myo- 
intimai proliferative response with endothelial swelling, areas of 
fibrin deposition, fibrinoid and cellular necrosis predominantly 
affecting small renal arteries and afferent arterioles [4 -8]. Acti- 
vation of the renal renin -angiotensin system (RAS) occurs in 
response to the afferent vascular pathology and a pressure in- 
duced diuresis and natriuresis [9, 10], and may serve to further 
increase blood pressure producing a vicious circle of accelerating 
blood pressure (BP) and RAS activation [2]. A microangiopathic 
hemolytic anemia results from intravascular hemolysis leading to 
the appearance of red cell fragments, spherocytes, microsphero- 
cytes and a reticulocytosis [11]. How environmental and genetic 
factors might determine susceptibility or induce transition to the 
malignant phase are poorly understood, but cigarette smoking 
[12], the oral combined contraceptive [13] and HLA type [14] 
Received for publication July il, 1994 
and in revised form September 12, 1994 
Accepted for publication September 13, 1994 
© 1995 by the International Society of Nephrology 
have all been implicated. Since there has been no available genetic 
model for this disease, animal models of malignant hypertension 
have only been made possible by dietary, surgical or pharmaco- 
logical manipulation [15 -17]. 
The transgenic rat line TGR(mRen2)27 exhibits sustained 
hypertension as a consequence of expression of the mouse Ren2 
renin gene in a Hannover Sprague -Dawley (HanSD) rat [18]. The 
exact mechanism of the hypertension is not clear but overexpres- 
sion of the transgene in adrenal cortex resulting in activation of 
the adrenal RAS [19 -21], a high circulating prorenin [22], in- 
creased vascular wall renin activity [23] and the response to 
converting enzyme inhibiton [24] suggest that blood pressure may 
well be Mg II dependent. Expected target organ damage is seen 
in the kidney and heart of heterozygotes from four to six months 
of age [25], but no hallmarks of malignant phase hypertension 
have been reported to date. In this study we have used the 
presence and function of the Ren2 transgene as a method of 
inducing hypertension in three rat strains and have observed a 
strain -dependent difference in the incidence of a phenotype 
analogous to malignant hypertension which was invariably termi- 
nal. Observed features included the adoption of a hunched 
posture with extreme lethargy, piloerection, a diuresis with a 5 to 
10% loss in body weight occurring over one to three days, and on 
occasion unilateral or bilateral seizures or hemiparesis. A second 
analytical cross demonstrated that segregation of the phenotype 
occurred independent of BP prior to onset of malignant phase, 
and was due to one or at most two genetic loci. 
Methods 
Animals 
All animals were housed in identical conditions with a 12:12 
hour light -dark cycle, controlled temperature (18 to 20 °C) and 
humidity (45 to 65 %). A normal sodium diet (0.32% sodium 
CRM diet, SDS, Witham, Essex, UK) was used with tap water ad 
libitum to drink. 
Fl hybrids, hemizygous for the Ren2 transgene (Ren2 / -) were 
derived from crossing male TGR(mRen2)27 homozygotes on a 
Hannover Sprague -Dawley (HanSD) background with: (i) female 
Edinburgh Sprague -Dawley (EdinSD) (Centre for Genome Re- 
search, University of Edinburgh, UK) to give hybrids of genotype 
HanRen2/Edin -; (ii) HanSD (Central Institute of Laboratory 
Animal Breeding, Hannover, Germany) to give HanRen2 /Han -; 
and (iii) Lewis rats (Harlan -Olac, Oxford, UK) to give HanRen2/ 
Lew -. Animals were closely observed for the appearance of 
terminal features of the phenotype as described, and were put 
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down for humane reasons in accordance with the Animals (Sci- 
entific Procedures) Act 1986. Where possible kidney, heart, 
descending thoracic aorta, superior mesenteric artery and brain 
were removed, fixed in 4% formal saline and paraffin embedded. 
Three p.m sections were stained with hematoxylin and eosin 
(H &E) according to standard methods [26]. Control tissues were 
obtained from age- and sex -matched healthy transgenic heterozy- 
gotes and non -transgenic HanSD and Edin SD. Blood, obtained 
by cardiac puncture from malignant phase male HanRen2/Edin 
(N = 5), and from healthy, hypertensive, age- matched male 
HanRen2/Edin littermates (N = 5) under halothane anesthesia 
was collected into tubes containing EDTA (Sarstedt Monovette 
2.7 ml tubes) before spreading and staining with Wright's stain. 
Plasma creatinine was assayed by a colorimetric method (Gemeni, 
Electro- nucleonics, Inc., NJ, USA) from blood obtained as above 
and collected into lithium heparin (1 ml tube, Teklab M.L. Ltd, 
Durham, UK). 
Blood pressure 
Continuous monitoring of BP in conscious, unrestrained male 
rats was performed using telemetry (Data Sciences International, 
St. Paul, MN, USA). Implantation of transmitters (TA11PA -C40) 
was performed at 37 to 49 days of age by aseptic technique, under 
halothane anesthesia (2 to 4% in oxygen), with placement of the 
catheter tip in the aorta distal to the origin of the renal arteries. 
Rats were housed singly in cages above a RA 1010 receiver pad. 
Receivers were connected to a BCM100 consolidation matrix and 
signals transmitted to a Dataquest IV acquisition system. BP was 
corrected for atmospheric pressure. Systolic (SBP), mean (MBP) 
and diastolic (DBP) pressures were collected at 10 minute inter- 
vals after recovery from surgery. Twenty-four hour MBP (group 
mean and sEM) for male HanRen2 /Edin- (N = 10), HanRen2/ 
Han- (N = 6), HanRen2/Lew- (N = 4), EdinSD (N = 3), 
HanSD (N = 3) and Lewis (N = 4) was recorded from 46 to 90 
days of age. 
Renin -angiotensin system parameters 
Plasma renin activity (PRA), angiotensin II (Ang II) and 
aldosterone were measured by radioimmunoassay, by methods 
described elsewhere [27 -29], in healthy seven to nine -week- old 
HanRen2/Edin -, HanRen2/Han -, HanRen2/Lew -, non- trans- 
genic controls (EdinSD, HanSD, Lewis) and malignant phase 
Ren2 hemizygotes. Blood, obtained by retro- orbital bleeding or 
cardiac puncture under halothane anaesthesia, was collected into 
pre -chilled tubes on ice: in lithium heparin (1 ml tube, Teklab 
M.L. Ltd, Durham UK) for PRA; in inhibitor (1 Al /m1) 1,10 
phenanthroline monohydrate (Sigma, UK) in EDTA (BDH Lab- 
oratory Supplies, UK) for Ang II; or for aldosterone determina- 
tion, with no anticoagulant, spun at 4000 g at 4 °C for 10 minutes 
to obtain plasma or serum and samples were stored at -70 °C 
before assay. Immunostaining for renin was performed on 3 µm 
de- paraffinized sections of kidney (fixed in 4% formal saline). A 
rabbit anti -mouse renin primary antibody (cross reacts with rat) 
was applied, with an avidin- biotin horseradish peroxidase second- 
ary detection system (Vectastain, Vector Laboratories, Inc., Bur- 
lingame, CA, USA). Primary antibody was omitted as a negative 
control. 
Analytical cross 
Seventy-three male Fl progeny (Edin,Han)Ren2/(Edin,Lew)- 
were bred from three (Han,Edin)Ren2 /(Han,Edin)Ren2 males 
(derived from a HanRen2/Edin intercross) and seven Edin -/ 
Lewis- females and housed and maintained as described above. 
Animals were examined for the terminal features suggestive of 
malignant phase hypertension as described, and diagnosis was 
confirmed postmortem by the presence of fibrinoid necrosis on 
light microscopy of 3 pm kidney sections (H &E stain). SBP was 
measured by tail cuff plethysmography (Model 179 blood pressure 
analyzer, Model 27 cuff pump, IITC Life Science Instruments, 
Norfolk, UK) under light halothane anaesthesia (2% in oxygen) 
on a heating pad (33 °C), in all 73 rats at 52 days and measured 
weekly in a subgroup of 28 rats from 35 days. 
Statistics 
Blood pressures are shown as group means and SEM. Student's 
t -test was used for unpaired comparisons of group means at each 
time point with the Bonferroni correction for multiple compari- 
sons where appropriate. Statistical comparisons made between 
malignant phase and each non -malignant phase group for PRA, 
Ang II and aldosterone levels were performed using unpaired 
t -tests with Bonferroni correction. Penetrance of the phenotype in 
crosses is shown with 95% confidence limits. The x2 test was used 
to compare penetrance of the malignant phenotype in the progeny 
of the analytical cross, (Edin,Han)Ren2/(Edin,Lew)- with that in 
HanRen2/Edin -. Observed penetrance and expected levels of 
penetrance (with 95% confidence intervals) if one, two or three 
genes were operating were also compared using x2 test. The level 
of statistical significance was taken to be P < 0.05. 
Results 
Characterization of the phenotype 
The spontaneous development of an altered phenotype in 
TGR(mRen2)27 heterozygotes was observed on crossing HanSD 
males homozygous for the Ren2 transgene (genotype HanRen2/ 
HanRen2) with EdinSD (genotype Edin - /Edin -). Animals 
were noted to have a diuretic phase resulting in up to 10% loss in 
body weight over one to three days. They adopted a hunched 
apathetic posture, with evidence of unilateral seizures or hemipa- 
resis in a minority. Death occurred between 33 and 103 days 
(median 57 days) of age in males and between 46 and 103 days 
(median 62 days) in females. 
Three different Fl hybrid groups resulting from crossing ho- 
mozygote HanRen2/HanRen2 with EdinSD, HanSD, or Lewis 
were compared for incidence of the phenotype in males and 
females on a 0.32% sodium diet, and maintained in identical 
conditions (Table 1). HanRen2/Edin- showed the highest inci- 
dence with the phenotype affecting 73.5% of males (65.7 to 81.3 %, 
95% confidence interval), and 52.5% (44.7 to 60.3 %) of females. 
For HanRen2/Han -, 18% (6 to 30 %) of males and 4% (0 to 
10 %) of females were affected. No HanRen2/Lew- males or 
females developed the phenotype. 
Histopathology of kidney from affected animals demonstrated 
both myointimal proliferation and fibrinoid necrosis, particularly 
affecting afferent arterioles, interlobular arteries and occasional 
glomerular tufts (Fig. 1, A -D). Changes indicative of chronic 
ischemic damage or long standing hypertension were not a feature 
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myocardial infarcts were found, occasionally seen to be related to 
fibrinoid necrosis of cardiac arterioles. Early lesions appeared as 
collections of cardiomyocytes showing evidence of focal necrosis, 
but granulation tissue and focal fibrotic scars suggested that a 
healing response did occur. Cerebral hemorrhage and infarction 
occurred infrequently and no significant pathology of either aorta 
or superior mesenteric artery was seen in the malignant phase 
(data not shown). All blood films from malignant phase HanRen2/ 
Edin- (N = 5) exhibited microangiopathic hemolytic anemia 
with red cell fragments, spherocytes, microspherocytes and reticu- 
locytosis, while films from age- matched controls (non -malignant 
HanRen/Edin- littermates (N = 5) showed no features of 
hemolysis (Fig. 1 E, F). Renal failure accompanied the clinical 
features with elevation of plasma creatinine (measured in 8 
affected animals) to a mean of 111.9 µmol /liter (range 59 to 239 
p,mol/liter) compared with a mean of 41.4 µmol/liter (22.8 to 60.0 
p,mol/liter, 95% confidence limits) for healthy but hypertensive 
age- matched transgenic heterozygotes (N = 55). 
An accelerated rise in MBP occurred in heterozygotes who died 
from malignant phase hypertension (N = 5) while on telemetry 
with a mean increase of 72 mm Hg (range 65 to 75mm Hg) 
occurring over the terminal six hours (Fig. 2A). MBP measured in 
the three Fl hybrids and in non -transgenic strains, EdinSD, 
HanSD and Lewis is illustrated in Figure 2B. HanRen2/Edin- 
showed a significantly higher MBP, from 52 to 60 days compared 
to either HanRen2/Han- or HanRen2/Lew- (P < 0.01), but on 
attaining the plateau phase at 70 days the MBP ± SEM for 
HanRen2/Han- and HanRen2/Lew- were 169 i- 11.9 and 177.3 
± 4.1 mm Hg respectively, which was not significantly different to 
the MBP -± SEM of HanRen2/Edin- at 60 days (180.7 ± 10.0 mm 
Hg), around the median age for onset of malignant phase. No 
significant difference in MBP was seen between non -transgenic 
strains. 
PRA, Ang II and aldosterone levels in plasma were significantly 
elevated in the malignant phase compared to both age- matched 
non -malignant transgenic heterozygotes and non -transgenic con- 
trols (Fig. 3A). Immunostaining of kidney sections using an 
anti -mouse renin antibody which cross reacts with rat renin 
showed marked, but selective, staining of afferent arterioles at the 
vascular poles of glomeruli from malignant phase kidneys (Fig. 
3B). Little renin staining was seen in healthy hypertensive age /sex 
matched hybrids, relative to both non -transgenics (not shown) as 
previously described [25], and malignant phase transgenic rats. 
Analytical cross 
A segregating cross for EdinSD alleles was designed (Fig. 4A). 
Seventy-three hybrid males of genotype (Han,Edin)Ren2/ (Edin, 
Lew)- were bred. Forty-two out of seventy-three (57.5 %, 95% 
confidence limits 45.9 to 69.5 %) developed signs of malignant 
phase hypertension, verified by the presence of fibrinoid necrosis 
on light microscopy of H &E stained kidney sections, and died 
between 53 and 103 days (median 66 days). This incidence was 
significantly different to that observed in HanRen2/Edin- (x2 _ 
5.181, df = 1,P < 0.05). Expected levels of penetrance if one, two 
or three genetic loci were involved were calculated, as discussed 
below, and compared with the observed penetrance in the cross. 
The results most closely fit a monogenic model where expected 
penetrance would be 55.1% (95% confidence interval 49.3 to 
61 %). 
SBP was measured in all 73 rats by tail cuff plethysmography at 
Table 1. F1 hybrids, hemizygous for the Rent transgene were derived 
from crossing male TGR(mRen2)27 homozygotes on a HanSD 
background with female EdinSD, HanSD and Lewis rats giving the 
genotypes shown 
Heterozygote cross Genotype 
Incidence of Malignant 
hypertension 
Male Female 
HanRen2 x Edin SD HanRen2/Edin- 86/117 (73.5 %) 83/158 (52.5 %) 
HanRen2 x Han SD HanRen2/Han- 7/39 (18 %) 2/44 (4 %) 
HanRen2 x Lewis HanRen2/Lew- 0/35 (0 %) 0/31 (0 %) 
The incidence (percentage) of male and female progeny developing 
malignant phase hypertension for each cross on a normal diet is shown. 
52 days of age and weekly in a subset of 28 rats from 35 days of age 
(Fig. 4B). At 52 days there was no significant difference in SBP 
between those rats destined to develop malignant hypertension 
and those who did not (mean ± SEM, 193.0 -1- 4.8 mm Hg and 
182.8 ± 4.8 mm Hg, respectively, P = 0.278), but at 35 days a small 
but significant difference did exist (malignant phase 141.9 ± 5.6 
mm Hg and non -malignant phase 124.2 ± 4.6 mm Hg, P = 0.02). 
Discussion 
The phenotype described above appears to be an excellent 
experimental model exhibiting within a defined age range all the 
main clinical characteristics of malignant phase hypertension, 
namely an accelerated rise in blood pressure, diuresis, impaired 
renal function, activation of the renal RAS, microangiopathic 
hemolytic anemia and the classical pathological changes of myo- 
intimal proliferation and fibrinoid necrosis. Some variation in the 
severity of pathological, biochemical and immunological change 
measured is to be expected due to the necessity for intervention 
for humane reasons when animals were showing signs of terminal 
malignant phase, as samples were therefore obtained at varying 
stages during the natural history of the established phenotype. 
Malignant phase hypertension is arising in a model where 
expression of the Ren -2 transgene has been used as a tool to 
elevate blood pressure, but without requiring dietary, surgical or 
pharmacological manipulation or selective breeding, an increased 
tendency for spontaneous transition to malignant phase is exhib- 
ited in certain animals. Although the underlying hypertension in 
this rat model may well be Ang II dependent, activation of the 
renal RAS system is seen during malignant phase. Elevated 
plasma renin, increasing Ang II and resulting hyperaldosteronism 
is thought to be central to the process of MH providing the drive 
for further BP elevation [30 -32]. In animal models, infusion of 
renin and aldosterone induced typical pathological changes [33], 
though while Ang II infusion in rabbits did cause acute renal 
failure and tubular necrosis, arteriolar changes were not observed 
[34]. In salt loaded SHR -SP, both ACE inhibition and the specific 
Ang II antagonist, Losartan, slowed both the rise in BP and 
prevented or delayed the development of renal arterial necrosis 
[35, 36]. 
Factor(s) provided by the genetic background appear to be 
acting in concert with "benign hypertenion" to induce the change 
in phenotype. Environmental factors do not play a major role as 
shown by the differing incidence of the malignant phenotype in 
the three transgenic hemizygote hybrids tested (HanRen2 /Edin -, 
HanRen2/Han- and HanRen2/Lew -), despite maintenance in 
identical conditions. The reason for the difference in incidence 
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Fig. 1. Kidney, heart, brain, aorta and mesenteric artery was fixed in 4% formal saline, paraffin-embedded and 3 ¡am sections were stained with hematoxylin and 
eosin. A. Normal kidney from SD (x 100) showing glomerulus (g). B. Fibrinoid necrosis and C. myointimal proliferation in HanRen2/Edin- kidney (x 100). 
D. Illustrates a microscopic infarct in heart (x 100). Blood films (Wright's stain, X 630) E and F show a normal film from a healthy hypertensive 







between male and female strains has not been addressed in this 
study. Small variations in dietary sodium (0.32% vs. 0.2 %) did not 
influence either MBP or survival in telemetered transgenic het - 
erozygotes [37]. Therefore, if genetic factors are important these 
Fig. 3. PRA, Ang II and aldosterone were 
measured by radioimmunoassay in 7- to 9 -week- 
old healthy A HanRen2lEdin- (N = 15,11,14 
for each assay respectively); ( ) 
HanRen2/Han- (N = 19,11,30); (E) 
HanRen2/Lew- (N = 14,12,19); () pooled 
non -transgenic EdinSD/HanSD/Lewis (N = 
18,14,13); (CI) and malignant phase Ren2 
hemizygotes (N = 14,11,15). Results are shown 
as group means -± SD. Significantly higher 
values were seen for PRA( *P < 0.008), Mg II 
(fP < 0.04) and aldosterone ( §P < 0.004) in 
the malignant phase compared to the other 4 
non -malignant groups (unpaired t -test with 
Bonferroni correction). B. Immunostaining of 3 
µm kidney sections using an anti -mouse renin 
antibody which cross reacts with rat shows (1) 
rat glomerulus (g) (X 400) from malignant 
phase Ren2 hemizygote demonstrating dense 
immunostaining of the afferent arteriole (aa) at 
the vascular pole, but (2) little staining of the 
vascular pole (aa) is seen in the non -malignant 
phase transgenic littermate (x 630). 
might take the form of either loci leading to an increase in 
baseline BP or act by some other mechanism independent of BP. 
There was no significant difference in MBP between telemetered 
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Fig. 2. A. Examples of recordings of MBP by telemetry from an individual HanRen2 /Han- ( -) with chronic hypertension and a HanRen2lEdin- (f) 
with malignant phase hypertension. B. MBP (24 hr average) as recorded by telemetry was plotted every 2 days for clarity as group mean ± SEM starting 
from 46 to 52 days of age for: () HanRen2/Edin- (N = 10); (0) HanRen2/Han- (N = 6); (A) HanRen2/Lew (N = 4); (D) EdinSD (N = 3); (0) 
HanSD (N = 3); and (A) Lewis (N = 3). 
A 
HanRen2/HanRen2 -- Edin--/Edin-- 
HanRen2/Edin-- -r HanRen2/Edin-- Edin--/Edin-- T Lew--/Lew-- 
(Han,Edin)Ren2/(Han,Edin)Ren2 Edin--/Lew-- 
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EdinSD and HanSD rats (N = 11 to 15 per group) had weekly tail 
cuff plethysmography performed under light halothane anesthesia 
from 35 to 90 days of age, and a slightly higher SBP was observed 
in HanSD compared to EdinSD [37]. 
HanRen2/Edin- showed the highest incidence of the malig- 
nant phenotype with a penetrance of 73.5% (65.7 to 81.3 %), and 
did show a significantly higher MBP at 57 days (median age of 
death) compared to MBP in the other two groups at that age, but 
it was not significantly different to MBP of 70- day -old HanRen2/ 
Han- or HanRen2/Lew -. Therefore absolute MBP may not be 
the critical factor precipitating the transition, but a higher blood 
pressure in younger rats may well be a marker of predisposition. 
Fig. 4. A. Seventy- three male FI progeny, 
genotype (Edin,Han)Ren2 /(Edin, Lew)- were 
bred from three (Han,Edin)Ren2 /(Han,Edin)Ren2 
males (derived from a HanRen2lEdin- 
intercross) and seven Edin -/Lew- females. At 
the gamete stage the probabilities of carrying 
EdinSD (pE), HanSD (pH) and Lewis (pL) 
alleles are shown. The probability of at least 
one allele for any locus being derived from 
EdinSD (pE) in the (Edin,Han)Ren2/ (Edin, 
Lew)- progeny is therefore 3/4 or 75 %. B. 
SBP was measured weekly by tail cuff 
plethysmography under light halothane 
anethesia in 28 of the progeny from 35 days of 
age and in all 73 rats at 52 days. The number of 
those destined to develop malignant (M, I) 
and non -malignant phase (NM, A) is shown for 
each time point. At 35 days, there was a small 
but significant difference ( *P = 0.02). 
To test for the possibility of genetic susceptibility to malignant 
phase hypertension, a segregating cross for EdinSD alleles was 
designed. The incidence of the malignant phenotype, as defined 
by the onset of the described signs and confirmed by the presence 
of fibrinoid necrosis was 42 of 73 or 57.5% (45.9 to 69.5 %) which 
was significantly different to the incidence seen in HanRen2/ 
Edin -, but the age range (53 to 103 days) and median age (66 
days) of affected animals was similar. SBP measured just before 
the expected time of onset of malignant phase (52 days) did not 
differ between malignant and non -malignant rats, but significantly 
higher SBP was observed in those destined to develop malignant 
phase hypertension at 35 days old. 
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The probability of at least one EdinSD derived allele being 
present at a given locus in the studied progeny is 3/4, thus if one 
dominant gene was responsible an expected penetrance would be 
55.1% (95% confidence interval 49.3 to 61 %), being 3/4 of 73.5% 
which is close to that observed. If two genes were involved, then 
the probability of EdinSD alleles being present at both loci would 
be 9/16, and hence the expected incidence would be 41.3% (95% 
confidence interval 36.9 to 45.7 %). Two loci cannot be excluded at 
the present time as the upper limit of expected penetrance is not 
significantly different to that observed (x2 ranging from 2.028 to 
6.18 for 1 df; P ranging from 0.01 to >0.05). Three genes can be 
excluded, the expected incidence being 22.6/73 or 31% (27.7 to 
34.3%, X2 ranging from 7.972 to 11.706; P < 0.01). These results 
therefore most strongly support a monogenic model. 
In conclusion, the spontaneous transition to malignant phase 
hypertension depends on either one or at most, two loci which 
confer susceptibility. A phenotypic marker of predisposition may 
be higher BP at a younger age, but absolute BP does not appear 
to be the single critical factor in precipitating transition. We 
speculate that an additional genetic factor is interacting with a 
rising BP, perhaps at the level of the endothelium, and is 
responsible for the stimulus initiating the transition into MH and 
allowing RAS activation. We believe that the HanRen2/Edin- 
cross offers a useful and clinically relevent model to study factors 
responsible for initiating malignant phase hypertension and its 
pathological sequelae, and will facilitate genetic mapping of the 
locus(ci) responsible. 
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Appendix. Abbreviations 
Ren2 - Mouse Ren2 renin transgene; BP - blood pressure; SBP - systolic 
blood pressure; MBP - mean, blood pressure; RAS - renin- angiotensin 
system; PRA - plasma renin activity; Mg II - angiotensin II; EdinSD - 
Sprague-Dawley (Edinburgh strain); HanSD - Sprague -Dawley (Han- 
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